Allergan Confiden tial Protocol 3101-303-002 Amendment 3
1 
ALLERGAN – CONFIDENTIAL
The following contains confidential, proprietary  information 
which is the propert y of Allergan
A PHASE 3, MUL TICENTER, RA NDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, P ARALLEL -GROUP  STUDY  TO EV ALUA TE THE EFFICACY , 
SAFETY , AND TOLERABILITY  OF ATOGEP ANT  FOR THE PREVENTION OF CHRONIC 
MIGRAINE (PROGRESS)
Protocol Number: 3101-303-002
EudraCT Number: 2018-004337-32
Phase : 3
Name of Study Intervention: Atogepant (AGN -241689)
Sponsor: Allergan Ltd
Marlow International,
The Parkway , Marlow , 
Buckinghamshire
SL7 1YL United Kingdom
US Agent Allergan Sales, LLC
2525 DuPont Drive
Irvine, California USA
92612
Emergency Telephone Number(s): +1-
866-438-8820
Serious Adverse Event Reporting 
Fax Number(s):+1-714-796-9504
(Back Up Fax No.: +1 -714-246-5295)
Email: IR-Clinical -SAE@allergan.com
Allergan Medical Safety Physician
Contact Information:Refer to the Study Contacts Page
Allergan Signatory: MS, MD
Vice President, Neuroscience Development
Original Protocol Date: 13December 2018
Protocol Amendment 1 Date: 08April 2019
Protocol Amendment 2 Date: 23September 2019
Protocol Amendment 3 Date: 29May 2020
[STUDY_ID_REMOVED]

Allergan Confiden tial Protocol 3101-303-002 Amendment 3
2The following information can be found on FDA  Form 1572 and/or study  contacts page: Name 
and contact information of the sponsor study  personnel and Emergency T elephone Numbers ; 
name, address, and statement of qualifications of each investigator; name of ea ch subinvestigator 
working under the supervision of the investigator; name and address of the research facilities to 
be used; name and address of each reviewing IRB; US 21 CFR 312.23 section 6(iii)b.
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
3INVESTIGA TOR SIGNA TURE P AGE
INVESTIGATOR:
I agree to:
Implement and conduct this study diligentl y and in strict compliance with the protocol, GCP, 
and all applicable laws and regulations.
Maintain all information supplied by  the sponsor in confidence and, when this information is 
submitted to an I RB, IECor another group, it will be submitted with a designation that the 
material is confidential.
Ensure that all persons assisting with the trial are adequatel y informed about the protocol, the 
study  intervention (s), and their trial -related duties and functio ns.
I have read this protocol in its entirety  and I agree to all aspects.
Investigator Printed Name Signature Date
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
4Table of Contents
Title Page ................................ ................................ ................................ ................................ ........ 1
Table of Contents ............................................................................................................................ 4
List of T ables ................................................................................................................................. 10
List of Figures ............................................................................................................................... 10
Protocol Summary ................................ ................................ ................................ ......................... 11
1.Background and Clinical Rationale ....................................................................................... 20
1.1 Background ...................................................................................................................20
1.2 Overview of Atogepant .................................................................................................21
1.3 Study Rationale .............................................................................................................22
1.4 Rationale for Doses and Dose Regimens Selected .......................................................22
1.5
Benefit/Risk Assessment...............................................................................................22
2.Study Objectives and Clinical Hypotheses ............................................................................ 22
2.1 Study  Objectives ...........................................................................................................22
2.2 Clinical Hy potheses ......................................................................................................23
3.Study Design .......................................................................................................................... 23
3.1 Structure ........................................................................................................................23
3.2 Data Safety  Monitoring Board
......................................................................................25
3.3 Adjudication Committee ...............................................................................................25
3.4 End of Study  Definition ................................................................................................25
4.Study Population and Entry Criteria ...................................................................................... 25
4.1 Number of Participants .................................................................................................25
4.2 Inclusion Criteria
...........................................................................................................26
4.3 Exclus ion Criteria .........................................................................................................26
4.4
Permissible and Prohibited Medications/Treatments....................................................30
4.4.1
Permissible Medications/T reatments ................................................................30
4.4.2 Prohibited Medications/T reatments ..................................................................31
4.4.3 Definition of W omen of (Non- )Childbearing Potential and/or Acceptable 
Contraceptive Methods ................................ ................................ ..................... 32
4.4.4 Special Diet or Activities ..................................................................................34
4.5 Screen Failures ................................ ................................ ................................ .............. 34
5.Study Interventions ................................ ................................ ................................ ................ 34
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
55.1 Study  Interventions and Formulations ..........................................................................34
5.2 Control I nterventions and Formulations .......................................................................34
5.3 Methods for Masking/Blinding .....................................................................................35
5.4
Treatment Allocation Ratio and Stratification ..............................................................35
5.5 Method for Assignment to Treatment Groups/Randomization .....................................36
5.6 Study  Intervention Regimen and Dosing ......................................................................37
5.7 Storage of Study  Interventions ......................................................................................38
6.Response Measures and Summary
 of Data Collection Methods ........................................... 38
6.1 Efficacy  Measures .........................................................................................................38
6.1.1 Migrai ne Day ....................................................................................................38
6.1.2 Headache Day ...................................................................................................39
6.1.3 Acute Medication Use Day  and Triptan Use Day .............................................40
6.2 Hea
lth Outcomes Measures ...........................................................................................40
6.2.1 Activity  Impairment in Migraine –Diary  (AIM -D).........................................40
6.2.2 Activity  Level and Activity  Limitation .............................................................40
6.2.3 Patient Satisfaction with Study Medication (PS
SM) ........................................41
6.2.4 Headache Impact Test (HIT -6) ..........................................................................41
6.2.5 Migraine Disability  Assessment (MIDAS) .......................................................41
6.2.6 Patient Global I mpression of Change (PGIC)...................................................41
6.2.7 Work Productivity  and Activity  Impairment Questionnaire: Migraine V2.0 
(WPAI:MIGRAINE) .........................................................................................41
6.2.8 European Quality  of L ife –5 Dimensional (EQ -5D-5L)..................................42
6.2.9 Patient Global I mpression –Severity  (PGI -S)..................................................42
6.2.10 Migraine Specific Quality of Life Questionnaire, V ersion 2.1 (MSQ v2.1) .....42
6.2.1
1 Patient- Reported Outcomes Measurement Information Sy stem Pain 
Interference – Short Form 6a (PROMI S
-PI).....................................................42
6.2.12 Patient Health Questionnaire (PHQ -
9) .............................................................43
6.3 Pharmacokinetics Measures ..........................................................................................43
6.4 Future Biomedical Research .........................................................................................44
6.5 Safet y Measures ................................ ................................ ................................ ............ 44
6.5.1 Adverse Events ..................................................................................................44
6.5.2 Adverse Events of Special Interest ...................................................................44
6.5.3 Clinical L aboratory  Determinations ..................................................................45
6.5.4 Vital Signs .........................................................................................................46
6.5.5 Physical E xamination ........................................................................................46
6.5.6 Electrocardiograms ...........................................................................................47
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
66.5.7 Columbia -Suicide Severity  Rating Scale ................................ .......................... 47
6.6 Other Study  Supplies ....................................................................................................48
6.7 Summ
ary of Methods of Data Collection .....................................................................48
7.Statistical Procedures ............................................................................................................. 49
7.1 Analy sis Populations .....................................................................................................49
7.2 Collection and Derivation of Primary  and Secondary  Efficacy  Assessments ..............49
7.2.1 Primary  Efficacy  Endpoint ................................................................................50
7.2.2 Secondary  Efficacy  Endpoints ..........................................................................50
7.2.3 Additional Ef ficacy  Endpoints ..........................................................................51
7.2.3.1 Other Health Outcome V ariables ........................................................ 53
7.3 Hypothesis and Methods of Anal ysis............................................................................53
7.3.1 Primary  Efficacy  Analyses................................................................................53
7.3.1.1 Sensitivity  Analyses in Missing Data Handling ................................. 54
7.3.1.2 Sensitivity  Analysis for Possible Violation of Normality  Assumption
............................................................................................................ 55
7.3.2 Secondary  Efficacy  Analyses............................................................................56
7.3.3 Additional Ef ficacy  Analyses............................................................................57
7.3.4 Safet y Analysis..................................................................................................58
7.4 Off
-treatment Hy pothetical Estimand Framework for EMA ........................................58
7.4.1 Treatment Condition of Interest ........................................................................58
7.4.2 Population .........................................................................................................59
7.4.3 Variable .............................................................................................................59
7.4.4
Accounting of Intercurrent Events....................................................................59
7.4.5 Population -Level Summary ..............................................................................59
7.4.6 Off
-Treatment Hy pothetical Estimand Approach for the Secondary  Endpoints60
7.5 Subgroup Analy ses.......................................................................................................60
7.5.1 Subgro up Anal yses for Evaluating the Consistency  of Treatment Effects Across 
Regions and Subpopulations .............................................................................60
7.5.2 Other Subgroup Anal yses..................................................................................61
7.6 Sample Size Calculation ...............................................................................................61
7.7 Pharmacokinetics and Exposure -
Response Anal yses...................................................62
7.8 Interim Anal yses...........................................................................................................62
8.Study V isit Schedule and Procedures .................................................................................... 62
8.1 Participant Entry  Procedures .........................................................................................63
8.1.1 Overview of Entry  Procedures ..........................................................................63
8.1.2 Informed Consent and Participant Privacy .......................................................63
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
78.1.3 Procedure for Duplicate Participant Identification – Verified Clinical T rials...63
8.2 Washout I ntervals..........................................................................................................63
8.3 Procedures for Final Study  Entry ..................................................................................64
8.4
Visits and Associated Procedures .................................................................................64
8.4.1
Visit 1 (Screening/Baseline) Day  -35 to Day  -28..............................................64
8.4.2
Double- blind Treatment Phase (12 W eeks) .......................................................65
8.4.2.1 Visit 2 (Randomization) Day  1 .......................................................... 65
8.4.2.2 Visits 3 to 6 (W eeks 2 to 8) ................................................................ 66
8.4.2.3 Visit 7/Early  Termination (W eek 12) ................................................. 67
8.4.3 Follow -up Period (4 W eeks) .............................................................................68
8.4.3.1 Visit 8/End of Study  (Week 16) ......................................................... 68
8.5
Instructions for the Participants ....................................................................................68
8.6 Unscheduled Visits .......................................................................................................69
8.7
Compliance with Protocol.............................................................................................69
8.8 Early Discontinuation of Participants ...........................................................................70
8.8.1 Participants Who Discontinue Study Intervention Earl y
..................................70
8.9
Withdrawal Criteria.......................................................................................................72
8.10 Study Termination .........................................................................................................72
9.Adverse Events ...................................................................................................................... 72
9.1
Definitions.....................................................................................................................72
9.1.1 Adverse Even
t ...................................................................................................72
9.1.2 Serious Adverse Event ......................................................................................73
9.1.3 Intensity .............................................................................................................75
9.1.4 Assessment o
f Causality ...................................................................................76
9.1.5 Follow -up of Adverse Events and Serious Adverse Events ..............................76
9.1.6 Adverse Reactions, Serious Adverse Reactions, and Suspected Unexpected 
Serious Adverse Reactions ................................................................................77
9.2 Procedures for Reporting Adverse Events ....................................................................77
9.3 Procedures for Reporting a Serious Adverse Event ......................................................77
9.3.1 Regulatory  Reporting Requirements for Serious Adverse Events ....................78
9.4 Exposure to Study  Intervention During Pregnancy ......................................................78
9.5
ALT or AST Elevations .................................................................................................79
9.5.1 Potential Hy ’s Law Cases ................................ ................................ ................. 80
9.6 Procedures for Unmasking of Stud y Medication ..........................................................81
10.Administrative I tems ............................................................................................................. 81
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
810.1 Protection of Human Participants ................................ ................................ ................. 81
10.1.1 Compliance W ith Informed Consent Regulations (US 21 CFR Part 50) and 
Relevant Country  Regulations ..........................................................................81
10.1.2 Compliance W ith IRB or I EC Regulations .......................................................82
10.1.3 Compliance W ith Good Clinical Practice
.........................................................82
10.1.4 Compliance W ith Electronic Records; Electronic Signatures Regulations (US 
21CFR Part 1 1)..................................................................................................82
10.2 Financial Disclosure ......................................................................................................82
10.3 Changes to the Protocol ................................................................................................82
10.4 Data Protection ..............................................................................................................83
10.5 Participant Confidentiality ............................................................................................83
10.6 Participant Privacy ........................................................................................................83
10.7 Documentation ..............................................................................................................84
10.7.1 Source Documents ............................................................................................84
10.7.2 Case Report Form Completion .........................................................................85
10.7.3 Study Summary .................................................................................................85
10.7.4 Reten
tion of Documentation .............................................................................85
10.8 Labeling, Packaging, and Return or Disposal of Study  Interventions/Treatments .......86
10.8.1 Labeling/Packaging ...........................................................................................86
10.8.2 Clinical Supply  Inventory .................................................................................86
10.8.3 Return or Disposal of Study Medications/T reatments and/or Supplies ............86
10.9 Monitoring b y the Sponsor ............................................................................................86
10.10 Handling of Biological Specimens ...............................................................................87
10.11 Publications ...................................................................................................................87
10.12 Coordina ting Investigator
..............................................................................................87
11.References .............................................................................................................................. 88
12.Attachments ................................ ................................ ................................ ........................... 91
12.1 International Classification of Headache Disorders, 3rdEdition ...................................91
12.2 Examples of Prohibited Medications ..........................................................................109
12.3 List of Migraine Preventive Medications With Proven Efficacy  & Criteria for 
Determining that a Prior Migraine Preventive Medication Has Been Failed
............. 111
12.3.1 List of Migraine Preventive Medications W ith Proven Ef ficacy .................... 111
12.3.2 Criteria for Determining That a Prior Migraine Preventive Medication has 
Been Failed ..................................................................................................... 112
12.4 Study  Visits Conducted Remotely ..............................................................................113
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
912.5 Glossary  of Abbreviations ................................ ................................ .......................... 116
12.6 Protocol Amendment 1 Summary ...............................................................................119
12.7 Protocol Amendment 2 Summary ...............................................................................123
12.8 Protocol Amendment 3 Summary ...............................................................................129
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
10List of Tables
Table 1 Schedule of V isits and Procedures ................................ ................................ ........ 17
Table 2 Study Interventions ............................................................................................... 37
Table3 Clinical L aboratory  Parameters ............................................................................ 46
Table 4 Statistical Power for Primary  and the First Three Secondary Endpoints .............. 62
Table 5 Remote V isits Schedule of Assessments (ie, Schedule of V isits and Procedures)
..............................................................................................................................11 4
List of Figur es
Figure 1 Study Diagram ...................................................................................................... 16
Figure 2 Study Diagram for Estimand Framework ............................................................. 71
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
11Protocol Summary
Study Compounds: Atogepant
Phase: 3
Study Objectives: 
To evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg o nce daily for the 
prevention of chronic migraine ( CM). 
To prospectively test for superiority of atogepant 30mg BID and 60 mg once daily versus placebo for the prevention 
of CM.
Clinical Hypotheses: In participants with CM, at least one of the following atogepant doses ( 30mg BID and 60 mg 
once daily ) is superior to placebo as measured by the change from baseline in mean monthly migraine days across 
the 12 -week treatment period.
Atogepant has an acceptable safety and tolerability profile in participants with CM.
Study Design
Structure: Multicenter, randomized, double- blind, placebo -controlled, parallel -group study
Duration : The study will consist of a 4 -week screening and baseline period, a 12 -week double -blind treatment 
period, and a follow -up period of 4 additional w eeks, for a total duration of 20 w eeks
Study Intervention : Atogepant 30mg BID and 60 mg once dail ytablets
Control : Atogepant -matching placebo
Dosage/Dose Regimen : Atogepant 30mg BID , atogepant 60mg o nce daily , and plac ebo will be administered for 
12weeks duration.
Randomization/Stratification : 
Approximately 750 p articipant s will be randomized to 1of 3 treatment arms in a 1:1:1 ratio as follows :
Placebo (n = 250)
Atogepant 30mg BID (n = 250)
Atogepant 60mg once daily (n=250)
Participants will be stratified by :
Randomization will be stratified by u se of acute headache medications during the bas eline period (a cute 
headache medication overuse Yes or No). A cute headache medication overuse (Yes) w ill be defined as 
follows: use of triptans on ≥10 days OR use of ergots on ≥10 days OR use of simple analgesics (ie, 
aspirin, nonste roidal anti -inflammat ory drugs [ NSAIDs ], or acetaminophen) on ≥ 15 days ,OR use of any 
combination of triptans, ergots or simple analgesics on ≥10 days.
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
12Approximately 70% of randomized participants will have taken at least 1 prior migraine prevention 
medication with proven efficacy (see Attachment 12.3)1. Randomization will be stratified based on 
migraine prevention medication exposure (Current Use, Past Use, or Never Used ) with proven efficacy. 
Participants with current or past use will be further stratified based on the number of medications failed 
with unique mechanisms of action: “failed 0 medications or failed 1 or more medication(s) w ith the same 
mechanism of action” or “failed 2 to 4 medications with different mechanisms of action” (see 
Attachment 12.3).Enrollment of participants with current use of a migraine prevention medication will be 
capped at ~15% .
oBelow  are examples to illustrate how  to im plement the stratification based on pr ior m igraine 
prevention medicat ions:
Examp le 1: Participant has taken metoprolol and propranolol. According to 
Attachment 12.3, these medications both belong to the beta -blocker pharmacologic 
category. This participant should be randomized to the “failed 0 medications or failed 
1 or more medication(s) with the same mechanism of action” stratum.
Example 2: Par ticipant has taken metoprolol, propranolol, and topira mate. According to 
Attachment 12.3,metoprolol and prop ranolo lbelong to the beta -blocker p harmacologic 
category and topira mate belongs to the antiepileptic pharmacologic category. This 
participant should be randomized to the “failed 2 to 4 medications with different 
mechanisms of action” stratum.
Example 3: Participant has taken metoprolol and topira mate. According to 
Attachment 12.3, metoprolol belongs to the beta- blocker p harm acologic category and 
topira mate belongs to the antiepileptic category; however, the patient stopped both of 
these medications because of a change in health insurance coverage and therefore did not 
meet the failure definition for either medication. This participant should be randomized to 
the "failed 0 medications or failed 1 or more medication(s) with the same mechanism of 
action" stratum.
Randomiz ation will be stratified by r egions (ie, North America, Europe, Japan, China, Other)
Visit Schedule : Participation will begin with a 4 -week screening/ baseline period. Participants who complete the 
4-week screening/ baseline period and meet all entry criteria will be randomized to the double- blind treatment period 
of thisstudy at Visit 2 (R andomization V isit). The double -blind treatment period w ill last 12 w eeks, with a follow -
up period of 4 additional w eeks.
There will be 8 s cheduled clinic visits: Visit 1 ( screening/ baseline), Visit 2 ( randomization), Visit 3 (Week 2), 
Visit 4 (Week 4), Visit 5 (Week 6), Visit 6 (Week 8), Visit 7 (Week 12) ,and Visit 8 ( follow -up). The Visit 8 
(follow -up) must be completed for all participant swho take at least 1dose of study medication , except for 
participants rolling over into Study 3101 -312-002 (long -term safety extension study in regions excluding Japan and 
China), Study 3101 -306-002 (long -term safety extension study in Japan) ,or Study 3101 -311-002 ( open -label safety 
extension study in China). For these rollover participants Visit 8 of Study 3101 -303-002 is not required, because the 
Follow -up Visit (Visit 8) w ill be performed after the OL treatment in the respective long -term safety study. For 
participants who screen fail for the long -term safety study , the Follow -up Visit (Visit 8) of Study 3101 -303-002 
must be completed. For details, see Table 1, Schedule of Visits and Procedures .
Study Population Characteristics
Number of Participant s: Approximately 750 participants will be randomized into this global study (ie, North 
America, Europe, Japan, China, Other ).
                                                
1All French participants must have taken at least 1 prior migraine prevention medication with proven efficacy to be eligible for 
Study 3101 -303-002.
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
13Condition/Disease : Chronic migraine
Key Inclusion Criteria :
Male or female participants age 18 to 80 years, inclusive, at Visit 1
At least a 1 -year history of CMconsistent with a diagnosis according to the International Classification 
of Headache Disorders, 3rdEdition ( ICHD -3, 2018 )
Age of the participant at the time of migraine onset < 50 years
Confirmation of headache/migraine headache day frequency as follows:
a.History of, on average, ≥15 headache days per month in the 3 months prior to Visit 1 in the 
opinion of the investigator AND
b.≥15 headache days during the 4 -week screening/baseline period per the electronic diary 
(eDiary) AND
c.≥8 days during the 4 -week screening/baseline period that qualify as being a migraine day per 
the eDiary
Key Exclusion Criteria :
Has a history of migraine, accom panied by diplopia or decreased level of consciousness ,or retinal 
migraine as defined by ICHD -3, 2018
Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster 
headache), or painful cranial neuropathy as defined by ICHD -3, 2018
History of an inadequate response to > 4 medications (2 of which have different mechanisms of action) 
prescribed for the prevention of migraine (see Attachment 12.3)
Usage of opioids and/or barbiturates > 4days/month in the 3 months prior to Visit 1 per investigator’s 
judgment, or during the baseline period (barbiturates are excluded 30 days prior to screening, and for 
the duration of the study )(see Attachment 12.2)
Participant s with any clinically significant hematologic, endocrine, cardiovascular, cerebrovascular, 
pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Response Measures
Efficacy: Efficacy assessments w ill be based on information recorded by the participant. An eDiary will be used 
daily at home to collect data on headache frequency, duration, characteristics, and symptoms ; acute medication use
and triptan use , which will be collectively applied to define migraine days and headache days per the criteria listed 
in Sections 6.1.1 , 6.1.2 , and 6.1.3 .
Health Outcomes : Activity Impairment in Migraine –Diary ( AIM -D); Activity Level and Activity Limitation; 
Patient Satisfaction with Study Medication (PSSM) ; Headache Impact Test ( HIT-6); Migraine Disability 
Assessment ( MIDAS ); Patient Global Impression of Change ( PGIC ); Work Productivity and Activity Impairment 
Questionnaire: Migraine V2.0 ( WPAI:MIGRAIN E); European Quality of Life –5 Dimensional ( EQ-5D-5L); Patient 
Global Impression – Sev erity (PGI-S) ; Migraine Specific Quality of Life Questionnaire, Version 2.1 ( MSQ v2.1 ); 
Patient -Reported Outcomes Measurement Information Systems Pain Interference –Short Form 6a ( PROMIS -PI); 
and Patient Health Questionnaire ( PHQ -9).
Pharmacokinetics : Bloodsamples w ill be collected for pharmacokinetic ( PK)analysis for pa rticipant s who consent .
Safety : Adverse events ( AEs) , clinical laboratory determinations, vital sign measurements, physical examinations, 
electrocardiogram ( ECG )parameters, and the Columbia -Suicide Severity Rating Scale ( C-SSRS )
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
14General Statistical Methods and Types of Analyses:
All efficacy analyses will be performed using the modified intent -to-treat ( mITT )population, which consists of all 
randomized participants who received at least 1 dose of study intervention , had an evaluable baseline period of 
eDiary data and at least 1 evaluable postbaseline 4-week period (Weeks 1 to 4, 5 to 8, and 9 to 12) of eDiary data
during the double -blind treatment period . All safety analyses w ill be performed using the safety population, which 
consists of all participant s who took at least 1 dose of study intervention . The analysis population for off-treatment 
hypothetical estimand includes all randomized participants who received at least 1 dose of study intervention , had an 
evaluable baseline period of eDiary data and at least 1 evaluable postbaseline 4
-week period (Weeks 1 to 4, 5 to 8, 
and 9to 12) of eDiary data during the study , regardless of whether on study treatment or off study treatment. This 
population is used for the primary estimand to support filing in Europe .
For allregulatory submissions, the primary efficacy endpoint will be the same. However, secondary efficacy 
endpoint s will differ. 
Primary Efficacy Endpoint
The primary efficacy endpoint is the change from baseline in mean monthly migraine days across the 12 -week 
treatment period. Baseline is defined as the number of migraine days during the last 28 days prior to the 
randomization date.
The primary comparison between treatment groups will be done by a mixed-effects model for repeated measures 
(MMRM )of the change from baseline. The statistical model w ill include treatment group, visit, region, acute 
medications during the baseline period (medication overuse Y/N), current and past use of migraine prevention 
medications and the number of medications failed with unique mechanisms of action (Current Use and “ failed 0 
medications or failed 1 or more medication(s) with the same mechanism of action”, Current Use and “failed 2 to 4 
medications with different mechanisms of action”, Past Use only and “failed 0 medications or failed 1 or more 
medication(s) w ith the s ame mechanism of action”, Past Use only and “failed 2 to 4 medications with different 
mechanisms of action”, and Never Used ), and treatment group by visit interaction as categorical fixed effects. The 
statistical model will also include the baseline score and baseline -by-visit interaction as covariates. Anunstr uctured 
covaria ncematrixwillbeused to model thecovariance of wi thin-pa rticipant rep eated measuremen ts.The K enwar d-
Rogerapproxima tion ( Kenward1997) willbe used to estima tethedenominator deg reesoffreedom . The analysis
willbe performed based on allpostbaseline values using only the observedcases witho ut imputa tion o f missing
value s. Pairwise contrasts in the MMRM model will be used to make the pairwise comparisons of each atogepant 
dose to placebo.
Seconda ry Efficacy E ndpoints forall regions ,except Europe and Canada :
Change from baseline in mean monthly headache days across the 12 -week treatment period
Change from baseline in mean monthly acute medication use days across the 12 -week treatment period
At least a 50% reduction in 3-month average of monthly migraine days
Change from baseline in MSQ v2.1 Role Function -Restrictive domain s core at Week 12
Change from baseline in mean monthly Performance of Daily Activities domain score of the AIM-D across 
the 12 -week treatment period
Change from baseline in mean monthly Physical Impairment domain score of the AIM -D across the
12-week treatment period 
Secondary Efficacy En dpoints for Europe and Canada :
Change from baseline in mean monthly headache days across the 12 -week treatment period
Change from baseline in mean monthly acute medication use days across the 12 -week treatment period
At least a 50% reduction in 3-month average of monthly migraine days
Change from baseline in the HIT -6 total score at Week 12
Change from baseline in MSQ v2.1 Role Function -Restrictive domain score at Week 12
Allergan Confiden tial Protocol 3101-303-002 Amendment 3
15The secondary endpoints for headache days, acute medication use days, MSQ v2.1 Role Function -Restrictive 
domain score, Performance of Daily Activities domain score of the AIM -D, Physical Impairment domain score of 
the AIM -D
,and HIT -6 total score will be analyzed in the same manner as that used to analyze the primary endpoint. 
The secondary endpoint of 50% responders, d efined as participants with at least a 50% reduction from baseline in 
the 3 -month average of monthly migraine days, will be assessed for each individual. A logistic regression model will 
be used to analyze 50% responders across the 12 -week treatment period . This model assumes a binary distribution 
for the response and uses a logit link. The analysis model will include treatment group, region, acute medications 
during the baseline period (medication overuse Y/N), current and past use of migraine prevention m edications and 
the number of medications failed w ith unique mechanisms of action as categorical fixed effects; baseline value will 
be included as a covariate. The analysis will be performed based on all postbaseline values using only the observed 
cases wit hout imputation of missing values. The treatment difference in terms of odds ratio betw een each atogepant 
dose group and placebo w ill be estimated and tested from this model. 
A logistic regression model will be used to analyze 50% responders across the 12 -week treatment period. This 
model assumes a binary distribution for the response and uses a logit link. The analysis model w ill include treatment 
group, region , acute medications during the baseline period (medication overuse Y/N), current and past use of
migraine prevention medications and the number of medications failed with unique mechanisms of action as 
categorical fixed effects; baseline value will be included as a covariate. The analysis will be performed based on all
postbaseline values using only the observed cases without imputation of missing values. The treatment difference in 
terms of odds ratio betw
een each atogepant dose group and placebo w ill be estimated and tested from this model. 
Incidence of treatment emergent adverse events ( TEAEs )will be tabulated by primary system organ class ( SOC )
and by specific event within each primary SOC. TEAEs will be analyzed after treatment start on Day 1 through the 
end of the study.
Sample Size Calculation : A total sample size of 250 randomized partici pants per treatment group w ill provide at 
least 96% power to detect the treatment difference between each of the 2 atogepant doses (assumed equally 
effective) and placebo for the primary efficacy endpoint. This sample size was selected to provide sufficien t power 
for the first 3 secondary endpoints . The pow er calculation sarebased on the following assumptions: 
1) thetreatment difference from placebo w ill be similar to the average value across the CMprevention studies for 
Botox®(Aurora 2010 ,Diener 2010 ) and TEV -48125 ( Bigal 2015 , Silberstein 2017 ). In particular ,the assumed 
treatment difference from placebo in change from baseline in mean monthly migraine days across the 12 -week 
treatment period is -2 days, and the standard deviation is 5.5 days . 
2) the study statistical testing plan controls the overall type I error at 5%. The pow er calculations of the primary and 
secondary endpoints have taken the multi ple comparisons into consideration by testing each dose versus placebo at a 
0.025 significance level, 2 -sided. Once the primary endpoint for each dose is significant at 0.025, 2 -sided, the 
secondary endpoints will be tested sequentially.
Allergan Confidential Protocol 3101-303-002 Amendment 3
16Figure 1 Study Diagram
BID = twice daily; V = visit .             
   
       
    
   
   
               
          
   
   
   
    
    
   
   
   
                  
              
        
    
Allergan Confidential Protocol 3101-303-002 Amendment 3
17Table 1 Schedule of Visits and Pr ocedures 
Study PeriodScreening/
Baseline
(4 weeks)Double -blind Treatment Period (12 weeks)Follow -up 
Period 
(4weeks)
Visit #aVisit 1Visit 2 
(Randomization)Visit 3 Visit 4 Visit 5 Visit 6 Visit 7/ ETb Visit 8c
(End of Study)
Day/Week Week -4 Day 1Week 2 
(Day 14)Week 4 
(Day 28)Week 6 
(Day 42)Week 8 
(Day 56)Week 12 
(Day 8 4)Week 16
(Day 112)
Visit WindowsDay –35 to 
Day -28NA ± 3 day s ± 3 day s ± 3 day s ± 3 days + 3 days ± 3 days
Obtain Informed Consent and 
participant privacyX
Obtain Informed Consent for future 
biomedical research (optional)X
Obtain Informed Consent for PK 
(optional)X
Obtain VCT consent and perform 
verification (United States and 
Canada only)X
Access IWRS X X X X X X X X
Assess i nclusion/exclusion criteria X X
Collect demographic information X
Collect medical history X
Collect migraine history X
Revie w prior m edications including 
migraine prophylactic medication useX
Perform physical examination X X X
Collect vital sign measurementsdX X X X X X X X
Perform ECG X X X
Perform urine pregnancy testeX X X X X X X X
Collect start date (first day) of last 
menstrual cycle for w omen having 
menstrual cyclesX X X X X X X X
Collect urine drug screen X
Collect clinical laboratory 
determinationsf X X X X X X X X
Collect PK sample (for those 
participating)g X X X X X X
Allergan Confidential Protocol 3101-303-002 Amendment 3
18Study PeriodScreening/
Baseline
(4 weeks)Double -blind Treatment Period (12 weeks)Follow -up 
Period 
(4weeks)
Visit #aVisit 1Visit 2 
(Randomization)Visit 3 Visit 4 Visit 5 Visit 6 Visit 7/ ETb Visit 8c
(End of Study)
Day/Week Week -4 Day 1Week 2 
(Day 14)Week 4 
(Day 28)Week 6 
(Day 42)Week 8 
(Day 56)Week 12 
(Day 8 4)Week 16
(Day 112)
Visit WindowsDay –35 to 
Day -28NA ± 3 day s ± 3 day s ± 3 day s ± 3 days + 3 days ± 3 days
Collect blood for future biomedical 
research (for those participating)X
Provide eDiary, and eDiary 
instructions and trainingh X
Participant eDiary data col lection X
Revie w of medication compliance X X X X X
Revie w eDiary  data (headache 
duration, frequency, characteristics 
and symptoms ; acute medication use, 
AIM -D, activity level and activity 
limitation) and complianceiX X X X X X
C-SSRS (eTablet)jX X X X X X X X
ASC -12(eTablet)k,lX
HIT-6 (eTablet)k,lX X X X X
PGIC (eTablet)k,lX
PGI- S (eTablet)k,lX X X X
WPAI:MIGRAINE (eTablet)k,lX X X X
PSSM (eTablet)k,lX X X
EQ-5D-5LmX X X X X X X X
MIDAS (eTablet)k,lX X
MSQ v2.1 (eTablet)k,lX X X X X
PROMIS -PI (eTablet)k,lX X X X
PHQ -9 (eTablet)k,lX X
Collect eDiary XnXoXp
Dispense study intervention XqX X X X
Adverse events X
Concomitant medications/concurrent 
proceduresX
Allergan Confidential Protocol 3101-303-002 Amendment 3
19ASC -12 = 12 -item Allodynia Symptom Checklist; AIM -D = Activity Impairment in Migraine –Diary ; C-SSRS = Columbia Suicide Severity Rating Scale; 
ECG =electrocardiogram; eDiary  = electronic diary; EQ -5D-5L = European Quality of Life – 5 Dimensional; ET = early terminati on; eT ablet = electronic tablet ; 
HIT-6 = Headache Impact T est; INR = international normalized ratio; IWRS = interactive web response system; MIDAS = Migrain e Disability Assessment; 
MSQ v2.1 = Migraine Specific Quality of Life Questionnaire, V ersion 2.1; OL = open -label; PGIC = Patient Global Impression of Change; PGI- S = Patient 
Global Impression –Severity; PHQ -9 = Patient Health Questionnaire; PK = pharmacokinetic; PRO =patient -reported outcome; PROMIS -PI = Patient -Reported 
Outcomes Measurement Information System Pain Interference –Short Form 6a; PSSM = Patient Satisfaction with Study Medication; VCT = verified clinical 
trial; WPAI:MIGRAINE = W ork Productivity and Activity Impairment Questionnaire: Migraine V2.0.
aVisit 1 , Visit 2, and either Visit 3 or Visit 4 must be conducted in office. All other visits, should be conducted in office unless it is necessary to conduct 
remote visits for the safety of participants (eg, COVID -19 or other pandemic): for details please refer to the Remote Visit Schedule of Assessments in 
Attachment 12.4.
bEffort should be made by site to not schedule V isit 7 earlier than Day 85 to ensure that participants complete the full 12 weeks of treatment and have eDiary 
data through Day 84.
cAllparticipants who take at least 1 dose of study intervention must complete the follow -up period, except for participants rolling over into 
Study 3101 -312-002 (long -term safety extension study in regions excluding Japan and China), participants rolling over into Study 3101- 306-002 (long -term 
safety extension study in Japan) ,or Study 3101- 311 - 002 ( open -label safety extension study in China). For these rollover participants the Follow -up V isit will 
be performed after the completion of the OL treatment in the respective long-term safety extension study .
dVital sign measurement s:height , weight, sitting and standing pulse rate, respiratory rate, sitting and standing blood pressure , and body temperature. Height 
will be measured only at V isit 1.
eFor w omen of childbearing potential only , a urine pregnancy test will be performed at all visits
fClinical laboratory determinations include chemistry , hem atology , INR, and urinalysis to be collected for all visits. Samples for serology and the urine drug 
screen will be collected only at screening (V isit 1).
gPK sample should be collected pri or to the first dose at V isit 2. One sample should be collected prior to the morning dose during one of the V isits 3 to 7, and 
the remaining samples should be collected 1 to 10 hours postdose. 
hParticipant should begin using the eDiary as soon as it is d ispensed. If it is subsequently determined that the participant has failed entry criteria, the eDiary 
should be returned to the site.
iParticipants must bring the eDiary to visits and review with coordinators.
jClinicians will complete on eT ablet. The sc
reening/baseline assessment of the C -SSRS will be completed. At all other visits, the ‘Since Last V isit’ C-SSRS 
will be completed. 
kParticipant w ill com plete on eT ablet.
lPRO m easures should be administered prior to any tests and/or evaluations unless indicated otherw ise in the protocol (eg, during Randomization V isit2, 
some tests will be conducted prior to the PROs for eligibility).
mEQ-5D-5L will be given on eDiary during 7 days in the baseline period and during specific time periods for V isit 1 to 7, except at V isit 8 (W eek 16) where it 
will be administered on an eT ablet.
neDiary will be collected on V isit 2 for screen failures.
oCollected at V isit 7/ET only for participants who complete the double -blind treatment period.
pCollected at V isit 8/Fo llow-up only for participants who discontinue from the double -blind treatment period.
qThe first dose of study intervention should be taken at the study site.
Allergan Confidential Protocol 3101-303-002 Amendment 3
201. Back ground and Clinical Rationale 
1.1 Back ground
Migraine affects 18% of women and 6% of men in the U nited States with peak prevalence 
occurring between the ages of 25 to55 years. Approximately  one-third of patients with migraines 
have 3 or more migraine headaches per month, and over half report severe impairment or the 
need for bed rest ( Lipton 2007 ). In the U nited States alone, work loss due to migraine is 
estimated to cost ~ $13 billion annually  (Hu 1999). Prevalence is similar in Europe, with 
migraine headache affecting on average 17.6% of women and 8% of men (Stovner 2010). The 
prevalence of migraine in China is 8.9% ,with a similar distrib
ution across males and females as
the U nited States,according to the Guidelines for Prevention and Treatment of Migraine in 
China (Yu 2016). In Japan, the overall prevalence of migraine was reported as 8.4%; 5.8% was 
migraine without aura and 2.6% was migraine with aura ( Sakai 1997
).Like W estern countries, 
migraine is more prevalent among women in Japan; women were observed to have a 5.9 -fold 
higher risk of migraine than men ( Takeshima 2004 ).The Global Burden of Disease Survey  2010 
estimated the global prevalence of migraine to be 14.7%, making it the third most common 
disease in the world in both males and females ( Vos 2012
). Migraine was ranked seventh highest 
among specific cau ses of disability  globally  (Steiner 2013).
Migraine is ty pically  characterized by  attacks of throbbing, unilateral headache of moderate or 
severe pain intensit y, associated with nausea, vomiting, and/or sensitivity
 to light (photophobia) 
and sound (phonophobia). I n about 25% of individuals, the migraine headache is preceded by  
focal neurological d ysfunction (aura). Improving diagnosis and optimizing treatments for 
migraine have been recognized as critically  important to overcoming current barriers to reduce 
the global burden of migraine.
Because there are no biological markers for migraine, diagnosis is based on clinical history , 
exam ination , and the exclusion of other headache disorders. Phy sicians apply  clinical criteria to 
guide diagnoses and subsequent treatment. Episodic migraine (EM) is a s yndrome diagnosis 
applied to patients with migraine (with or without aura) who have 1 to 14 headache day s per 
month. CM is a specific ICHD -3 diagnosis applied to a subset of patients with ≥15 headache 
days per month ( Katsarav a 2012, Olesen 2006, ICHD -3 2018). Approximately  1.3% of the 
United States population (approximately  3 million people) and 1.3% to 2.4% of the European 
population suf fer from CM. CMis recognized as the population suf fering most from migraine 
and as a disabling, underdiagnosed, and undertreated disorder ( Bigal 2008). Studies have 
established that those suffering from CM have impaired qualit y of life a nd that they  suffer 
substantial socio -economic burden due to increased medical needs, referral to medical specialists, 
Allergan Confidential Protocol 3101-303-002 Amendment 3
21drug utilization, work absenteeism, and reduced ef fectiveness at work ( Blumenfeld 2011 ; 
Muna kata 2009).
This study  will evaluate the efficacy
, safet y and tolerability of atogepant in participants with CM.
1.2 Overview of Atogepant
Atogepant is a potent, selective oral CGRP  receptor antagonist being developed for migraine 
preventi on. CGR Pisaneuropeptide implicated in thepathoph ysiology  ofmigraine. CGR P
levels inthecranial venous outflow (ie, external jugular vein) areincreased durin g a migraine
attack and exogenous lyadministered CGR Phasbeen shown to trigger migraine- likeheadache in 
patients with migraine .The majorit y (80% to 90%) oftrigeminal Aδfibers thatinnervate the
dura contain CGRP ,
suggesting that these fibers may be involved insterile neurogenic
inflammation and migraine pain transmission. Furthermore, the CGRP receptor is present on 
human meningeal andcerebral blood vessels. These observations suggest that activation of the 
trigeminovascular s ystem, with release of CGRP , may p lay a ke y roleinmigraine pathogenesis
andthatinhibition ofCGRP may yield anovel therapeutic approach totreating migraine.
Theabilit y of CGR Pinhibition toinduce pain relief inthe acute treatment of migraine was
initially  observed with an IVformulation ofolcegepant (Olesen 2004 )andreplicated by Merck
&Co.,Inc. with anoral formulation of MK -0974 (telcagepant ), ahighlyselective CGR P
receptor antagonist. In Phase 3studie s,telcagepant was superior to placebo inthe primary  
endpoints of 2-hour pain freedom, 2- hour pain relief, and the absence of associated symptom s
(photophobia, phonophobia, andnausea), aswell asthekey secondar y endpoint of 24-hour
sustained pain freedom (Connor 2009 )
.However , serum ALT increases were observed with 
telcagepant. For this reason, the development of these oral CGRP  antagonists was stopped.
A Phase 2/3 clinical study (Stud y CGP- MD-01) was conducted, which compared atogepant 
10mg once dail y, atogepant 30 mg once dail y, atogepant 30 mg BID, atogepant 60 mg once 
daily  and atogepant 60 mg BID to placebo in EM prevention. Overall, all the atogepant doses 
tested were well tolerated and the AE profile of all atogepant doses did not significantl y differ 
from placebo. For the primary  efficacy  endpoint of cha nge from baseline in mean monthly  
migraine day s across the 12-week treatment period, all atogepant doses demonstrated a 
statistically  significant reduction compared to placebo in patients with EM.
Additional information on nonclinical pharmacology , toxicol ogy, and PK properties of atogepant 
can be found in the investigator ’s brochure.
Allergan Confidential Protocol 3101-303-002 Amendment 3
221.3 Study Rationale
The purpose of this stud y is to prospectively assess the safet y, tolerability  and ef ficacy  of 
atogepant doses 30mg BID and 60 mg once daily compared with placebo in the prevention of 
CM, in a randomized, double -blind, placebo -controlled, parallel -group, Phase 3 study . This study 
is designed to be a pivotal trial and will be used to support registration applications.
1.4 Rationale f or Doses and Dose Regimens Selected 
This study  will test 2 doses of atogepant, 30 mg BID and 60 mg once dail y, selected based on the 
results from Study CGP -MD-01 in patients with EM. All atogepant doses investigated in 
Study CGP- MD-01 demonstrated good safety  and tolerability . Whil st all atogepant doses also 
demonstrated a statistically  significant reduction from baseline in mean monthly  migraine day s 
across the 12-week treatment period compared to placebo, there was no clear dose- response 
relationship. However , there was a suggesti on that the BID regimen may  provide better ef ficacy  
than the once -daily regimen. The current stud y will therefore investigate both atogepant 30 mg 
BID; and the highest once daily  dose previousl y tested, atogepant 60 mgonce dail y,with a 
12-week treatment period.
1.5 Benefit/Risk  Assessment
Based on the currentl
y available data, atogepant has demonstrated ef ficacy  for the prevention of 
episodic migraine; in addition, atogepant has been well tolerated with no safety  concerns to date. 
The protocol is designed to ensure that patient safety  is assessed adequatel y throughout the stud y. 
An independent DSMB will review unblinded safety  data throughout the trial and make 
recommendations to the sponsor , including modification or early  termination of the trial, if 
emergin g data show unexpected and clinicall y significant adverse ef fects of treatment. Although 
this is a 12- week placebo -controlled trial, treatment for acute migraine is allowed during the 
study  and patients already  receiving a migraine prevention medication at screening can continue 
treatment during the study . Overall the assessment of benefit/risk is favorable.
2. Study Objectives and Clinical Hypotheses 
2.1 Study Objectives
To evaluate the safety  and tolerability  of atogepant 30 mg BID and atogepant 60mg once dail y 
for the prevention of CM.
To prospectivel y test for superiority of atogepant ( 30 mg BID and atogepant 60 mg once daily ) 
versus placebo for the prevention of CM.
Allergan Confidential Protocol 3101-303-002 Amendment 3
232.2 Clinical Hypotheses
In participant s with CM , at least one dose of atogepant (30 mg BID and at ogepant 60 mg once 
daily ) is superior to placebo as measured by  the change from baseline in mean monthly  migraine
days across the 12
-week treatment period.
Atogepant has an acceptable safet y profile and is well tolerated in participant s with CM .
3. Study Design
3.1 Structure
This is a multicenter , randomized, double -blind, placebo -controlled, parallel -group , Phase 3
study  conducted at approximately  140 sites worldwide. 
Approximately  750 participant s will be randomized to 1of 3treatment arms in a 1:1:1 ratio as 
follows:
Placebo (n = 250)
Atogepant 30 mg BID (n = 250)
Atogepant 60 mg once daily (n = 250)
Participan ts will be stratified b y:
Randomization will be stratified b y use of acute headache medications during the 
baseline period (acute headache medicatio n overuse Yes or No). Acute headache 
medication overuse (Yes) will be defined as follows: use of triptans on ≥10 day s OR 
use of ergots on ≥ 10 days OR use of simple analgesics (ie, aspirin, nonsteroidal 
anti-inflammatory  drugs [NSAI Ds], or acetaminophen) on ≥ 15 day s OR use of any  
combination of triptans, ergots or simple analgesics on ≥10 day s.
Approximately  70% of randomized participants will have taken at least 1 prior 
migraine prevention medication with proven efficacy  (see Attachment 12.3).2
Randomization will be stratified based on migraine prevention m
edication exposure 
(Current Use, Past Use, or Never Used) with proven efficacy . Participants with 
current or past use will be further stratified based on the number of medications failed 
                                                
2All French participants must have taken at least 1 prior migraine prevention medication with proven efficacy to be 
eligible for Study 3101 -303-002.
Allergan Confidential Protocol 3101-303-002 Amendment 3
24with unique mechanisms of action: “failed 0 medications or failed 1 or more 
medication(s) with the same mechanism of action” or “failed 2 to 4 medications with 
different mechanisms of action” (see Attachment 12.3). Enrollment of participants 
with current use of a migraine prevention medication will be ca
pped at ~15%.
oBelow are examples to illustrate how to implement the stratification based on 
prior m igraine prevention medications:
Example 1: Participant has taken metoprolol and propranolol. 
According to Attachment 12.3, these medications both belong to the 
beta-blocker pharmacologic category . This participant should be 
randomized to the “failed 0 medications or failed 1 or more 
medication(s) with the same mechanism of action” stratum.
Example 2: Participant has taken me toprolol, propranolol, and 
topiramate. According to Attachment 12.3, metoprolol and propranolol 
belong to the beta -blocker pharmacologic category a nd topiramate 
belongs to the antiepileptic pharmacologic category . This participant 
should be randomized to the 
“failed 2 to 4 medications with different 
mechanisms of action” stratum.
Example 3: Participant has taken metoprolol and topiramate. 
According t o Attachment 12.3, metoprolol belongs to the beta- blocker 
pharmacologic category  and topirama te belongs to the antiepileptic 
category ; however , the patient stopped both of these medications 
because of a change in health insurance coverage and therefore did not 
meet the failure definition for either medication. This participant 
should be randomized to the "failed 0 medications or failed 1 or more 
medi cation(s) with the same mechanism of action" stratum.
Randomization will be stratified b y regions (ie, North America, Europe, Japan, China, 
Other)
Participation will begin with a 4-week s creening/ baseline period. Participants who complete the 
4-week screening/ baseline period and meet all entry  criteria will be randomized to the 
double -blind treatment p eriod of this study  at Visit 2 (Randomization Visit). The double -blind 
treatment period will last 12 weeks, with a follow -up period of 4 additional weeks. 
There will be 8 scheduled clinic visits: Visit 1 ( screening/ baseline), Visit 2 ( randomization), 
Visit3 (W eek 2), V isit 4 (W eek 4), V isit 5 (W eek 6), V isit 6 (W eek 8), V isit 7/ ET (W eek 12), and 
Visit 8 ( follow -up). The V isit 8 (follow -up) must be compl eted for all participants who take at 
least 1 dose of stud y medication, except for participants rolling over into Study 3101 -
312-002 
(long -term safet y extension study in regions, excluding Japan and China), Study 3101 -306-002 
(long -term safet y extension st udy in Japan), or Study 3101
-311-002 ( open -label safety  extension 
study  in China). For these 
rollover participants Visit 8 of Study  3101-303 -002 is not required, 
Allergan Confidential Protocol 3101-303-002 Amendment 3
25because the Follow -up Visit (Visit 8) will be performed after the OL treatment in the respective 
long-term safet y stud y. For participants who screen fail for the long -term safet y stud y, the
Follow -up V isit (Visit 8) of Study 3101 -303-002 must be completed. For more details on study  
schedule , please see Table 1, Schedule of Visitsand Procedures.
3.2 Data Safety Monitoring Board
An independent DSMB will be established to review unblinded safet y data and summary reports, 
identify  any safety  issues and trends, and make recommendations to the sponsor , including 
modification or ETof the study , if emerging data show unexpected and clinically  significant AEs 
of treatment. 
Details of the DSMB memberships, standard operational procedures for data moni toring/review , 
frequency  of review , and other pertinent details will be provided in a separate DSMB Charter .
3.3 Adjudication Committee
An Adjudication Charter will be established and will describe the process for the blinded 
surveillance, monitoring, and adju dication b y the Clinical Adjudication Committee of events of 
post-treatment elevations of ALT and/or AST ≥ 3 × ULN in the atogepant program. The purpose 
of this committee charter will be to provide a standardized process for the adjudication of data 
associ ated with these events in order to determine whether the elevation was related to atogepant.
3.4 End of S tudy Definition
The end of the stud y is defined 
asthe date of the last visit of the last participant in the study . For 
Russia, end of study is defined as the last Close Out Visit.
4. Study Population and Entry Criteria
4.1 Number of P articipant s 
Approximately  750 participant s will be randomized at approximatel y 140 sites worldwide ( North 
America, Europe, Japan, China, Other
). 
Allergan Confidential Protocol 3101-303-002 Amendment 3
264.2 Inclusion Criteria
The following are requirements for entry  into the study : 
1.Written informed consent and participant privacy  information (eg, Written 
Authorization for Use and Release of Health and Research Study Information) 
obtained from the participant prior to initiation of any  study -specific procedures
2.Male or female participants ages 18 to 80 years, inclusive, at Visit 1
3.At least a 1- year history  of CMconsistent with a diagnosis ac cording to the 
ICHD -3, 2018
4.Age of the 
participant at the time of migraine onset < 50 y ears
5.Confirmation of headache/migraine headache day  frequency  as follows:
a.History  of, on average, ≥15 headache day s per month in the 3 months prior to 
Visit 1 in the opinion of the investigator AND
b. ≥ 15 headache day s during the 4 -week s creening/ baseline period per the 
electronic diary  (eDiary )AND
c.≥8 day s during the 4-week s creening/ baseline p eriod that qualify  as being a 
migraine day  per the eDiary
6.Completed at least 20 out of 28 day s in the eDiary  during baseline period and is able 
to read, understand, and complete the stud y questionnaires and eDiary per 
investigator ’s judgment
7.Participant s must be using a medicall yaccep table andeffective method of birth 
control during the course of the entire stud y,as defined in Section 4.4.3
4.3 Exclusion Criteria
The following are criteria for exclusion from participating in the stud y:
1. Dif ficult y distinguishing migraine headaches from tension -type or other headaches
2.Has a history  ofmigraine ,accompanied b y diplopia or decreased level of 
consciousness, or retinal migraine as defined b y ICHD -3, 2018
Allergan Confidential Protocol 3101-303-002 Amendment 3
273.Has a current diagnosis of new persistent daily  headache, trigeminal autonomic 
cephalgia (eg, cluster headache), or painful cranial neuro pathy as defined by ICHD -3, 
2018
4.History  of an inadequate response to > 4 medications (2 of which have dif
ferent 
mechanisms of action) prescribed for the prevention of migraine ( see
Attachment 12.3)
5.Currently  taking more than 1 medication with demonstrated efficacy  for the 
prevention of migraine OR participant s who a re taking 1 migraine prevention 
medication, but in the opinion of the investigator:
the dose has not been stable and/or the medication has not been well -tolerated 
for at least 12 weeks prior to Visit 1
the participant is not willing or able to maintain taking this medication at a 
stable dose and dosage regimen throughout the study
Note: T herapeutic or cosmetic botulinum toxin injections (eg, Dy sport®, 
Botox®, Xeomin®, Myobloc®, JeuveauTM) into areas of the head, face, or neck 
are excluded 6 months prior to screening and for the duration of the study
6.Requirement for an y medication, diet (ie , grapefruit juice), or non- pharmacological 
treatment that is on the list of prohibited concomitant medications or treatments (see 
Section 4.4.2 andAttachment 12.2) that cannot be discontinued or switched to an 
allowable alternative medication or treatment
7.Usage of opioids and/or barbiturates > 4 day s/month in the 3 months prior to Visit1 
per investiga tor’s judgment, or during the baseline period (barbiturates are excluded 
30 day s prior to screening and for the duration of the study )(see Attachment 12.2)
8.Woman is pregnant, planning to become pregnant during the course of the study , or 
currentl y lactating. W omen of childbearing potential must have a negative urine 
pregnancy  test at V isit 1 and Visit 2.
9.An ECG with clinically
 significant abnormalities at screening (V isit 1) as determined 
by the investigator
10.QTcF> 450 msec for males and QT cF > 470 msec for females at Visit 1 on the final 
central vendor ECG report 
Allergan Confidential Protocol 3101-303-002 Amendment 3
2811.Clinically  significant cardiovascular or cerebrovascular disease per the investigator ’s 
opinion including, but not limited to:
Clinically  significant ischemic heart disease (eg, unstable angina pectoris)
Clinically  significant cardiac rhy thm or conduction abnormalities (eg, atrial 
fibrillation, second -or third -degree heart block) or risk factors for Torsade de 
Pointes (eg, heart failure, hy pokalemia, brad ycardia)
Myocardial infarction, transient ischemic attack, or stroke within 6 months 
prior to Visit 1
Heart failure defined as New York Heart As sociation functional classification 
system, Class III or IV
12.Hypertension as defined by  sitting s ystolic BP> 160 mm Hg or sitting diastolic 
BP> 100 mm Hg at Visits 1 or Visit 2. Vital sign measurements that exceed these 
limits may  be repeated only  once .
13. C linically  significant laboratory  values OR an y of the following laboratory values at 
Visit 1:
ALT or AST > 1 ×ULN OR
tot
al bilirubin > 1 × ULN (except for participant s with a diagnosis of Gilbert’s 
disease) OR
serum albumin < 2.8 g/dL
14.Any clinically  signi ficant hematologic, endocrine, cardiovascular , cerebrovascular , 
pulmonary , renal, hepatic, gastrointestinal, or neurologic disease
If there is a history  of such a disease, but the condition has been stable for 
more than 1 year prior to Visit 1, and is judg ed by the investigator as not 
likely  to interfere with participation in the study , the participant may be 
included .
Participants on dialy sis for renal failure are excluded.
15.History  of acute hepatitis within 6 months of screening (V isit 1); or chronic hepatitis 
(including nonalcoholic steatohepatitis) ,or a positive result on anti -hepatitis A IgM 
antibody , hepatitis B surface antigen, anti
–hepatitis C antibody , or anti -hepatitis E 
IgM antibody  testing
Allergan Confidential Protocol 3101-303-002 Amendment 3
2916.In the opinion of the investigator , confounding psyc hiatric conditions, dementia, 
epilepsy  or significant neurological disorders other than migraine
17.Participant has an y other concurrent pain condition that, in the opinion of the 
investigator , may  significantly  impact the current headache disorder 
(eg, fibr omyalgia, facial pain)
18.Significant risk of self -harm based on clinical interview and responses on the C -SSRS, 
or of harm to others in the opinion of the investigator; participant s must be excluded 
if they  report suicidal ideation with intent, with or witho ut a plan, 
(ie, T ype 4 or 5 on the C -SSRS) in the past 6 months or report suicidal behavior in the 
6 months prior to Visit 1 or V isit 2 assessments
19.History  of malignancy  in the 5 y earsprior to Visit 1, except for adequatel y treated 
basal cell or squamous cell skin cancer , or in situ cervical cancer
20.History  of any  gastrointestinal prior procedures or gastrointestinal conditions 
(eg, diarrhea s yndromes, inflammatory  bowel disease) that may  affect the absorption 
or metabolism of study  intervention ; particip ants with prior gastric bariatric 
interventions (eg, Lap Band) which have been reversed are not excluded.
21.At V isit 1, a user of recreational or illicit drugs or has had a history  within the past 
year of drug or alcohol abuse or dependence
22.Positive result on the urine drug screen at V isit 1 unless explained by  concomitant 
medication use (eg, opioids prescribed for migraine pain)
23.Currently  participating or has participated in a study  with an investigational 
compound or device within 30 day s prior to Visit 1 (this includes studies using 
marketed compounds or devices)
24.Previous exposure to:
atogepant (AGN -241689 or MK80 31)OR
injectable monoclonal antibodies blocking the CGRP  pathway  within the past 
6 months OR
ubrogepant and took more than 3 doses of ubrogepant OR
rimegepant andtook more than 3 doses of rimegepant 
Allergan Confidential Protocol 3101-303-002 Amendment 3
3025.History  of hypersensitivity  or clinicall y significant adverse reaction to a CGRP  
receptor antagonist or hypersensitivity  to an y component of the study  interventio ns 
(atogepant or placebo)
26.Employ ed by or is an immediate famil y member (parents, spouses, siblings or 
children) of one of the investigators, stud y staf f, or the sponsor
27.Participant has a condition or is in a situation which in the investigator's opinion ma y 
put the participant at significant risk, may  confound the study  results, or may  interfere 
significantl y with participation in the study
28.Any medical or other reasons (eg, unlikely  to adhere to the study  procedures, keep 
appointments, or is planning to rel
ocate during the study ) that, in the investigator ’s 
opinion, might indicate that the participant is unsuitable for the study
4.4 Permissible and Prohibited Medications/T reatments
4.4.1 Permissible Medications/T reatments
Medications which are not specificall y prohibi ted in Section 4.4.2 are allowed, with the 
following clarifications and restrictions:
The following medications for the acute treatment of migraine are allowed during the study :
any triptan
any ergot derivative
any opioid
any other form of analgesic (including acetaminophen)
any NSAID agent
any antiemetic agent
Aspirin up to 325 mg/day  is allowed for cardiac prophy laxis.
SSRI sor SNRI swill be permitted provided that treatment is stable for at least 60 day s prior to 
screening (V isit 1) and continues without change in dose throughout the study .
Allergan Confidential Protocol 3101-303-002 Amendment 3
31Therap y considered necessary  for the participant 's welfare may  be given at the discretion of t he 
investigator . If the permissibility  of a specific medication/treatment is in question, please contact 
the sponsor.
4.4.2 Prohibited Medications/T reatments
The following medications are prohibited 30 day s prior to Visit 1 (unless otherwise indicated) 
and throughout the study  period: 
Strong and moderate CYP3A4 inhibitors, including but not limited to: sy stemic (oral/IV) 
itraconazole, ketoconazole, fluconazole ; erythromy cin, clarithrom ycin, telithromy cin3; 
diltiazem, verapamil; aprepitant, cy closporine, nefazodone3, cimetidine, quinine, and HIV 
protease i nhibitor s (see Attachment 12.2)
Strong and moderate CYP3A4 inducers, including but not limited to: barbiturates (eg, 
pheno barbital and primidone), s ystemic (oral/IV) glucocorticoids, nevirapine, efavirenz, 
pioglitazone, carbamazepine, phen ytoin, rifampin, rifabutin, and St. John’s wort (see 
Attachment 12.2)
Strong OATP1B1 inhibitors (eg, gemfibrozil3, cyclosporine ) 
Drugs with narrow ther apeutic margins with theoretical potential for CYP drug 
interactions (eg, warfarin)
Medications with demonstrated efficacy  for the prevention of migraine (eg, amitripty line, 
propranolol , topir amate )are prohibited when used for an y indication other than mi
graine 
prevention. See Attachment 12.3.
oParticipants taking onemedication with demonstrated efficacy  for the prevention 
of migraine may  be randomized p rovided that in the opinion of the investigator:
Dose has been stable and the medication has been well -tolerated for at 
least 12 weeks prior to Visit 1 AND
Participant is willing and able to maintain at a stable dose and dosage 
regimen during the stud y, which should be assessed to ensure compliance 
at each stud y visit
Enrollment of participants with current use of a migraine prevention 
medication will be capped at ~15%
                                                
3not approved in Japan
Allergan Confidential Protocol 3101-303-002 Amendment 3
32Therapeutic or cosmetic botulinum toxin injections (eg, Dy sport®, Botox®, Xeomin®, 
Myobloc®, Jeuveau™) into areas of the head, face, or neck within 6 months prior to 
Visit 1 and throughout the study  period
Acupuncture, noninvasive neuromodulation devices (eg, transcutanous supraorbital 
neurostimulator, single pulse transcranial magnetic stimulator, vagus nerve stimulator) , 
cranial traction, noci ceptive trigeminal inhib ition, occipital nerve block treatments, or 
dental splints for headache, within 4 weeks prior to entry  into the baseline phase at 
Week –4 or at an y time during the stud y (including the Week –4 to Day  1 baseline 
phase)
Injectable monoclonal antibodies blocking the CGRP pathway  (eg, Aimovig™, 
Emgalit y™, Ajovy®) within 6 months prior to Visit 1 and throughout the study  period
For China, South Korea, Japan , and Taiwan, herbal and traditional medicine is prohibited 
from the time the ICF is signed and for the d uration of study  participation.
Cannabidiol (CBD) oil, cannabis.
Therap y considered necessary  for the participant's welfare may  be given at the discretion of the 
investigator . The decision to administer a prohibited medication/treatment is done with the sa fety 
of the study  participant as the primary consideration. The sponsor should be notified about 
administration of prohibited medication/treatment as soon as possible.
4.4.3 Definition of Women of (Non- )Childbearing Potential and/or 
Acceptable Contraceptive Meth ods
For purposes of this study , women will be considered of childbearing potential unless they  are 
naturall y postmenopausal (ie, no menses for 2 years) or permanentl y sterilized (ie, bilateral tubal 
ligation, bilateral tubal occlusion [eg, Essure®placement4with HSG confirmation] , bilateral 
salpingectom y, bilateral oophorectom y, or hy sterectomy ). For women of childbearing potential 
who may  participate in the study , the following methods of contraception, if properl yused, are 
generally  considered highly  effective:
Combined (estrogen and progestogen containing) hormonal contraception such as oral, 
intravaginal4, or transdermal4(ie,pill, patch4, vaginal ring4)
Progestogen -only hormonal contraception (with inhibition of ovulation) that are oral, 
injectable4, or implantable4
                                                
4Contraceptive methods not approved in Japan
Allergan Confidential Protocol 3101-303-002 Amendment 3
33IUD or IUS
Vasectomized partner (provided that the partner is the s ole sexual partner of study  
participant and that the vasectomized partner has received medical assessment of the 
surgical success)
Sexual abstinence , defined as refraining from heterosexual intercourse for the entire 
duration of the study ,from Visit 1 thr ough the end of study  (Visit 8/Follow -up Visit) 
oNote: Periodic abstinence (calendar, s ymptothermal, post -ovulation methods) is 
not an acceptable method of contraception . The reliability  of sexual abstinence 
should be evaluated in relation to the duration of the clinical trial and the 
preferred and usual lifesty le of the subject . 
Acceptable birth control methods which may  not be considered as highl y effective:
Progestogen -only oral hormonal contraception (where inhibition of ovulation is not the 
primary  mode of action)
Male or women condom with or without spermicide4(women and male condoms should 
not be used together)
Cap4, diaphragm4,or sponge4with spermicide
A combination of male cond om with either cap4, diaphragm4,or sponge4with spermicide 
(double barrier methods) are also considered acceptable, but not highl y effective, birth 
control methods
For males who may  participate in the study , the following methods of contraception, if properl y 
used, are generall y considered reliable: post
-bilateral vasectom y, barrier contraception, or sexual 
abstinence. Male participants must also refrain from donating sperm during the course of the 
study .
The investigator and each participant will determine the appropriate method of contraception for 
the participant during the participation in the study .
If a woman becomes pregnant during the study , the investigator will notify  the sponsor
immediately after the pregnancy  is confirmed and the participant will be exited from the study  
after appropriate follow -up. The investigator will (1) notify the participant’ s phy sician that the 
participant was being treated with an investigational dru g atogepant , and (2) follow the progress 
of the pregnancy . The investigator must document the outcome of the pregnancy  and provide a 
copy  of the documentation to the sponsor.
Allergan Confidential Protocol 3101-303-002 Amendment 3
344.4.4 Special Diet or Activities 
Participant s should refrain from consuming grapefruit or grapefruit juice from the time the 
consent form is signed until completion of the study . Participant s should also refrain from 
making significant changes to their diet or caf feine intake during the study .
Alcohol intake should be limited to no more tha n 1 drink per day  throughout the study . A drink is 
defined as a 12 -ounce (or 355 mL )can/bottle of beer , a 4-ounce (or 118 mL) glass of wine, or 
1ounce (or 30 mL) of liquor .
4.5 Screen Failures
Screen failures are defined as participants who consent to partic ipate in the study  but are not 
subsequently  randomized to treatment. Rescreening of screen failures is permitted in certain 
situations (ie, failure to adequatel y screen due to 
COVID -19), with permission from the sponsor.
However , participants with clinical ly significant laboratory  values at Visit 1 ( ie, screening; 
including ALT or AST >1 × the ULN, total bilirubin > 1 ×ULN or serum albumin < 2.8g/dL), or 
those with a positive UDS result atVisit 1 for recreational (including marijuana regardless of 
legality ) or illicit drugs or non -disclosed5concomitant medications are not allowed to be 
rescreened.
5. Study Interventions 
5.1 Study Interventions and Formulations
Tablets containing atogepant 30 mg (Formulation Number 1 1280X) or atogepant 60 mg 
(Formulation Number 1 1281X).
5.2 Contr ol Interventions and Formulations
Tablets containing matching placebo 30 mg (Formulation 01 1326X) for atogepant 30mgand 
matching placebo 60 mg for atogepant 60mg (Formulation 01 1317X).
                                                
5For participants in the People’s Republic of China, a p ositive UDS will result in screen failure regardless of 
disclosed concomitant medications.
Allergan Confidential Protocol 3101-303-002 Amendment 3
355.3 Methods for Maski ng/Blinding
A double -dummy  design will be used to maintain the blind. All study  interventions will be 
provided in identical blister cards to maintain masking of the stud y.
All participants will be instructed to take their study intervention twice daily (ie, 2 tablets in the 
morning and 2 tablets in the evening) at approximately  the same times each day . Participants, 
therefore, will receive either placebo BID, atogepant 30 mg BID, or a morning dose of atogepant 
60
mg with an evening dose of placebo.
5.4 Treatment Allocation Ratio and S tratification
Approximately  750 participant s will be randomized to one of three treatment arms in a 1:1:1 
ratio as follows:
Placebo (n = 250)
Atogepant 
30mg BID (n = 250)
Atogepant 60 mg once daily (n = 250)
Participant will be stratified by :
Randomization will be stratified b y use of acute headache medications during the 
baseline period (acute headache medication overuse Yes or No). Acute headache 
medication overuse (Yes) will be defined as follows: use of triptans on ≥ 10 day s OR use 
of ergots on ≥10 day s OR use of simple analgesics (ie, aspirin, NSAIDs , or 
acetaminophen) on ≥ 15 day s OR use of any  combination of triptans, ergots
, or simple 
analgesics on ≥10 day s.
Approximately  70% of randomized participants will have tak en at least 1 prior migraine 
prevention medication with proven efficacy  (see Attachment 12.3)6. Randomization will 
be stratified based on migraine prevention medication exposure 
(Current Use, Past Use, 
or Never Used) with proven efficacy . Participants with current or past use will be further 
stratified based on the number of medications failed with unique mechanisms of action: 
“failed 0 m edications or failed 1 or more medication(s) with the same mechanism of 
action” or “failed 2 to 4 medications with different mechanisms of action” (see 
Attachment 12.3). Enro llment of participants with current use of a migraine prevention 
medication will be capped at ~15%.
                                                
6All French participants must have taken at least 1 prior migraine prevention medication with proven efficacy to be 
eligible for Study 3101 -303-002.
Allergan Confidential Protocol 3101-303-002 Amendment 3
36oBelow are examples to illustrate how to implement the stratification based on 
prior migra ine prevention medicati ons:
Example 1: Participant has taken metoprolol and propranolol. According 
to Attachment 12.3, these medications both belong to the beta -blocker 
pharmacologic category . This participant should be randomized to the 
“failed 0 medications or failed 1 or more medication(s) with the same 
mechanism of action” stratum.
Example 2: Pa rticipant has taken metoprolol, propranolol, and topira mate. 
According to Attachment 12.3, metoprolol and prop r anolol belong to the 
beta-blocker p harmacologic category  and topira mate belongs to the 
antiepileptic pharmacologic category . This participant should be 
randomized to the “failed 2 to 4 medications with different mechanisms of 
action” stratum.
Example 3: Participant has taken metoprolol and topira mate. According to 
Attachment 12.3, metoprolol belongs to the beta- blocker p harmacolog ic 
category  and topira mate belongs to the antiepileptic category ; however , 
the patient stopped both of these medications because of a change in 
health insurance coverage and therefore did not meet the failure definition 
for either medication. This particip ant should be randomized to the "failed 
0 medications or failed 1 or more medication(s) with the same mechanism 
of action" stratum.
Randomization will be stratified b y regions (ie, North America, Europe, Japan, China, 
Other)
5.5 Method for Assignment to Treatment Gr oups/Randomization
Prior to initiation of study intervention , each 
participant who provides informed consent will be 
assigned a participant number that will serve as the participant identification number on all study  
documents.
At the time of r andomization (V isit 2), eligible participant s will be randomized in a 1:1:1 ratio 
into the following arms: placebo, atogepant 30mg BID, or atogepant 60mg once dail y.
All participants will be centrall y assigned to randomized study  intervention using an IW RS. 
Before the stud y is initiated, log in information and directions for the IWRS will be provided to 
each site.
Study intervention will be labeled with medication kit numbers. The I WRS sy stem will provide 
the site with the specific medication kit number(s ) for each randomized participant at the time of 
randomization. Sites will dispense study  intervention according to the IWRS instructions. Sites 
Allergan Confidential Protocol 3101-303-002 Amendment 3
37will also log onto the I WRS at subsequent visits to obtain a kit number for dispensing study  
intervention . Site s will receive the IWRS confirmation notifications for each transaction. All 
notifications are to be maintained with the study  source documents.
Study intervention will be dispensed at the stud y visits summarized in Table 1, Schedule of Visits 
and Procedures .Returned study  intervention should not be re -dispensed to the participants.
5.6 Study Intervention Regimen and Dosing
Treatments to be used in this trial are listed in Table 2. Participant s who meet all the study  entry  
criteria at V isit 2 will be randomized and provide d with study  intervention to be taken on an 
outpatient basis. Sites will subsequently  dispense study  intervention to participant s at V isits 3, 4, 
5, and 6. Participant s will take their first dose of study  intervention at the clinic at Visit 2. All 
particip
ants will be instructed to take their stud y intervention twice daily (2 tablets in the 
morning and 2 tablets in the evening) at approximately  the same times each day . Details of PK 
samples with respect to timing of study  intervention are provided in Section 6.3. Study 
intervention will be administered orall y for 12 weeks, and participants will be followed for 
4weeks following stud y completion or discontinuation of study  intervention.
Table 2 Study Interventions
Drug/DoseStudy Intervention Product and Matching 
PlaceboStudy 
Intervention 
FrequencyRoute of 
Administration
Placebo Placebo 30 mg and Placebo 60 mg BID Oral
Atogepant 30 mg Atogepant 30 mg and Placebo 60 mg BID Oral
Atogepant 60 mg AM: Atogepant 60 mg and Placebo 30 mg
BID Oral
PM:  Placebo 30 mg and Placebo 60 mg
AM = morning dose; BID = twice daily; PM = evening dose.
Allergan Confidential Protocol 3101-303-002 Amendment 3
385.7 Storage of S tudy Interventions
The study  intervention must be stored at room temperature in a securel y locked cabinet. Further 
details regarding the storage of the stud y intervention are in the Stud y Reference Manual.
6. Response Measures and Summary of Data Collection Methods
6.1 Efficacy Measur es
Efficacy  assessments will be based on information recorded by  the 
participant. An eDiary  will be 
used daily  at home to collect data on headache frequency , duration, characteristics, and
symptoms ; acute medication use and triptan use, which will be collectivel y applied to define 
migraine day sand headache day s per the criteria listed in Sections 6.1.1 , 6.1.2 ,and 6.1.3 . 
The AIM-D, Activity  Level, and Activity  Limitation will also be collected daily  via an eDiary . 
EQ-5D- 5L will also be collected via an eDiary  for a period of 1 week in the screening period 
(administered on Study Day 22 through 28 for a total of 7 day s after screening), randomization 
(Study Day 1) until Visit 3 (14 consecutive day s from randomization), Visit 4 (± 3 day s,ie, Study 
Days 25 to 31from randomization for a total of 7 day s), Visit 5 (± 3 day s,ie, Study Days 39 to 
45 from randomization for a total of 7 day s), Visit 6 (± 3 day s,ie, Study Days 53 to 59 from 
randomization for a total of 7 day s), and Visit 7 ( - 7days,ie, Study D ays 77 to 83from 
randomization for a total of 7 day s). At V isit 8, the EQ -
5D-5L will be administered on an eT ablet.
Additi onal health outcome measures, namel y, the PSSM scale, HI T
-6, M IDAS, PGI C, 
WPAI:MIGRAINE, PGI -S, MSQ v2.1, P ROMI S-PI, and PHQ -9 will also be administered onan 
eTablet at specified clinic visits.
6.1.1 Migraine Day
A migraine day  is defined as an y calendar day on which a headache occurs which meets criteria 
A, B, and C OR meets criteria D and E, as listed below , as per participant eDiary . Calendar day s 
begin at midnight and last until 1 1:59 PM (23:59). 
A.Headache has at least 2of the following 4 characteristics:
i. Unilateral location
ii. Pulsating quality
iii. Moderate or severe pain intensity
iv. Aggravated by or causing avoidance of routine physical activity (eg, walking or 
climbing stairs)
Allergan Confidential Protocol 3101-303-002 Amendment 3
39B.At least 1of the following:
i. Nausea and/ or vomiting 
ii. Photophobia and phonophobia 
iii. Typical aura (ie, visual, sensory , or speech/language) accompany ing or within
60minutes before headache begins
C.Duration of headache lasting 2 hours or longer on a calendar day  unless an acute, 
migraine-specific medication (ie, triptan or ergot derivative) was used after the start of 
the headache, in which case no minimum duration will be specified
OR
D.Any headache which fulfills 1criterion from (1) and at least 1criterion from (2) 
OR 
fulfills at least 2 criteria from (1) and no criteria from (2).
1) Headache characteristics:
i.Unilateral location
ii.Pulsating quality
iii.Moderate or severe pain intensity
iv.Aggravated b y or causing avoidance of routine physical activity 
(eg,walking or climbing stairs)
2)Symptoms:
i.Nausea and/or v omiting
ii.Photophobia and phonophobia
iii.Typical aura (ie, visual, sensory , or speech/language) accompany ing or 
within 60 minutes before headache begins
E.Duration of headache lasting 2 hours or longer on a calendar day  unless an acute, 
migraine- specific medication (ie, triptan or ergot derivative) was used after the start of 
the headache, in which case no minimum duration will be specified.
6.1.2 Headache Day
A headache day  is defined as any calendar day  on which headache pain lasting 2 hours or longer 
occurs unless an acute headache medication (eg, ibuprofen, triptan) was used after the start of the 
headache, in which case no minimum duration will be specified. Calendar day s begin at midnight 
and last until 1 1:59 PM (23:59).
Allergan Confidential Protocol 3101-303-002 Amendment 3
406.1.3 Acute Medication Use Day and Triptan Use Day
An acute medication use day  is defined as any  day on which a participant reports , per eDiary , the
intake of allowed medication(s) to treat an acute migraine. The allowed medications include the 
following categories of drugs: triptans, ergots, opioids, analgesics (including acetaminophen), 
NSAIDs (including aspirin), and antiemetics.
A triptan use day  is defined as an y day  on which a participant reports intake of a triptan to treat a 
migraine per participant diary .
6.2 Heal th Outcomes Measures
6.2.1 Activity Impairment in Migraine –Diary (AIM-D)
The AIM-D is an 1 1-item daily  diary  measure that assesses the impact of migraine and is 
comprised of two domains that evaluate performance of daily  activities (7 items) and ph ysical 
impairment (4 items). Participants are asked to rate the level of dif ficult y experienced in the past 
24 hours with performance of daily  activities (ie, dif ficulty  with household chores, errands, 
leisure activities at home, leisure or social activities outside the home, strenuous phy sical 
activities, concentrating, and thinking clearl y) and phy sical impairment (ie, dif ficulty  walking, 
moving bod y, bending forward, moving head) using the 6-point rating scale :“Not dif ficult at 
all,” “A  little dif ficult,” “Somewhat dif ficult,” “V ery difficult,” “Extremely  difficult,” and 
“Icould not do it at all.” Three items include a response of “I did not…,” for example, “I did not 
have errands planned.” The AIM
-D was developed as an electronic dail y diary  with the same set 
of questions administered in headache and non -headache versions. The Headache version is 
administered on day s when a participant reports a headache and the Non -Headache version is 
administered on day s when a participant does not report having a headache. The AIM-D instructs 
participants to answer each question based on the level of dif ficulty  experienced in the past 
24hours for both versions, with “during your headache” indicated for the AIM-D Headache 
version. In addition to the tw o domain scores, a total score using all 1 1 items can also be 
calculated. Each raw daily domain score, as well as the raw dail y total score, are transformed to a 
0-100 scale, with higher scores indicating greater impact of migraine (ie, higher disease burd en).
6.2.2 Activity Level and Activity Limitation
Twoitems based on a 24 -hour recall will be administered dail y using Headache and 
Non-
Headache versions as additional health outcome measures and for evaluation of the AIM-D. 
The first item will be used to assess activity  level within the past 24 hours with a 5- level 
response ranging from “No activity  –Spent all day  lying down” to “Exercised –Brisk walk, 
Allergan Confidential Protocol 3101-303-002 Amendment 3
41running, jogging, biking or other activity  for 30 or more minutes.” The second item will be used 
to evaluate activity  limitation with a 5-level response ranging from “Not at all limited –I could 
do every thing” to “Extremely  limited.”
6.2.3 Patient Satisfaction with S tudy Medication (PSSM)
Overall satisfaction with the study  medication for prevention of migraine will be assessed using a 
single item and a 7 -point rating scale ranging from extremely  satisfied (0) to extremely  
dissatisfied (6). 
6.2.4 Headache Impact Test(HIT -6)
The HIT -6is a 6 -question assessment used to measure the impact headac hes have on a 
participant ’s ability  to function on the job, at school, at home ,and in social situations. I t assesses 
the ef fect that headaches have on normal daily  life and the participant ’s ability  to function. 
Responses are based on frequency  using a 5- point scale ranging from “ never ”to “alway s.”The 
HIT-6 total score, which ranges from 36 to 78, is the sum of the responses –each of which is 
assigned a score ranging from 6 points (never) to 13 points (alway s).
6.2.5 Migraine Disability Assessment (MIDAS)
TheMIDAS is a 7- item questionnaire designed to quantify headache -related disability  over a 
3-month period. The MIDAS score is the sum of missed work or school days, days at work or 
school plus day s of household work where productivity  was reduced by  half or 
more, missed 
household work day s, and missed non -work activity  days due to headaches in the last 3 months.
6.2.6 Patient Global Impression of Change (PGIC)
The PGI C is a single item questionnaire used to measure the participant ’s impression of overall 
change in migraine since the first dose of study  medication. The measure uses a 7 -point rating 
scale with responses ranging from “very  much better” to “very  much worse.”
6.2.7 Work Productivity and Activity Impairment Questionnair e: 
Migraine V2.0 (WPAI:MIGRAINE)
The WP AI:MIGRAINE will be used to assess work productivity  specific to migraine. The
measure uses a 1-week recall and contains 6questions related to work productivity . The WPAI 
measures both presenteeism and absenteeism. The measure yields four scores expressed as 
impairment percentages ranging from 0 to 100%: Percent work time missed, percent impairment 
Allergan Confidential Protocol 3101-303-002 Amendment 3
42while working, percent overall work impairment, and percent activity  impairment due to 
migraine.
6.2.8 European Quality of Life –5 Dimensional (EQ-5D-5L)
EQ-5D- 5L is a generic instrument for use as a measure of health status. The EQ -5D- 5Lconsists 
of 2 components –the EQ -5D descriptive sy stem and the EQ VAS.The descriptive sy stem 
comprises 5 dimensions (mobility , self -care, usual activities, pain/discomfort, and 
anxiety /depression). The respondent is asked to indicate his/her health state by ticking (or 
placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. 
The scoring range of the EQ -5D descriptive s ystem is ty picall y from 0 (dead) to 1 (full health). 
The EQ V AS records the respondent’s self- rated health on a vertical VASwhere the endpoints 
are labelled “Best imaginable health state” and “Worst imaginable health state.” The scoring 
range of the EQ V AS is from 0 (worst imaginable health) to 100 (best imaginable health).
6.2.9 Patient Global Impression –Severity (PGI -S)
The PGI -S is a single item questionnaire used to measure the participant ’s impression of severit y 
in relation to migraine s ymptoms overall at the time of administration of the measure. The 
measure uses a 5- point rating scale with responses ranging from “none” to “very  severe.”
6.2.10 Migraine Specific Quality of Life Questionnair e, Version 2.1
(MSQ v2.1)
The MSQ v2.1 is a 14 -item questionnaire designed to measure health -related quality -of-life 
impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role 
Function Restrictive assesses how migraines limit one’ s d
aily social and work- related activities; 
Role Function Preventive assesses how migraines prevent these activities; and the Emotional 
Function domain assesses the emotions associated with migraines. Participant s respond to items 
using a 6 -point scale rangin g from “none of the time” to “all of the time.” Raw dimension scores 
are computed as a sum of item responses and rescaled to a 0 to100 scale, where higher scores 
indicate better quality  of life.
6.2.11 Patient-Reported Outcomes Measur ement Information System Pain 
Interference –Short Form 6a (PROMIS -PI)
The PROMI S-PI measures self -reported interference of pain on relevant aspects of dail y life (ie, 
social, cognitive, emotional, phy sical, recreational) over the past 7 day s. A 5-level response scale 
Allergan Confidential Protocol 3101-303-002 Amendment 3
43for all six items ranges from “Not at all” to “ Very much.” Scores range from 6 to 30, with higher 
scores indicating greater pain interference.
6.2.12 Patient Health Questionnaire (PHQ -9)
The PHQ -9 is a concise, self -administered, validated, screening and diagnostic tool for mental 
health disorder , which has been field- tested in of fice practice. The screener is quick and user-
friendl y, improves the recognition rate of depression ,and facilitates diagnosis and treatment. The 
PHQ -9 consists of the 9 diagnostic criteria for depressive disorders in the past 2 weeks from the 
DSM -IV . Participant s are asked to indicate the frequency  with which they  have been bothered by  
9 symptoms of depressive disorders over the previous 2 weeks, on a 4 -point scale: 0 (not at all), 
1 (several day s), 2 (more than half the day s), and 3 (nearl y every  day). The total score ranges 
from 0 to 27 (from best to worst). A score of 15 to 19 is considered as moderatel y severe 
depression and 20 to 27 as severe depression.
6.3 Pharmacok inetics Measures
A blood sample 
for PK analysis will be collected on site at Visits 2, 3, 4, 5, 6, and 7/ET  from 
participant s who consent to participate in the PK substudy . Participants can withdraw consent at 
any time and should have no further PK samples collected. Each participant in the PK substudy  
will be asked to provide a total of 6 blood samples (1 per visit); At V isit 2, the sample should be 
collected prior to the initial dose of stud y intervention taken at the clinic. During 1 of the V isits 3 
to 6, the sample should be collected prior to the morning dose of study  intervention (participant
should wait to take the morning dose in the clinic after PK sample collection) ,and the samples 
collected at the remaining visits should be collected 1 to 10 hours post the morning dose and 
prior
to the evening dose . At V isit 7 the sample should be collected 1 to 10 hours post the 
morning dose.
The date and time of collection of each PK sample will be recorded in the eCRF . In addition, for 
each of the PK samples collected (except the V isit 2 sampl e) the date and time of the 2dosesof 
study  intervention prior to the PK sample should be recorded. PK samples will be collected, 
stored (frozen) ,and shipped according to instructions provided in the Study Reference Manual.
The treatment codes will be provided to the bioanaly tical lab using a secure process, ensuring no 
one outside the bioanal ytical team is unblinded, to allow only  atogepant- treated participant PK 
samples to be anal yzed. The bioanal ytical method for the determination of individual plasm a 
concentrations of atogepant and the performance of the assay during validation and sample 
analysis will be summarized in a separate bioanaly tical report, including the results obtained 
Allergan Confidential Protocol 3101-303-002 Amendment 3
44from anal ysis of the PK samples. The bioanaly tical report will be appended to the integrated 
clinical study report. 
6.4 Future Biomedical Research
Blood samples will be collected from all participants who consent to participate in the substudy , 
for the purposes of future biomedical research. The samples will be obtained at the Screening
Visit. All samples will be sent to the designated central laboratory  and shipped to a biorepository  
for storage. Please refer to the Central Laboratory  Manual for the genetic blood sampling 
procedures, shipping instructions, and contact information. Anony mized samples may  be stored 
in the biorepository  database for potential anal ysis under separate protocols for up to 15 years. 
Samples may  be stored for a longer time if a regulatory  or governmental authority  has active 
questions that are being answered. Inthis special circumstance, samples will be stored until these 
questions have been adequately  addressed. The anony mized genetic material from the blood 
samples may  also be used for future, unspecified research, not limited to the disease being 
studied in this particular clinical study .
All participant s enrolled in the clinical trial will be considered for enrollment in the future 
biomedical research substudy ; however , participation is optional and will require a separate ICF . 
A participant who ini tially  consents can withdraw that consent at any  time and have his or her 
sample destro yed including an y by-products of the sample whenever possible.
6.5 Safety Measures
6.5.1 Adverse Events
Subjective AEs will be collected from the time of consent through the last visit. For all AEs, the 
investigator must provide an assessment of the severit y, causal relationship to the investigational 
product, start and stop date, and seriousness of the event (eg, SAE), document all actions taken 
with regard to the investigational product, and detail any  other treatment measures taken for the 
AE. For events noted as SAEs, the sponsor must be notified immediatel y to meet their reporting 
obligations to appropriate regulatory  authorities.
6.5.2 Adverse Events of Special Interest
Selected non
-serious and SAEs are of special interest and will require immediate reporting, 
recording ,and follow -up. The following events will be closely  monitored:
Allergan Confidential Protocol 3101-303-002 Amendment 3
45Treatment -emergent suicidal ideations with intent, with or without a plan, (ie, Ty pe 4 or 5 on 
the C -SSRS) or any  suicidal behaviors 
Treatment -emergent e levated ALT or AST lab value that is ≥ 3 × ULN
Potential Hy ’s law cases: elevated ALT or AST lab value that is ≥ 3 × ULN and an elevated 
total bilirubin lab value that is ≥ 2 × ULN and, at the same time, an alkaline phosphatase lab 
value that is < 2 ×ULN.
Reporting requirements for ALT or AST elevations and potential Hy ’s law cases are outlined in 
Sections 9.5and9.5.1. Responses to the C - SSRS that meet the above criterion will captured on 
the eT ablet and monitored by  the sponsor. These AEs or e vents that are determined to be SAEs 
must be reported appropriately  via the designated eCRF and 
safet y forms. 
6.5.3 Clinical Laboratory Determinations
Blood and urine samples for clinical laboratory  tests will be collected at the visits outlined in 
Table 1. Hematology , chemistry , coagulation parameters (INR), and urinaly sis will be conducted 
at these visits. Serology  and the urine drug screen w ill be conducted at screening (V isit1). The 
investigator will assess the clinical significance of an y values outside the reference ranges 
provided b y the central laboratory. Participant s with abnormalities judged to be clinicall y 
significant laboratory  values that meet exclusionary  criteria ,
orpositive results on the urine drug 
screen at s creening (V isit 1) ,will be excluded from the study . 
Women of childbearing potential will be required to have a urine pregnancy test at all visits. A 
positive pregnancy test at Visit 1 or Visit 2 will exclude the participant from the study .
Investigators may  also perform unscheduled clinical laboratory  determinations at any  time for 
the purpose of participant safet y. 
Participant s are not required to fast overnight before coming in for their appointments.
The clinical laboratory  parameters to be measured are shown in Table3.
Allergan Confidential Protocol 3101-303-002 Amendment 3
46Table3 Clinical Laboratory Parameters
Category Parameter
ChemistrySodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, creatinine, total 
bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, 
lactate dehydrogenase, creatine kinase, total protein, albumin, calcium, phosphorus, uric 
acid, total cholesterol. The estimated glomerular filtration rate w ill be calculated by the 
central laboratory
Hem atologyHem oglobin; hematocrit; red blood cell count; red blood cell indices (mean corpuscular 
volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concent ration); 
white blood cell count including differential (neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils); platelet count
UrinalysisUrine dip stick for specific gravity, pH, protein, glucose, ketones, bilirubin, and blood; 
microscopic exam including red blood cells/high -power field, w hite blood cells/high -power 
field, and casts/low -power field
Coagulation International normalized ratio
Serolog yAt Visit 1 only: anti -hepatitis A IgM antibody, hepatitis B surface antigen, anti -hepatitis C 
antibody , anti -hepatitis E IgM antibody
Urine Drug ScreenScreening for drugs of abuse (eg, marijuana, cocaine, phencyclidine, amphetamines, 
benzodiazepines, b arbiturates, opiates) w ill be conducted using a urine drug screen at 
Visit 1. UDS positive for recreational (including marijuana regardless of legality) or illicit 
drugs or non -disclosed concomitant medications are not allow ed to be repeated. All other 
positive urine drug screens may be repeated w ith permission from the sponsor ; a negative 
result or an explanation of a positive result due to concomitant medication use (eg, opioids 
prescribed for migraine pain) will be required for randomization.
IgM = immunoglobulin M .
Please note: For participants in the People’ s Republic of China , apositive UDS will result in screen failure 
regardless of disclosed concomitant medications.
A central laboratory  will be used to evaluate all urine and blood samples, which will be collected, 
processed, and stored according to the instructions provided by the laboratory .
6.5.4 Vital Signs
Vital sign measurements, including sitting and standing BP , sitting and standing pulse rate, 
respiratory  rate, temperature, body  weight, and height (at Visit 1 only ), will be performed at 
every  visit. Sitting and standing BP  and pulse rate will be determined as follows: BP  and pulse 
measurements will be performed after the participant sits quietly  for 5 minutes, followed by  a 
second set of measurements taken after the participant stands for at least 3 minutes (but no longer 
than 10 minutes).
6.5.5 Physical Examination
A complete phy sical examination will be performed at the visits outlined in Table 1. A 
professionall y trained phys ician or healthcare professional licensed to perform phy sical 
examinations will examine the participant for an y detectable abnormalities of the following bod y 
Allergan Confidential Protocol 3101-303-002 Amendment 3
47systems: general appearance ,neck (including thy roid) ,head, ey es, ears, nose, and throat ,lungs,
heart/cardiovascular ,abdomen ,neurologic ,extremities ,back ,musculoskeletal ,lymphatic ,skin,
and other . The neurologic examination should be conducted to detect the presence of an y 
significant sensory /motor abnormalities.
6.5.6 Electrocardiograms
A 12-lead E CG will be performed at the visits outlined in Table 1. All ECGs should be 
performed after the participant has been supine for at least 5 minutes. All ECG sperformed will 
be saved as source document
s. ECGs will be transmitted electronicall y to the central ECG 
laboratory  for anal ysis according to the instructions provided by  the laboratory to be centrally  
read b y a cardiologist. The overall interpretatio n of the clinical significance of the ECG will be 
determined b y the investigator and recorded in the participant ’s eCRF . 
6.5.7 Columbia -Suicide Severity Rating Scale
The C -SSRS is a clinician -rated instrument that reports the severit y of both suicidal ideation and 
behavior . Suicidal ideation is classified on a 5 -item scale: 1 (wish to be dead), 2 (nonspecific 
active suicidal thoughts), 3 (active suicidal ideation with any  methods [not plan] without intent to 
act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active 
suicidal ideation with specific plan and intent). The C -SSRS also captures information about the 
intensity  of ideation, specificall y the frequency , duration, controllabilit y, deterrents, and reasons 
for the most severe t ypes of ideation. Suicidal behavior is classified on a 5 -item scale: 0 (no 
suicidal behavior), 1 (preparatory  acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), 
and 4 (actual attempt). More than 1 classification can be selected provide d they  represent 
separate episodes. For actual attempts only , the actual or potential lethality  is classified for the 
initial, most lethal, and most recent attempts. The C -SSRS will be completed at all study  visits. 
At screening (Visit 1), the C -SSRS will be completed for history of suicidal ideation and suicidal 
behavior for the participant
’s lifetime and 6 months prior to screening. At all other visits, the 
C-SSRS will be completed for ideation and behavior since the previous visit. The C -SSRS will 
be com pleted on the eT ablet by  the investigator or designee with current and valid training in 
administering the assessment. A participant should not be released from the study  center until the 
results of C -SSRS are reviewed and it is confirmed that the participant is not considered to be at 
risk. Participants who reply  with “y es” to questions 4 or 5 in the suicidal ideation section or 
“yes” to any  question in the suicidal behavior section of the C -SSRS at Visits 3 through 6 must 
be withdrawn from the study  and s hould receive appropriate follow -up as in routine clinical 
practice, including the ET  Visit 7 and the follow -up V isit 8. These participants must continue to 
complete their dail y eDiary through V isit 8 follow -up.
Allergan Confidential Protocol 3101-303-002 Amendment 3
486.6 Other S tudy Supplies
The following will be p rovided by  the sponsor or a delegate:
All supplies needed for blood and urine sampling (central laborat ory anal ysis, urine, and 
urine dipstick reagent strips
)
All supplies needed for on -site urine pregnancy  test
All supplies needed for PK and future biomedical research sample collections 
Shipping materials for shipment of laboratory  samples to central laboratory
All supplies needed for ECG assessment including ECG machine 
Electronic d iaries
Electronic t ablet (s)
6.7 Summary of Methods of Data Collection
An IWRS will be used to randomize participant s and manage study  intervention inventory . All 
visit data (ie, non -diary  data) for this study  will be collected by  either on the eT ablet or, if 
conducted remotel y (Attachment 12.4), utiliz ingaweb-portal (eg, questionnaires for PROs) or 
eCRFs via an electronic data capture s ystem. Source documents will be used at the sites and may  
include a participant ’s medical record, hospital charts, clinic charts, the investigator ’s participant
study  files, as well as the results of diagnostic tests such as laboratory  tests, ECGs, etc. 
Acentralized clinical laboratory  will be used for the anal ysis of all blood and urine samples and 
for ECG assessments. Additional information on the collection and handling of samples is 
detailed in the Lab Procedure Manual.
Participant s will use an eDiary  daily to record the daily  total duration of headache, headache 
characteristics, asso ciated sy mptoms, the worst pain severit y, and acute medication use both in 
the screening/ baseline period and double -blind treatment period until Visit 7/ET . Training for the 
eDiary  will be provided for qualified participant s during the S creening/ Baseline V isit (V isit1).
Allergan Confidential Protocol 3101-303-002 Amendment 3
497. Statistical Pr ocedur es
7.1 Analysis Populations
The ITT population will consist of all randomized participant s. All ef ficacy anal yses will be 
performed using the m ITT population, consisting of all randomized participant s who received at 
least 1 dose of stud y intervention , had an evaluable baseline period of eDiary  data , and had at 
least 1 evaluable postbaseline 4-week period (W eeks 1 to 4, 5 to 8, and 9 to 12) of eDiary  data
during the double- blind treatment period . All safety  analy ses will be performed using the safet y 
population, consisting of all participant s who received at least 1 dose of study  intervention .
The primary  efficacy  analy sis population to support filing in Europe for of f-treatment estimand 
(defined in S ection 7.4) includes all randomized participants who received at least 1 dose of 
study  intervention , had an evaluable baseline period of eDiary  data and had at least 1 evaluable
postbaseline 4- week period (W eeks 1 to 4, 5 to 8, 9 to 12) of eDiary  data during the study , 
regardless of whether on study  treatment or off study treatment.
7.2 Collection and Derivation of Primary and Secondary Efficacy 
Assessmen ts
On a dail y basis during the 28- daybaseline period and throughout the study , participant s are to 
record ,into an eDiary ,information on the dail y total duration of headache, headache specific 
characteristics and s ymptoms, the worst pain severity , and use of an y acute medication. 
Participant s will be able to report headache data, including absence of headache, for the day  of 
the diary  report and for the day  immediatel y prior to the day of the diary report, as long as 
information reported is for a time sub sequent to the participant ’s most recent report. This is 
defined as a 1-day “missing -recall” window .
Following randomization on Day  1, there are 4 visits at 2 -week intervals, followed by  2 visits at 
4-week intervals; altogether encompassing a 12-week double- blind treatment phase of the study  
and a 4 -week follow -up phase. In practice, there may  or may  not be exact 2 -week or 4
-week 
durations between 2 consecutive visits ,and the visits might not align with each 28 -day period 
recorded in the eDiary  (ie, Weeks 1 to 4, 5 to 8, and 9 to 12, corresponding to D ays 1to 28, 
29to56,and 57 to 84). Therefore, for data anal ysis purposes, the number of migraine days 
during the last 28 day s prior to the randomization date , will serve as the baseline, and change 
from baseline will be calculated for consecutive 28- day periods beginning with the date of the 
first dose of study  intervention .
Allergan Confidential Protocol 3101-303-002 Amendment 3
50In order to be randomized, a participant should be in the baseline phase for at least 28 day s and 
must report diary  data for at least 20 day s (including missing recall) during the 28- day baseline 
period. If less than 28 day s of baseline data are reported, the number of headache day s and other 
such counting variables for baseline will be pro rated to standardize the count to a 28- day 
equivalent. Subsequent to treatment start, the number of headache day s will be counted in 
successive and non- overlapping 4 -week (ie, 28- day) windows. Headaches that continue into a 
subsequent 4- week period will be counted (with recorded severity  and duration) as occurring in 
each period.
If any postbaseline diary  window for a participant has at least 14 ,but less than 28 day s,of 
reported data, the prorated approach will be used. If a participant reports less than 14 days of 
eDiary  data, the participant’s  observed counts in that particular 28 -day diary window will be set 
to missing for that window . These prorating rules will be applied to all ef ficacy  anal yses of diary  
data unless otherwise stated.
7.2.1 Primary Efficacy Endpoint
The primary  efficacy  endpoint is the change from baseline in mean monthly migraine days 
across the 12-week treatment period. Baseline is defined as the number of migraine days during 
the last 28 day s prior to the randomization date .
7.2.2 Secondary Effi cacy Endpoints
The Secondary Efficacy En dpoints for all regions except Europe and Canada :
Change from baseline in mean monthly  headache day s across the 12- week treatment 
period
Change from baseline in mean monthly  acute medication use day
s across the 12-week 
treatment period
At least a 50% reduction in 3- month average of monthly  migraine day s
Change from baseline in MSQ v2.1 Role Function -Restrictive domain score at Week 12
Change from baseline in mean monthly  Performance of Daily  Activities domain sco re of 
the AIM -D across the 12 -week treatment period.
Change from baseline in mean monthly  Physical Impairment domain score of the AIM -D 
across the 12-week treatment period.
Allergan Confidential Protocol 3101-303-002 Amendment 3
51The Secondary Efficacy End points for Europe and Canada :
Change from baseline in mea n monthly  headache day s across the 12- week treatment 
period
Change from baseline in mean monthly  acute medication use day s across the 12-week 
treatment period
At least a 50% reduction in 3- month average of monthly  migraine day s
Change from baseline in the HIT-6 total score at Week 12
Change from baseline in MSQ v2.1 Role Function -Restrictive domain score at Week 12
7.2.3 Additional Efficacy Endpoints
Additional ef ficacy  endpoints for the United States and Europe are provided below . Related 
analysis will be documented in the statistical anal ysis plan ( SAP).
≥ 25%, ≥ 30%, ≥ 50%, ≥ 75%, 100% improvement (decrease) in monthly  migraine days 
at W eeks 1 to 4, 5to 8, and 9 to 12
≥ 25%, ≥ 30%, ≥ 75%, 100% improvement (decrease) in 3- month average of monthly  
migraine day s
Change from baseline in monthly  migraine days at Weeks 1 to 4, 5to 8, and 9 to 12
Change from baseline in monthly  headache day s at Weeks 1 to4, 5to 8, and 9 to 12
Change from baseline in monthly cumulative headache hours at Weeks 1 to 4, 5to 8, 
9to12, and average across the 12 -week treatment period
Change from baseline in monthly  acute medication use day s at W eeks 1 to 4, 5to 8, and 
9to 12
Change from baseline in monthly  triptan use day s at Weeks 1 to 4, 5to 8, 9to 12, and 
average across the 12 -week treatment period
Change from baseline in monthly  moderate/severe headache day s at Weeks 1 to 4, 5to 8, 
9to 12, and average across the 12-week treatment period
Change from baseline in monthly  severe headache day s at Weeks 1 to 4, 5to 8, 9to 12, 
and average across the 12 -
week treatment period
Change from baseline in weekl y migraine day s at Weeks 1 -4
Allergan Confidential Protocol 3101-303-002 Amendment 3
52Participant having a migraine day  on the day  of initial dose and on each day of the 6 day s 
post the initial dose.
Change from baseline in the HIT -6 total score at W eeks 4 , 8, and 16 ( for Europe and 
Canada )
Change from baseline in the HIT -6 total score at Weeks 4, 8, 12 , and 16 (for all regions
except Europe and Canada )
At least a 5- point improvement (decrease) from baseline in HI T-6 total score at Weeks 4, 
8, 12, and 16
Participant assessed by the PGI C as “much better” or “very  much better” at Week 12
Participant reporting “
satisfied ” or “extremely  satisfied” with study  medication for 
migraine prevention at Weeks 4, 8, and 12
Change from baseline in percent work time missed, percent impairment while working, 
percent overall impairment, and percent activit y impairment due to migraine a t Weeks 4, 
8, and 12 as assessed b y the WPAI :MIGRAINE
Change from baseline in the MIDAS total score at Week 12
Change from baseline in MI DAS absenteeism score (Questions 1, 3, and 5) at Week12
Change from baseline in MI DAS presenteeism score (Questions 2 and 4) at W eek 12
Change from baseline in PGI -S score at Weeks 4, 8, and 12
C
hange from baseline in the MSQ v2.1 Role Function- Restric tive domain score at 
Weeks 4, 8, and 16
Change from baselin e in the MSQ v2.1 Role Function -Preventive domain score at 
Weeks
4, 8, 12, and 16
Change from baseline in the MSQ v2.1 Emotional Function domain score at Weeks 4, 8,
12, and 16
Change from baseline in monthly  Performance of Daily  Activities domain score of the 
AIM
-D at Weeks 1 to 4, 5 to 8, and 9 to 12
Change from baseline in monthly  Physical I mpairment domain score of the AI M -D at 
Weeks 1 to 4, 5 to 8, and 9 to 12
Change from baseline in mean monthly  Performance of Daily  Activities domain score of 
the AIM -D across the 12 -week treatment period (for Europ e and Canada only )
Allergan Confidential Protocol 3101-303-002 Amendment 3
53Change from baseline in mean monthly  Physical Impairment domain score of the AIM -D 
across the 12- week treatment period (for Europe and Canada onl y)
Change from baseline in monthly  AIM-D total score at Weeks 1 to 4, 5 to 8, 9 to 12, and 
average across the 12 -week treatment period
Change from baseline in monthly  activity  level at Weeks 1 to 4, 5to 8, 9to 12, and 
average across the 12 -week treatment period
Change from baseline in monthly  activity  limitation at Weeks 1 to 4, 5to 8, 9to 12, and 
average across the 12 -
week treatment period
Change from baseline in PHQ- 9 score at Week 12
7.2.3.1 Other Health Outcome V ariables
Other health outcome endpoints are listed below . The related health outcome anal yses will be 
documented in the health economics and outcomes research SAP .
Change from baseline in EQ -5D- 5L descriptive s ystem index score at Weeks 1 to 2, at 
specified windows around Weeks 4, 6, 8, 12, and 16
Change from baseline in the EQ -5D- 5L VAS score at Weeks 1 to 2, at specified windows 
around We eks 4, 6, 8, 12, and 16
Change from baseline in PROMI S-PI total score at Weeks 4, 8, and 12
7.3 Hypothesis and Methods of Analysis
For ef ficacy  anal yses, data will be anal yzed according to participants’  randomization 
assignments, regardless of actual treatment received.
For safet y data anal yses, the participants will be analy zed according to actual treatment received 
(rather than as randomized).
7.3.1 Primary Efficacy Analyses
The primary  efficacy  endpoint is the change from baseline in mean monthly migraine days 
across the 12- week treatment period. The primary null hypothesis is that atogepant 30mg BID 
and 60 mg once dail yare each equall y effective asplacebo in mean change from baseline in 
mean monthly  migraine days across the 12 -week treatment period . The alterna tive hy pothesis is 
that at least 1of the 2 doses of atogepant has a greater effect than placebo.
Allergan Confidential Protocol 3101-303-002 Amendment 3
54The primary  comparison between treatment groups will be done by  an MMRM of the change 
from baseline. The statistical model will include treatment group, visit , region, acute migraine 
medications during the baseline period (medication overuse Y/N), current and past use of 
migraine prevention medications and the number of medications failed with unique mechanisms 
of action (Current Use and “failed 0 medications o r failed 1 or more medication(s) with the same 
mechanism of action”, Current Use and “failed 2 to 4 medications with dif ferent mechanisms of 
action”, Past Use onl y and “failed 0 medications or failed 1 or more medication(s) with the same 
mechanism of actio n”, Past Use only  and “failed 2 to 4 medications with dif ferent mechanisms 
of action”, and Never Used) , and treatment group by  visit interaction as categorical fixed ef fects. 
The statistical model will also include the baseline score and baseline -by-visit interaction as 
covariates. An unstructured covariance matrix will be used to model the covariance of within -
participant repeated measurements. The Kenward- Roger approximation ( Kenward 1997 ) will be 
used to estimate the deno minator degrees of freedom. The anal ysis will be performed based on 
allpostbaseline values using onl y the observed cases without imputation of missing values. 
Pairwise contrasts in the MMRM model will be used to make the pairwise comparisons of each 
atogepant dose to placebo. This is the primary  analy sis method for the primary  efficacy  endpoint 
in support of US filing. Only  data collected during the double -blind period will be included in 
the anal ysis. Participants are alway s analy zed based on the tre atment group assigned b y 
randomization.
7.3.1.1 Sensitivity Analyses in Missing Data Handling
Multiple sensitivity  analyses for missing data handling will be conducted and summarized below . 
Details of the sensitivity  anal yses will be provided in the SAP .
ANCOV A Model Based on 3 -month Average of the Monthly Migraine Days
A supportive anal ysis will be performed on the primary  endpoint using an ANCOV A model. The 
response variable for the ANCOV A model is the change from baseline in the calculated average 
monthly  migr aine day s during the 12 -week treatment period for each participant. The ANCOV A 
model includes terms for treatment, region, acute medications during the baseline period 
(medication overuse Y/N), current or past use of migraine prevention medications and the
number of medications failed with unique mechanisms of action, and baseline score. The 
treatment dif ference for atogepant doses versus placebo will be estimated and reported along 
with the corresponding 95% CI  and nominal p -value for superiority  testing.
Allergan Confidential Protocol 3101-303-002 Amendment 3
55Within-group Imputation Based on Observed Data
Sensitivity  anal ysis will be performed based on imputation using participants from the same 
treatment group with observed data under the missing at random ( MAR )assumption. Missing 
data for participants who pr ematurel y discontinued are assumed to cop y the profile of 
participants in the same treatment group with observed data.
Copy- Refer ence Appr oach
Copy -reference approach will be performed on the primary  endpoint to assess the robustness of 
the MMRM analy sis to possible violation of the MAR assumption. This sensitivity  anal ysis is 
one ty pe of pattern mixture model (PMM), under which data could be missing not at random 
(MNAR), with repeated anal yses combined via the reference based multiple imputation (MI) 
proce dure. Participants who discontinued in the Atogepant groups are assumed to have no 
treatment ef fect after the discontinuation. Participants are assumed to cop y the profile of placebo 
arm and missing values are imputed based on the distribution estimated fr om the placebo group 
under the MAR using copy  reference approach.
MMRM Based on Primary Measures Collected During the Double -blind and Follow -up 
Periods
The details for this analysis are provided in Section 7.4. The primary anal ysis in support of EU 
filing will serve as one sensitivity anal ysis in support of US filing.
7.3.1.2 Sensitivity Analysis for Possible Violation of Normality Assumption
The normality  test is performed on the residuals which are generated by the same MMRM as 
used for the primary  efficacy  analy sis. The residuals are scaled by  the inverse Cholesky  root of 
its estimated variance- covariance matrix. The Kolmogorov- Smirnov test for normality  is applied 
to the de- correlated and scaled residuals and normality  test is rejected if p- value from the 
Kolmogorov -Smirnov test is less than 0.01. 
If the normalit y test is rejected, the sensitivity  analy sis uses MI in conjunction with robust
regression to assess the robustness of the primary  MMRM analy sis to the possible violation of 
normality  assumption. This method has been described and is referred to as ADAP  [R] in 
Mehrotra 2012. The detail of the sensitiv ity anal yses will be provided in the SAP . 
Allergan Confidential Protocol 3101-303-002 Amendment 3
567.3.2 Secondary Efficacy Analyses 
The secondary  efficacy  variables are identified in Section 7.2.2 .
The second ary endpoints for headache day s, acute medication use day s, MSQ v2.1 Role 
Function-Restrictive domain score, Performance of Dail y Activities domain score of the AIM-D, 
Physical Impairment domain score of the AIM-D , and HIT -6 total score will be analy zed in the 
same manner as that used to analy ze the primary  endpoint. 
The secondary  endpoint of 50% responders, defined as participants with at least a 50% reduction 
from baseline in the 3 -month average of monthly  migraine day s, will be assessed for each 
individ ual. A logistic regression model will be used to analyze 50% responders across the 
12-week treatment period. This model assumes a binary  distribution for the response and uses a 
logit link. The analy sis model will include treatment group, region, acute med ications during the 
baseline period (medication overuse Y/N), current and past use of migraine prevention 
medications and the number of medications failed with unique mechanisms of action as 
categorical fixed ef fects; baseline value will be included as a c ovariate. The anal ysis will be 
performed based on all postbaseline values using only  the observed cases without imputation of 
missing values. The treatment dif ference in terms of odds ratio between each atogepant dose 
group and placebo will be estimated an d tested from this model. 
The overall ty pe I error rate for multiple comparisons across two atogepant doses and the 
primary  and secondary  efficacy  endpoints will be controlled at the 0.05 level using a graphical 
approach (Bretz 201
1). The primary endpoint will serve as the gatekeeper for the sec ondary  
endpoints. A complete graph and details of the graphical multiple comparison procedure will be 
presented in the SAP.
However , for Japan, the Hochberg procedure ( Hochberg 1988 ) will be used to control the overall 
Type I error rate at a 0.05 level (2 -sided) for multiple comparisons of 2 atogepant doses with 
placebo for the primary  efficacy  endpoint onl y. Detailed procedure is provided below .
Let p(1)andp(2)denote the nominal p -values in increasing order from the 2 comparisons of 
atogepant doses versus placebo.
Step 1: If p(2)is ≤ 0.05, then both the 2 comparisons are considered statistically  
significant at the 2 -sided significance level of 0.05 and stop here; otherwise, go to
Step 2.
Allergan Confidential Protocol 3101-303-002 Amendment 3
57Step 2: If p(1)is ≤ 0.025, then the corresponding comparison for p(1)is considered
statistically  significant at the 2 -sided significance level of 0.05; otherwise, stop
here.
Adjusted p- values using Hochberg procedure will also be provided. 
7.3.3 Additional Efficacy Analyses
In general, other ef ficacy anal yses are performed at the nominal significance level, without 
adjusting for multiplicit y.
Other ef ficacy  variables will be anal yzed as follows:
For selected diary  variables with a continuous response range, the baseline score will be 
included as a covariate in an MMRM analy sis of the change from baseline. These 
analyses will be performed similarly  to the primary  MMRM, with focus aga in on the 
pairwise contrasts of each dose group to placebo.
For weekl y data anal ysis purposes, baseline is defined to be the baseline derived in 
monthly  basis divided by 4, and change from baseline in the weekly migraine day s will 
be calculated for consecu tive 7 -day periods beginning with Day  1. Subsequent to 
treatment start, the number of headache day s will be counted in successive and non -
overlapping 1 -week (ie, 7 -day) windows. Headaches that continue into a subsequent 
1-week period will be counted (with recorded severity  and duration) as occurring in each 
period. If an y postbaseline eDiary  window for a participant has at least 4, but less than 
7days, of reported data, the prorated approach will be used. If a participant reports less 
than 4 day s of headac he data, the participant’s observed counts in that particular 7 -day 
eDiary  window will be set to missing for that window.
For variables where the data are essentiall y binar y, comparisons between treatment 
groups will be done with logistic regression for va riables with only  one postbaseline
assessment or using generalized linear mixed model for variables with multiple
postbaseline assessments.
Descriptive statistics will be provided b y visit for each ef ficacy  variable by treatment group. 
Analy sis of some variables will be limited to descriptive summary  statistics. Details will be 
specified in the SAP.
Allergan Confidential Protocol 3101-303-002 Amendment 3
587.3.4 Safety Analysis
The safety  anal yses will be performed using the safet y population. The safety parameters will 
include AEs, clinical laboratory  evaluations, vital sign measurements, ECG parameters, and the 
C-SSRS. For each of the clinical laboratory , vital sign, and ECG parameters, the last non- missi ng 
safet y assessment before the first dose of treatment will be used as the baseline for all analyses of 
that safet y parameter .
Continuous variables will be summarized by  the number of participants, and mean, SD, median, 
minimum, and maximum values. Catego rical variables will be summarized by  number and 
percentage of participants.
7.4 Off-treatment Hypothetical Estimand Framework for EMA
This section defines an estimand, termed as off -treatment hy pothetical estimand, which will be 
the primary  estimand in suppor t of EU filing and serve as one sensitivity  analy sis in support of 
US filing.
7.4.1 Treatment Condition of Interest
Participants take assigned treatment b y randomization during the double -blind treatment period. 
In addition, permissible and prohibited medic ations are described below:
Participants are allowed to take acute migraine medications (Section 4.4.1 ) to keep the 
participants in the study
Medicat ions with demonstrated efficacy  for the prevention of migraine (eg, amitripty line, 
propranolol, topiramate ) are prohibited when used for an y indication other than migraine 
prevention. See Attachment 12.3
oParticipants taking onemedication with demonstrated efficacy  for the prevention 
of migraine may  be randomized provided that in the opinion of the investigator:
Dose has been stable and the medication has been well -tolerated for at 
least 12 weeks prior to Visit 1 ,AND
Participant is willing and able to maintain at a stable dose and dosage 
regimen during the stud y, which should be assessed to ensure compliance 
at each stud y visit
Enrollment of participants with current use of a migraine prevention 
medication will be capped at ~15%
Allergan Confidential Protocol 3101-303-002 Amendment 3
597.4.2 Population
The target population is patients suf fering from CM satisfying the inclusion and exclusion 
criteria as specified in Section 4.
The anal ysis population is defined to be all randomized participants who received at least 1 dose 
of study  intervention, had an evaluable baseline period of eDiary  data and had at least 
1evaluable postbaseline 4- week period (W eeks 1 to 4, 5 to 8, or 9 to 12) of eDiary  data, 
regardless of whether on study  intervention or of f study  intervention . 
7.4.3 Variable
The variable is the same as the primary  efficacy  endpoint defined in Section 7.2.1 , which is the 
change from baseline in the patient’ s mean monthly  (4-weeks) migraine day s across the 12
-week 
treatment period as derived from the eDia ry data.
7.4.4 Accounting of Inter current Events
Intercurrent events and their handling rules are as follows:
Participants who started a new migraine p revention treatment after the first dose of 
double -blind treatment will have th eir data after the end of the double -blind treatment 
period following the start of the new migraine prophy laxis treatment excluded from the 
analysis.
Participants who discontinue study  intervention due to all reasons other than starting a 
new migraine prop
hylaxis treatment will have their data collected after discontinuation of 
study  intervention ,and those of f -treatment data will be included in the analy sis.
Detailed methods and procedures will be documented in the SAP prior to study  completion.
7.4.5 Population -Level Summary
The population -level summary  for the primary  endpoint is the dif ference in primary  variable 
means between each atogepant group and placebo.
Participants are alway s analy zed based on their treatment assignment by  randomization. To 
obtain the estimate of treatment ef fect defined in the of f-treatment h ypothetical estimand, a 
MMRM similar to the primary  anal ysis specified in Section 7.3.1, will be performed on observed
data including both on -treatment and of f
-treatment monthly  migraine day s.
Allergan Confidential Protocol 3101-303-002 Amendment 3
607.4.6 Off-Tr eatment Hypothetical Estimand Approach for the Secondary 
Endpoints
Continuous secondary  endpoints will be handled using the same estimand approach defined 
above for the primary  endpoint.
Secondary  endpoint of 50% responders will be derived using both on- treatment and of f-treatment 
observed data as defined in the primary  endpoint above. The population -level summary  for this 
endpoint is the odds ratio for each atogepant group relative to placebo.
7.5 Subgr oup Analyses
7.5.1 Subgr oup Analyses for Evaluating the Consistency of Treatment 
Effects Across Regions and Subpopulations
To estimate the treatment ef fect on the primary  efficacy  endpoint for individual regions , the same 
model as that of the primary  MMRM model in primary  efficacy  analy sis in Section 7.3.1 will be 
utilized. I n addition, the model will include region, region b y treatment (2 -way interaction) and 
region b y treatment b y visit (3- way interaction) as categorical fixed ef fects. An unstructured 
covariance matrix will be used to model the covariance of within participant repeated 
measurements. Pairwis e contrasts in the MMRM model will be used to compare each atogepant 
dose to placebo for treatment ef fect in patients enrolled in each region.
The estimate of the between -group treatment ef fect (with a 95% CI) for each atogepant dose 
versus placebo for the primary  efficacy  endpoint for each region and overall treatment effect will 
be plotted in a forest plot to visualize the consistency  of treatment effect across regions. 
For key  efficacy  endpoints, the estimate of the between
-group treatment effect (with 95% CI) for 
each atogepant dose versus placebo will be summarized overall and for each region in a table to 
facilitate the comparison. The test of treatment -by-region interaction will be provided as 
recommended in I CH E17 Section 2.2.7 on Examination of C onsistency  across Regions and 
Subpopulations. 
Additional analy ses to fulfill region specific regulatory  requirement will be performed as 
appropriate. If models do not converge, descriptive statistics for subgroups will be provided. 
Details will be provide d in the SAP.
Allergan Confidential Protocol 3101-303-002 Amendment 3
617.5.2 Other Subgr oup Analyses
A subgroup anal ysis by  exposure to migraine prevention medication , preventive medication 
failures, and acute medication overuse is planned for the following ef ficacy endpoints:
Change from baseline in mean monthly  migraine day s across the 12 -week treatment 
period
Change from baseline in mean monthly  headache day s across the 12- week treatment 
period
Change from baseline in mean monthly  acute medication use day s across the 12-week 
treatment period
At least a 50% reduc tion in 3-month average of monthly  migraine day s
At least a 75% reduction in 
3-month average of monthly  migraine day s
A100% reduction in 3- month average of monthly  migraine day s
If models do not converge, descriptive statistics for subgroups will be provi ded. Details will be 
provided in the SAP.
7.6 Sample Size Calculation
A total sample size of 250 participants will be randomized per treatment group and that will 
provide at least 96% power to detect the treatment dif ference between each of the 2 atogepant 
doses (assumed equally  effective) and placebo for the primary  efficacy  endpoint. The sample size 
of this study  was selected to provide suf ficient power for the first 3 secondary  endpoints as 
shown in Table 4. The power calculations are based on the following assumptions:
1) The treatment dif ference from placebo will be similar to the average value across the CM 
prevention studies for Botox ( Aurora 2010, Diener 2010) and TEV -48125 ( Bigal 2015, 
Silberstein 2017 ). In particular , the assumed treatment dif ference from placebo in change from 
baseline in mean monthly  migraine day s across the 12- week treatment period is –2 day s, and the 
standard deviation is 5.5 day s. Detailed treatment dif ference and standard deviati on assumptions 
are listed in Table 4. 
2) The stud
y statistical testing plan controls the overall t ype I error at 5%. The power 
calculations of the pr imary  and secondary  endpoints have taken the multiple comparisons into 
consideration b y testing each dose versus placebo at a 0.025 significance level, 2 -sided. Once the 
primary  endpoint for each dose is significant at 0.025, 2- sided, the secondary  endpoin ts will be 
tested sequentiall y. A detailed graphical multiple comparison procedure will be presented in the 
SAP.
Allergan Confidential Protocol 3101-303-002 Amendment 3
62Table 4 Statistical Power  for Primary and the First Three Secondary Endpoints
Hypothesis 
Testing EndpointTreatment 
Differ ence 
from PlaceboStandard 
DeviationStatistical 
Power
PrimaryChange from baseline in mean 
monthly  migraine day s across 
the 12- week treatment period–2 5.5 96%
Secondary  1Change from baseline in mean 
monthly  headache day s across 
the 12-week treatment period–2 6.0 93%a
Secondary  2Change from baseline in mean 
monthly  acute medication use 
days across the 12-week 
treatment period–1.8 5.5 92%a
Secondary  3Atleast a 50% reduction in mean 
monthly  migraine day s across 
the 12- week treatment period33% 
Placebo Rate49% 
Atogepant 
Rate92%a
a:Statistical power sfor secondary endpoints are conditional on success of prior endpoints (assuming 
independence among th e endpoints) in the sequence for the comparisons of each dose versus placebo 
7.7 Pharmacok inetics and Exposure -Response Analyses
A graphical evaluation of the PK and PD data of atogepant will be performed for the 
identification of possible trends. The PK will be evaluated using the existing population PK 
model ,updated with data from this study . Individual predictions of atogepant exposure 
(including but not limited to steady  state AUC 0-Tauand C min) will be evaluated graphically  for 
potential relationships wi th efficacy  and/or safety  endpoints. If graphical evaluation identifies 
possible trends, exploratory  PK/PD analy ses will be performed for the evaluation and 
quantification of potential relationships via nonlinear mixed ef fects modeling. Ef ficacy  endpoints 
to be evaluated will include migraine days and responder rates. A stand- alone pharmacometric 
analysis plan will be written, and the analy ses results will be reported separately  from the 
integrated clinical study report.
7.8 Interim Analyses
There is no interim analysis planned.
8. Study Visit Schedule and Procedures
Please seeTable 1fora s chematic oftheSched uleof Vis itsandProceduresandFigure 1fora 
studyvisit flowcha rt.
Allergan Confidential Protocol 3101-303-002 Amendment 3
638.1 Participant Entry Procedures
8.1.1 Overview of Entry Procedures
Prospective participant s as defined b y the criteria in Section s4.2and 4.3(inclusion/exclusion 
criteria) will be considered for entry  into this study .
8.1.2 Informed Consent and Participant Privacy
The study  will be discussed with the participant ,and a participant wishing to participate must 
give informed consent prior to any  study -related procedures or change in treatment. The 
partici pant must also g ive a uthorization (United States only), data protection consent (Europe an 
Union only), and other written documentation in accordance with the relevant country  and local 
privacy  requirements (where applicable) prior to any  study -related pro cedures or change in 
treatment.
Each participant that provides informed consent and/or assent will be assigned a 
participant
identification number that will be used on participant docum entation throughout the study .
The investigator or qualified designee w ill explain the PK and future biomedical research
substudy  consents to the participant and answer all of his/her questions. Participants will sign 
separate consent forms to participate in the PK substudy  and future biomedical research before 
performing an y
procedure related to the substudies, respectivel y.
8.1.3 Procedure for Duplicate Participant Identification –Verified Clinical 
Trials
Atparticipating sites, a central vendor will be used to verify  participants ’current and past 
research stud y status in order to mitigate safety  concerns associated with duplicate enrollment 
and protocol deviations associated with multiple trial enrollment. Following proper informed 
consent and after issuing a p articipant number , each participant will be checked in the VCT  
databa se, indicated in the Schedule of Visits and Procedures ( Table 1). Partial identifiers will be 
utilized. Pa rticipant s who are identified as verification failures b y VCT should not be enrolled 
without documented approval from the sponsor.
8.2 Washout Intervals
This study  will not include a washout period.
Allergan Confidential Protocol 3101-303-002 Amendment 3
648.3 Procedures for Final S tudy Entry
At the S creening and Randomization Visits (V isits 1 and 2), participant s must meet all of the 
inclusion criteria and must not meet any  of the exclusion criteria. Rescreening of participant s 
may be considered with permission from the sponsor. However , participants with clinically  
significant l aboratory  values at Visit 1 (including ALT or AST >1 × the ULN, total bilirubin 
>
1 ×ULN or serum albumin < 2.8 g/dL), or those with a positive result on the Visit 1 urine drug 
screen for recreational (including marijuana regardless of legality ) or illici t drugs or non -
disclosed concomitant medications are not allowed to be rescreened. Also, all women of 
childbearing potential must have negative results on the urine pregnancy  test at the Screening 
andRandomization Visits (V isits 1 and 2) , prior to the fir st administration of study  intervention .
Prior to randomization, confirm that the participant had ≥ 15 headache day s per month in the 
3months prior to Visit 1 in the opinion of the investigator, and ≥ 15 headache day s during the 
4-week screening/baseline period per the eDiary , and ≥ 8 day s during the 4 -week 
screening/baseline period that qualify  as a migraine day per the eDiary  (see Section 6.1.1 for 
definition) ,and completed the eDiary  for at least 20 of the 28 day s.
See Section 5.5for the method for assignment to treatment groups/ randomization.
8.4 Visits and Associated Procedures
There will be 8 scheduled clinic visits: Visit 1 (screening/baseline), V isit 2 (randomization), 
Visit 3 (W eek 2), V isit 4 (W eek 4), V isit 5 (W eek 6), V isit 6 (W eek 8), V isit7/ET  (Week 12), and 
Visit 8 ( follow -up). For details, please see Table 1, Schedule of Visitsand Procedures.
8.4.1 V
isit 1 (Screening/ Baselin e) Day -35 to Day -28
Obtain informed consent and participant privacy .
Obtain informed consent for future biomedical research (optional).
Obtain informed consent for PK substudy  (optional) .
Obtain VCT consent and perform verification at participating sites (United States and 
Canada onl y).
Register participant in IWRS .
Assess inclusion/exclusion criteria .
Collect demographic information.
Allergan Confidential Protocol 3101-303-002 Amendment 3
65Collect medical history .
Collect migraine history (3-month retrospective) and confirm diagnosis.
Review prior medications taken in the past 6 months, and allprior headache medications 
including migraine prophy lactic medication use and concomitant medications/procedures.
Assess C -SSRS on eTablet (the ‘Screening/Baseline’ assessment of the C -SSRS will be 
completed) .
Collect ASC -12 on eTablet.
Perform ph ysical examination.
Collect 
vital sign measurements including: height, weight, sitting and standing pulse rate, 
respiratory  rate, sitting and standing BP, and body  temperature.
Collect start date (first day )of last menstrual cy cle for women having menstrual cy cles.
Perform and transmit ECG.
Perform urine pregnancy test (for women of childbearing potential onl y).
Collect urine for drug screen.
Collect clinical laboratory determinations including: chemistry , hematology, INR, 
screening serology , and urinaly sis.
Collect blood for future biomedical research
(for those participants who consented )
Provide eDiary , along with training and instructions. Participants to bring eDiary  to all 
visits.
Review and assess AEs.
8.4.2 Double -
blind Treatment Phase (12 Weeks)
8.4.2.1 Visit 2 (Randomization) Day 1
Review eDiary  data ( participant s must bring eDiary to visits).
Perform urine pregnancy test for women of childbearing potential .
Collect vital sign measurements including: weight, sitting and standing pulse rate, 
respiratory  rate, sitting and standing BP, and body  temperature.
Collect start date (first day ) of last menstrual cy cle for women having menstrual cy cles.
Allergan Confidential Protocol 3101-303-002 Amendment 3
66Assess C -SSRS (the “Since Last Visit ” assessment of the C -SSRS will be completed) .
Assess inclusion/exclusion criteria.
If the participant continues to meet study  entry  criteria, including acceptable results from V isit 1 
clinical laboratory  and pregnancy  tests and the urine drug screen (see Section 6.5.3 ) the 
following procedures will be carried out at the randomization visit (V isit 2):
Administer PRO measures including: HIT-6, PGI -S, WPAI :MIGRAINE , MIDAS, 
MSQ v2.1, PROMI S-PI, and PHQ -9.
Upda te concomitant medications and concurrent procedures (including all prior headache 
medications) .
Review and assess AEs.
Randomize the participant in IWRS and obtain the kit number for study  intervention .
Collect 
pretreatment PKsample (for those participants who consented) .
Collect pretreatment blood and urine samples for chemistry , hematology , INR, and 
urinaly sis.
Dispense study  intervention . The first dose of study  intervention should be taken at the 
study  site.
8.4.2.2 Visits 3 to 6(Weeks 2to 8)
Prior to any  other test or evaluations, administer PRO measures including: HIT -6, PGI -S, 
WPAI :MIGRAINE, PSSM , MSQ v2.1, and PROMI S -PIat the times outline don the 
Schedule of Visits and Procedures.
Review eDiary  data ( participant s must bring eDiary to visi ts).
Perform urine pregnancy test for women of childbearing potential.
Collect vital sign measurements including: weight, sitting and standing pulse rate, 
respiratory  rate, sitting and standing BP, and body  temperature.
Collect start date (first day ) of la st menstrual cy cle for women having menstrual cy cles.
Assess C -SSRS (the “Since Last Visit ” assessment of the C -SSRS will be completed).
Perform 
and transmit ECG (Visit 5 [Week 6] only )
Update concomitant medications and concurrent procedures (including al l prior headache 
medications).
Allergan Confidential Protocol 3101-303-002 Amendment 3
67Review and assess AEs.
Collect previous visit study  intervention, review participant compliance, and perform 
accountabilit y.
Collect PK sample (for those participants who consented) . During 1 of the Visits 3 to 6, 
the sample 
should be collected prior to the morning dose of investigational product 
(participant should wait to take the morning dose in the clinic after PK sample collection) 
and the samples collected at the remaining visits should be collected 1 to 10 hours post 
the morning dose and prior to the evening dose.
Dispense study  intervention .
Collect blood and urine samples for chemistry , hematology , coagulation parameters
(INR) , and urinal ysis.
Access IWRS and obtain the kit number for study  intervention and enter accountability .
8.4.2.3 Visit 7/Early Termination (W eek 12)
Prior to any  other test or evaluations, administer PRO measures including: HIT -6, PGIC, 
PGI-S, WPAI :MIGRAINE, PSSM , MIDAS, MSQ v2.1, PROMI S-PI, and PHQ -9.
Perform ph ysical examination.
Review eDiary  data ( participant s must bring eDiary to visits).
Collect eDiary  from participant , if the participant completed the treatment period 
(eDiary  collection will occur at Visit 8 for participants who discontinue study  
intervention earl y [see Section 8.8.1 ]).
Perform urine pregnancy test for women of childbearing potential.
Collect vital sign measurements including: weight, sitting and standing pul se rate, 
respiratory  rate, sitting and standing BP, and body  temperature.
Collect start date (first day ) of last menstrual cy cle for women having menstrual cy cles.
Assess C -SSRS (the “Since Last Visit ” assessment of the C -SSRS will be completed).
Perform a nd transmit ECG.
Update concomitant medications and concurrent procedures (including all prior headache 
medications).
Collect previous visit study  intervention, review participant compliance, and perform 
accountabilit y.
Allergan Confidential Protocol 3101-303-002 Amendment 3
68Review and assess AEs.
Access IWRSand enter accountability .
Collect PK sample (for those participants who consented) .The PK sample should be 
collected 1 to 10 hours post the morning dose.
Collect blood and urine samples for chemistry , hematology , INR, and urinaly sis.
8.4.3 Follow -up Period (4 Weeks)
8.4.3.1 Visit 8/End of S tudy (W eek 16)
Prior to any  other test or evaluations, administer PRO mea sures including: EQ -5D- 5L, 
HIT-6, and MSQ v2.1.
Collect eDiary  from participant, if the participant discontinued study  intervention earl y 
[see Section 8.8.1 ]).
Perform ph ysical examination.
Assess C -SSRS (the “Since Last Visit” assessment of the C -SSRS will be completed).
Collect vital sign measureme nts including: weight, sitting and standing pulse rate, 
respiratory  rate, sitting and standing BP, and body  temperature.
Collect start date (first day ) of last menstrual cy cle for women having menstrual cy cles.
Perform urine pregnancy test for women of chi ldbearing potential.
Collect blood and urine samples for chemistry , hematology , INR, and urinaly sis.
Update concomitant medications and concurrent procedures (including all prior headache 
medications).
Review and assess AEs.
Access IWRSto enter study  visit .
8.5 Instructions for the Participant s
Section 4.4.4 provides diet and activit y instructions for participant s enrolled in the study .
Participant s will be provided with instructions on daily  completion of the eDiary . A practice 
session with a hy pothetical scenario should be administered to ensure the participant ’s 
comprehension of the questions and the information to be entered. In addition, prohibited 
Allergan Confidential Protocol 3101-303-002 Amendment 3
69medications should be reviewed with the participants. Participant s will be instructed to bring 
their eDiary  to each clinic visit and return their study  intervention (used and unused blister 
packs ).
Participant s should be instructed to take study  intervention BIDat approximately  the same times 
each day  (approximately  12 hours between doses). For dos ing on Day  1 (V isit 2), the first dose is 
to be taken at the stud y site, and 
participant s should be advised to take the second dose 
depending on the time of the site visit and the participant ’s usual routine. Study intervention may  
be taken with or without food. W ater is allowed as desired.
Participant s should use appropriate contraceptive measures for the duration of t heir participation 
in the study (see Section 4.4.3 ).
8.6 Unscheduled Visits
Additional examinations and laboratory  assessments may  be performed as necessary  to ensure 
the safet y and well -being of the participant s during the study  period. Unscheduled visit eCRFs 
should be completed for each unscheduled visit.
8.7 Compliance with Pr otocol
All assessments will be conducted at the appropriate visits as outlined in Table 1, and the timing 
of the vis its should occur as close as possible to the day  specified. At each visit, the participant
will be asked if the participant changed the dose/regimen of an y existing concomitant 
medications or initiated the use of an y new concomitant medications since the l ast visit to ensure 
compliance with the protocol. 
Study intervention compliance during any  period will be closely  monitored by  counting the 
number of tablets dispensed and returned. Every  effort will be made to collect all unused study  
intervention .
Allergan Confidential Protocol 3101-303-002 Amendment 3
708.8 Early Discontinuation of Participant s
A premature discontinuation will occur when a participant who signed the ICF and has been 
randomized ceases participation in the study , regardless of circumstances, before completion of 
the study . Participant s can be prematurel y discontinued from the stud y for one of the following 
reasons:
AE
Lack of efficacy
Lost to follow -up
Non-compliance with study  intervention
Other (specify  reason)
Pregnancy
Protocol deviation
Site terminated by  sponsor
Study  terminated by  sponso r
Withdrawal by  participant
Participant s may  voluntarily  withdraw from the study  at any  time. Notification of earl y 
participant discontinuation from the study  and the reason for discontinuation will be made to the 
sponsor and will be clearly  documented on the appropriate e CRF.All randomized participant s 
who prematurely  discontinue from the study , regardless of cause, should be seen for final study  
assessments. The final assessments will be defined as completion of the eva luations scheduled 
for V isit 7/ ETand V isit 8 (follow -up), 4 weeks post the last dose of study  intervention .
8.8.1 Participants Who Discontinue S tudy Intervention Early
All participants who discontinue study  intervention earl y (defined as prior to W eek 12 [V isit7]) 
for reasons other than withdrawal of consent or lost to follow -up should remain in the study  for 
the purpose of collecting ef ficacy  data to support the estimand framework for EMA. These 
participants should return to the clinic for E T procedures (V isit7) and the F ollow -
up Visit 
(Visit8) per the Schedule of V isits and Procedures ( Table 1). If Visit 8 occurs on or after 
Week12 (relative to randomizati on), no Final Study V isit is required ( Figure 
2, Scenario A). If 
Visit 8 occurs before W eek 12 (relative to randomization) participants should return t o the clinic 
Allergan Confidential Protocol 3101-303-002 Amendment 3
728.9 Withdrawal Criteria
Women who become pregnant (Section 9.4) and participant s who meet study  intervention
discontinuation criteria related to abnormal liver function tests ( Section 9.5), and advised not to 
be rechallenged, will be withdrawn from the study and should refrain from taking study  
intervention .The participant should return to the clinic for ETprocedures (V isit 7) and the 
Follow -
up Visit (Visit8). Participant s who repl y with “yes” to questions 4 or 5 in the suicidal 
ideation section or “y es” to any  question in the suicidal behavior section of the C -SSRS at Visits 
3 through 6 must be withdrawn from the study and should receive appropriate follow -up as in 
routine clinical practice, including the ETVisit (V isit 7) and the F ollow -up Visit (Visit 8).
A participant with a condition and/or a situation tha t, in the investigator's opinion, may  put the 
participant at significant risk, may  confound the study  results, or may  interfere significantly  with 
the participant’ s participation in the study  may  be withdrawn from treatment.
8.10 Study Termination
The study  may be stopped at his/her study  site at any  time by  the site investigator. The sponsor
may stop the study  (and/or the study  site) for an y reason with appropriate notification.
9. Adverse Events
AEs occu rring during the study will be recorded on a n AECRF.If AEs occur , the first concern 
will be the sa fety of the study participants.
9.1 Definitions
9.1.1 Adverse Event
An AE is any  untoward medical occurrence in a patient or clinical study  participant associated 
with the use of study intervention, whether or not considered r elated to the study  intervention. An 
AE can therefore be an y unfavorable and unintended sign (including an abnormal laboratory  
finding), s ymptom, or disease (new or exacerbated) temporall y associated with the use of study 
intervention. In addition, during the screening period, AEs will be assessed regardless of the 
administration of a pharmaceutical product.
AEs will be reported b y the participant (or , when appropriate, by  a caregiver , surrogate, or the 
participant’ s legall y authorized representative).
Allergan Confidential Protocol 3101-303-002 Amendment 3
74d.Results in persistent disabi lity/incapacity
The term disability  means a substantial disruption of a person’ s abilit y to conduct normal 
life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nause a, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) which may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other  situations:
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may  not be 
immediately  life threatening or result in death or hospitalization but may  jeopardize the 
participant or may  require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive intervention in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that 
do not result in hospitalization, or development of drug dependency  or drug abuse.
The sponsor considers all cancer AEs as SAEs. The sponsor consi ders any  spontaneous abortion 
as an SAE. Elective abortions can be SAEs or AEs depending on the reason for the elective 
abortion (eg, fetal death, still birth, congenital anomalies, ectopic pregnancy , which would make 
the elective abortion an SAE) .
Pre-planned surgeries or procedures for pre -existing, known medical conditions for which a 
participant requires hospitalization is not reportable as an SAE.
Any pre-planned surgery  or procedure should be clearl y documented in the site source 
documents by  the medi cally  qualified investigator at the time of the p articipant ’s entry  into the 
study . If it has not been documented at the time of the p articipant’ s entry  into the study , then it 
should be documented as a SAE and reported to the sponsor .
Allergan Confidential Protocol 3101-303-002 Amendment 3
77additional laboratory  tests or investigations, histopathological examinations, or consultation with 
other health care professionals.
New or updated information will be recorded i n the originally  completed eCRF .
The investigator will submit any  updated SAE data to the sponsor within 24 hours of receipt of 
the information.
9.1.6 Adverse Reactions, Serious Adverse Reactions, and Suspected 
Unexpected Serious Adverse Reactions
For the purpos es of expedited reporting within the EU, the sponsor will follow the applicable 
definitions for ARs, SARs ,and SUSARs (for example, as outlined in Article 2 [n,o,p] of 
Directive 2001/20/EC, see below). Also, seriousness criteria for AEs/ ARs (as would appl yto 
SARs and SUSARs) arecurrentl y included in the protocol, listed in Section 9.1.2 .
Adverse Reaction: all untoward and unintended responses to an investigational medicinal 
product related to an y dose administered
Serious Adverse Reaction: an adverse reaction that results in death, is life -threatening, 
requires hospitalisation or prolongation of existing hospitalisation, results in persistent or 
significant disabilit y or incapacity, or is a congenital anomaly or birth defect 
(see Section 9.1.2 for further details pertaining to seriousness criter ia)
Suspected Unexpected Serious Adverse Reaction: a serious adverse reaction, the nature or 
severit y of which is not consistent with the applicable product information (eg, the 
Investigator’s Brochure).
9.2 Procedures for Reporting Adverse Events
Any AE must be recorded on the appropriate CRF .
All AEs that are drug -related and unexpected (not listed as treatment-related in the current 
investigator's brochure) must be reported to the governing IRB/IEC as required by  the IRB/ IEC, 
local regulations, and the governing health authorities. Any AE that is marked ‘ongoing’  at the 
exit visit must be followed -up as appropriate .
9.3 Procedures for Reporting a Serious Adverse Event
Any SAE occurring during the study  period (beginning wi th informed consent) until the 
Follow- up V isit (V isit 8) or 30 day s after the last dos e of study  intervention if the Follow -up V isit 
is not done must be immediatel y reported but no later than 24 hours after learning of an SAE. 
Allergan Confidential Protocol 3101-303-002 Amendment 3
78SAEs must be reported to the sponsor (or agent of the sponsor ) aslisted on the Study Contacts 
Page and recorded on the SAE form. All pa rticipant s with an SAE must be followed up and the 
outcomes reported. The investigator must suppl y the sponsor and the IRB/IEC with any  
additional requested information (eg, autops y rep orts and discharge summaries).
9.3.1 Regulatory Reporting Requirements for Serious Adverse Events
Prompt notification by  the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participa nts and the safet y of 
a study  intervention under clinical investigation are met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The sponsor will comply with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , IRBs/IECs, and investigators
Investigator safety reports must be prepared for SUSARs according to local regulatory 
requirements and the sponsor ’spolicy  and forwarded to investigators as necessary .
An investigator who receives an investigator safety  report describing an SAE or other 
specific safet y information (eg, summary or listing of SAEs from the sponsor will review
and then file it along with the investigator’s brochure and will notify  the IRB/IEC, if 
appropriate according to local requirements.
9.4 Exposure to St udy Intervention D uring Pregnancy
Details of all pregnancies in female participants and female partners of m ale participants will be 
collected after the start of study  intervention and until the Follow -up V isit (V isit 8) or 30 days 
after the last dose of study  intervention if the Follow -up V isit is not done. Study center personnel 
must report every  pregnancy  on the Pregnancy  Form (within 24 hours of learning of the 
pregnancy  to the Serious Adverse Event Reporting Fax Number: +1-714- 796-9504 [back up fax 
number: +1-714-246- 5295], email: I R-Clinical -SAE@allerga n.com) , even if no AE has occurred. 
The pregnancy  must be followed to term and the outcome reported by  completing a follow -up 
Pregnancy  Form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic preg nancy ) are considered SAEs . Elective abortions can be SAEs 
or AEs depending on the reason for the elective abortion (eg, fetal death, still birth, congenital 
anomalies, ectopic pregnancy , which would make the elective abortion an SAE). For pregnancy  
relate d SAEs, in addition to the Pregnancy  Form, a separate SAE Form must be filed as 
described in Section 9.3with the appropriate serious criterion (eg, hospitalization) indicated.
Allergan Confidential Protocol 3101-303-002 Amendment 3
799.5 AL T or AST Elevations
Atreatment -emer gent AL T ≥ 3 × ULN and/or AST ≥ 3 × ULN is considered an AEof special 
interest . Any participant with this laboratory result after studyintervention was taken must have 
repeat testing within 48 to 72 hours to confirm the abnormality. For this repeat testing, the 
following lab orator ytests must be drawn: hematology andchemistry panels, INR, serum 
acetaminophen level, urine drugs of abuse s creen, and blood alcohol level. An extra blood 
serology sample must be collected and sent to the central laboratory for further diagnostic testing, 
at a later date, if needed. In addition, the investigator will perform a complete history and 
examination to evaluate the participant for possible liver disease.
AllAEs of special interest must be reported to the sponsor within 24 hours of the time the 
investigator becomes aware of the event using the abnormal liver function reporting f orm and the 
AE eCRF . All new elements of history , phy sical examination, diagnostic testing results, and other 
relevant medical reports are to be reported for each AE of special interest .
If an AL T or AST ≥3 × ULN is confirmed ,close medical follo w-upisrequired:
Forthese partic ipant s, the following laboratory  tests must be performed: anti -hepatitis A IgM, 
hepatitis B surface antigen, anti- hepatitis B core IgM, hepatitis C antibody , hepatitis C 
quantitative RNA  by poly merase chain reaction, anti -hepatitis E IgM, anti-hepatitis EIgG, 
Cytomegalovirus IgM antibody , and Epstein -Barr V irus IgM antibod y.The participant must be 
followed clinicall y and further medical evaluation (for other causes of acute hepatic injur y) 
should be done per the judgment of the investigator and in conjunc tion with medical personnel at
the sponsor. In general, the chemistr ypanel should be repeated 1 to 2 times per week to follow 
the c ourse ofALT/AST elevation.
Study intervention must be discontinued if any of the following criteria ar e met:
AL T or AST ≥ 3× ULN and the participant is symptomatic with the appearance of 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or 
eosinophilia (> 5%)
AL T or AST ≥ 3×ULN and total bilirubin > 2 × ULN
AL T or AST ≥ 3×ULN and INR > 1.5
AL T or AST ≥ 5×ULN for more than 2 weeks
AL T or AST ≥ 8×ULN
The participant may be rechallenged with study  intervention only after consultation with the
sponsor medical monitor . For participant s who are not rechallenged with study  intervention , the 
Allergan Confidential Protocol 3101-303-002 Amendment 3
80participant should be discontinued from the study and complete an ET  visit (Visit7/ET) and 
4-week follow - up visit. Participant s should receive appropriate follow -up as per standard of care.
The investigator  must contact the sponsor medical monitor to discuss all cases of confirmed 
ALT/AST elevation ≥ 3 × ULN. All ALT/AST elevations must be followed until ALT and 
AST r eturn to < 1.5 ×ULN and ther e is full clinical r esolution.
9.5.1 Potential Hy’ s Law Cases
Sites must report every  participant who meets th e following potential Hy ’s law criteria if this 
occurs within the time the p articipan
t signs the ICF until 30 day s after the last dose of 
investigational product:
ALT or AST ≥ 3 × ULN AND
Total bilirubin ≥ 2 × ULN AND
Alkaline phosphatase < 2 × ULN
Study site personnel must report every  participant who meets these criteria. T ypicall y, all 
3analytes will be obtained from the same sample, but they  may  come from multiple samples 
taken within a 24 -hour period. This requirement applies from the time the participant signs the 
ICF for the stud y until 30 day s after the final protocol -defined stud y visit or the last known dose 
of study  intervention (if the final visit does not occur).
A laboratory  alert for possible Hy ’slaw cases will be in place and must notify  investigators and 
the sponsor immediately  when the above criteria have been met. A possible Hy ’s law case must 
be faxed to the sponsor on an abnormal liver function reporting form as soon as possible (within 
24hours of learning of the possible Hy ’s law cas e) to the fax number on the form or the SAE fax 
number , eve n if no AEhas occurred. If the event is serious, please complete the SAE form. The 
eCRF for possible Hy ’s law cases must be completed within 7 calendar days. Every  effort to 
determine the cause of the liver enz yme abnormalities must be made, and close monitoring 
should be initiated in conjunction with the medical monitor and medical safety  physician and in 
accordance with the FDA  Guidance for Industry , Drug -Induced Liver Injury: Premarketing 
Clinic al Evaluation, July  2009. The participant should return to the study  site and be evaluated as 
soon as possible, preferably  within 48 hours from the time the investigator becomes aware of the 
abnormal results. This evaluation should include laboratory tests , detailed history , and phy sical 
assessment.
Allergan Confidential Protocol 3101-303-002 Amendment 3
819.6 Procedures for Unmasking of S tudy Medication
The I WRS will be programmed with blind -breaking instructions. In case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’ s study  
intervention assignment is warranted. Participant safet y must always be the first consideration in 
making such a determination. I f the investigator decides that unblinding is warranted, the 
investigator should make every  effort to cont act the sponsor medical monitor prior to unblinding 
a participant’ s study  intervention assignment unless this could delay emergency  treatment of the 
participant. If a participant’ s study  intervention assignment is unblinded, the sponsor medical 
monitor must be notified within 24 hours after breaking the blind. The date and reason that the 
blind was broken must be recorded in the source documentation.
10. Administrative Items
This protocol is to be conducted in accordance with the applicable GCP regulations and 
guidelines ( eg, the ICH Guideline on GCP ) and applicable regulations in relevant countries.
10.1 Protection of Human Participant s
10.1.1 Compliance With Informed Consent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations
Written informed consent is to be obtained from each participant prior to any study -related 
activities or procedures in the study , and/or from the participant 's legally  authorized 
representative.
The following process will be followed:
The investigator or his/her represent ative will explain the nature of the study  to the 
participant or his/her legally  authorized representative and answer all questions regarding 
the study . 
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representatives will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
HIPAA requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.
Allergan Confidential Protocol 3101-303-002 Amendment 3
82Participants must be re- consented to the most current version of the ICF(s) during their 
participation in the study if required b y the IRB . 
A cop y of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representative.
10.1.2 Compliance With IRB or IEC Regulations
This study  is to be conducted in accordance with IRB regulations (U S 21 CFR Part 56.103) or 
applicable IEC regulations. The investigator must obtain approval from a properl y constituted 
IRB/IEC prior to initiating the stud y and re -approval or review at least annuall y. The sponsor is 
to be notified immediately if the responsible IRB/IEC has been disqualified or if proceedings 
leading to disqualification have begun. Copies of all IRB/IEC correspondence with the 
investigator should be provided to the sponsor.
10.1.3 Compliance With Good Clinical Practice
This protocol is to be conducted in accordance with the applicable G CPregulations and 
guidelines.
10.1.4 Compliance With Electr onic Records; Electr onic Signatures 
Regulations ( US 21CFR Part 1 1)
This study  isto be conducted in compliance with the regulations on electronic records and 
electronic signature.
10.2 Financial Disclosur e
Investigators and subinvestigators will provide the sponsor with suf ficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators are 
responsible for providing information on financial interests during the course of the stud y and for 
1 yearafter completion of the stud y.
10.3 Changes to the Pr otocol
The investigator must not implement any  deviation from or changes of the protocol without 
approval b y the sponsor and prior review and documented approval/favorable opinion from the 
IRB/IEC (and the a ppropriate regulatory  agency , if required by  national law) of a protocol 
amendment, except where necessary  to eliminate immediate hazards to study  participant s, or 
Allergan Confidential Protocol 3101-303-002 Amendment 3
83when the changes involve only  logistical or administrative aspects of the study  (eg, change in 
monitors, change of telephone numbers).
10.4 Data Pr otection
Participants will be assigned a unique identifier . Any participant records or datasets that are 
transferred to the sponsor will contain the identifier only ; participant names or any  information 
which would make the participant identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be used by  the 
sponsor
in accordance with local data protection law . The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor , by 
appropriate IRB/IEC members, and b y inspectors from regulatory  authorities.
10.5 Participant Confidentiality
A report of the results of this study  may  be published or sent to the appropriate health authorities 
in any  country  in which the study
 intervention may  ultimatel y be marketed, but the participant’ s 
name will not be disclosed in these documents. The participant's name may  be disclosed to the 
sponsor of the stud y, or the governing health authorities or the FDA  if they inspect the study  
records. Appropriate precautions will be taken to maintain confidentiali ty of medical records and 
personal information.
10.6 Participant Privacy
Written authorization (United States sites only ), data protection consent (European sites onl y), 
and other documentation in accordance with the relevant country  and local privacy  requireme nts 
(where applicable) is to be obtained from each participant prior to enrollment into the study , 
and/or from the 
participant's legall y authorized representative in accordance with the applicable 
privacy  requirements (eg, HI PAA, European Union Data Protec tion Dir ective 95/46/EC [“EU 
Directive”] ).
In accordance with HIPAA requirements , additional purposes of this study  may include
publish ing of anon ymous participant data from the study .
Allergan Confidential Protocol 3101-303-002 Amendment 3
8410.7 Documentation
10.7.1 Sour ce Documents
Source documents may  include a participant 's medical records, hospital charts, clinic charts, the 
investigator's participant study  files, as well as the results of diagnostic tests such as X- rays, 
laboratory  tests, and ECGs . The investigator's copy of the CRFs serves as part of the 
investigator's record of a participant 's study -related data.
The following information should be entered into the participant 's medical record:
Participant ’s name
Participant ’s contact information
The date that the participant entered the study , participant number, and study  intervention 
kit numbers
The study  title and/or the protocol number of the study  and the name of the sponsor
A statement that informed consent was obtained (including the date). A statement that 
written a uthorization (U nited States sites only), data protection consent (European U nion
sites only ), or other country  and local participant privacy  required documentation for this 
study  has been obtained (including the date)
Dates of all 
participant visits
Participant s medical history
Informatio n regarding participant ’s diagnosis of migraine headache
All concurrent medications ( List all prescription and non-prescription medications being 
taken at the time of enrollment. At each subsequent visit, changes to the list of 
medications should be recorded.)
Occurrence and status of any  AEs
The date the participant exited the study , and a notation as to whether the participant
completed the stud y or reason for discontinuation.
The results of laboratory  tests performed b y the site (eg, results of uri
ne pregnancy  tests).
Key study  variables
Allergan Confidential Protocol 3101-303-002 Amendment 3
85Source documentation practices must follow Section 4.0 of I CH E6, GCP: Consolidated 
Guidance ,and ALCOA  (ie, records must be Attributable, Legible, Contemporaneous, Original 
andAccurate )
.
10.7.2 Case Report Form Completio n
The investigator is responsible for ensuring that data are properl y recorded on each participant 's 
eCRF s and related documents. An investigator who has signed the protocol signature page 
should personally  sign for the eCRFs (as indicated in the eCRFs ) toensure that the observations 
and findings are recorded on the eCRFs correctl y and completel y. The eCRF s are to be submitted 
to the sponsor in a timely manner at the completion of the study , or as otherwise specified b y the 
sponsor and will be maintained in a central data repository .
10.7.3 Study Summary
An investigator's summary  will be provided to the sponsor within a short time after the 
completion of the stud y, or as designated b y the sponsor . A summary is also to be provided to the 
responsible IRB/IEC.
10.7.4 Retention of Documentation
All study  related correspondence, participant records, consent forms, participant privacy  
documentation, records of the distribution and use of all study  intervention s, source documents, 
and copies of e
CRFs should be maintained on file.
For countries falling within the scope of the ICH guidelines, the sponsor- specific essential 
documents should be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region ,or at least 2 y ears have elapsed since the formal discontinuation of 
clinical development of the study  intervention . These documents should be retained for a longer 
period, however , ifrequired by  the applicable regulatory  requirement(s) or if needed by  the 
sponsor .
In addition, for countries not falling within the scope of the ICH guidelines, local regulatory  
requirements should be followed regarding the retention of clinical study  documentation.
The sponsor requires that it be notified in writing if the investigator wishes to relinquish 
ownership of the data so that mutually  agreed
-upon arrangements can be made for transfer of 
ownership to a suitabl y qualified, responsible person.
Allergan Confidential Protocol 3101-303-002 Amendment 3
8610.8 Labe ling, Pack aging ,and Return or Disposal of S tudy 
Interventions /Treatments
10.8.1 Labeling/Pack aging
Study intervention will be supplied in blister cards and will be labeled with the protocol number , 
storage information, warning language, and instructions to take the tablets as directed. The card 
will also include the medication number . Immediately  before dispensing the bl ister card, the 
investigator or designee will write the participant number and date dispensed on the blister card.
10.8.2 Clinical Supply Inventory
The investigator must keep an accurate accounting of the number of investigational units 
received from the sponsor ,dispensed or administered to the participant s, the number of units 
returned to the investigator by  the participant (if applicable) , and the number of units returned to 
the sponsor during and at the completion of the study . A detailed inventory  must be completed 
for the stud y medication. The study 
intervention must be dispensed or administered only by an 
appropriatel y qualified person to participant s in the study . The medication is to be used in 
accordance with the protocol for participant s who are under the direct supervision of an 
investigator .
10.8.3 Return or Disposal of Study Medications/T reatments and/or  Supplies
All clinical study  interventions/treatments and/or supplies will be retu rned to the sponsor or
designee for destruction.
10.9 Monitoring by the Sponsor
A representative of the sponsor will monitor the study on a periodic basis. The determination of 
the extent and nature of monitoring will be based on considerations such as the obje ctive, 
purpose, design, complexity , blinding, siz e, and endpoints of the study .
Authorized representatives of the sponsor or regulatory  authorit y representatives will conduct 
on-site visits to review , audit ,and copy  study -related documents. These represen tatives will meet 
with the investigator(s) and appropriate staf f at mutually  convenient times to discuss study -
related data and questions.
Allergan Confidential Protocol 3101-303-002 Amendment 3
8710.10 Handling of Biological Specimens
Urine pregnancy  test kits will be provided by  the central lab; all urine pregnancy  testing will be 
administered on site according to instructions in the central lab manual.
Samples of blood and urine for evaluation of hematology , blood chemistry , urinaly sis, urine drug 
screen , INR, and serology  will be anal yzed at a centralized clinical l aboratory  with certification 
from a recognized accreditation agency  (eg, College of American Pathology  or Clinical 
Laboratory  Improvement Amendments certification). All samples for future biomedical research
will be sent to the designated central laborator y and shipped to a biorepository for storage.
PK samples obtained from participant s in the PK substudy  will be stored at the centralized 
clinical laboratory  until ready  for PK anal yses by the sponsor ’s Pharmacokinetics and Drug 
Distribution department using a validated method. This laboratory  meets GLP requirements.
All sampl es will be re turned tothe sponsor orsponsor ’s designee for d estruct ion.The sponsor
shall have full ownership rights to an y biological specimens/samples derived from the study . For 
additional details regarding handling of biological specimens, please refer to the Study Reference 
Manual.
10.11 Publications
The sponsor has proprietary  interest in this study . Authorship and manuscript composition will 
reflect joint cooperation between multiple investigators and sites and the sponsor personnel. 
Authorship will be established prior to the writing of the manuscript. As this study  involves 
multiple centers, no individual publications will be a
llowed prior to completion of the final 
report of the multicenter study  except as agreed with the sponsor.
10.12 Coordinating Investigator
A signatory  Coordinating I nvestigator will be designated prior to the writing of the clinical study 
report.
Allergan Confidential Protocol 3101-303-002 Amendment 3
8811. References
Aurora SK, Dodick DW , Turkel CC, DeGry se RE, Silberstein SD, L ipton RB, et al ; PREEMPT  1 
Chronic Migraine Study Group. OnabotulinumtoxinA  for treatment of chronic migraine: results 
from the double -blind, randomized, placebo -controlled phase of the PREEMPT  1 trial. 
Cephalalgia. 2010 Jul;30(7):793 -
803.
Bigal ME, Dodick DW , Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safet y, tolerability , 
and efficacy of TEV -48125 for preventive treatment of high -frequency  episodic migraine: a 
multicentre, randomised, do uble-blind, placebo -controlled, phase 2b stu dy. Lancet Neurol. 
2015;14:1081-1090.
Bigal M, Rapoport A, Sheftell F , Tepper D, and T epper S. Memantine in the preventive treatment 
of refractory  migraine. Headache .2008;48:1337- 1342.
Blumenfeld A, Varon SF , Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability , HRQo L 
and resource use among chronic and episodic migraineurs: results from the I nternational Burden 
of Migraine Stud y (IBMS). Cephalalgia. 201 1 Feb;31(3):301 -315
Bretz F , Posch M, Glimm E, Klinglmueller F , Maurer , Rohmey er K. Graphical approaches for 
multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. 
Biometrical Journal. 53 (201 1) 6, 894-913.
Connor KM,Shapiro RE,Diener HC, Lucas S,Kost J,FanX,et al.Randomized, controlled
trial oftelcagepant fortheacute treatment ofmigraine. Neurolog y. 2009 Sep 22;73(12):970 -977.
Diener HC, Dodick DW , Aurora SK, T urkel CC, DeGry se RE, Lipton RB, et al; PREEMPT  2 
Chronic Migrai ne Study Group. OnabotulinumtoxinA  for treatment of chronic migraine: results 
from the double -blind, randomized, placebo -controlled phase of the PREEMPT  2 trial. 
Cephalalgia. 2010 Jul;30(7):804 -
814.
Evers S, Afra J, Frese A, Goadsb y PJ, Linde M, May A, et al. EFNS guidel ines on the drug 
treatment of migraine –revised report of an EFNS task force. E ur J Neurol .
2009 Sep;16(9):968 -
981.
Headache Classification Committee of the I nternational Headache Societ y (IHS). The 
International Classification of Headache Disorders, 3rd edition. Cephalalgia. 201 8;38(1): 1-211.
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika .
1988;75(4):800 -
802.
Allergan Confidential Protocol 3101-303-002 Amendment 3
89Hoffmann J, Akerman S, Goadsb y PJ. Ef ficacy  and mechanism of anticonvulsant drugs in 
migraine. Expert Rev Clin Pharmacol .2014;7:191-201.
Hu XH, Markson LE,Lipton RB, Stewart WF,Berger ML. Burden ofmigraine inthe United 
States. Arch Intern Med. 1999;159:813 -818.
Katsarava Z, Buse DC, Manack AN, L
ipton RB. Defining the Differences Between Episodic 
Migraine and Chronic Migraine. Curr Pain Headache R ep. 2012:16:86-92.
Kenward MG , Roger JH. Small sample inference for fixed ef fects from restricted maximum 
likelihood. Biometrics .1997;53:983 -
997. 
Lipton RB, Bigal ME, Diamond M, Freitag F , Reed ML , Stewart WF . Migraine prevalence, 
disease burden, and the need for preventive therapy . Neurology .2007;68:343 -349.
Mehrotra DV , Li X, Liu J, L u K. Anal ysis of longitudinal clinical trials with missing data using 
multiple imputation in conjunction with robust regression. Biometrics. 2012;68(4):1250-1259. 
Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF , Tierce J, et al. Economic burden of 
transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) 
Study . Headache. 2009 Apr;49(4):498-508.
Olesen J, Bousser M -G, Diener H -C, Dodick D, First M et al. New appendix criteria open for a 
broader concept of chronic migraine. Cephalalgia, 2006;26:742-746.
Olesen J,Diene r H-C, Husstedt IW,Goadsb yPJ,Hall D, Meie r U, et al.Calcitoni ngene -related
peptide receptor antagonist BIBN 4096 BSfortheacute treatment ofmigraine. NEngl J Med. 
2004:350;1 104-1110.
Sakai F , Igarashi H. Prevalence of Migraine in Japan: a nationwide survey . Cephalalgia 
1997;17:15-22.
Schürks M, Diener HC, Goadsb y P. Update on the Prophy laxis of Migraine. Current Treatment 
Options in Neurology . Springer US [New York]; 2008 Jan;10(1):20-29.
Silberstein SD, Holland S, Freita F , Dodick DW , Argoff C, Ashman E. Evidence -based guideline 
update: pharmacologic treatment for ep isodic migraine prevention in adults. Neurology  
2012;78:1337-1345.
Allergan Confidential Protocol 3101-303-002 Amendment 3
90Silberstein SD, Dodick DW , Bigal ME, Yeung PP , Goadsb y PJ, Blankenbiller T ,et al. 
Fremanezumab for the Preventive T reatment of Chronic Migraine, N Engl J Med 
2017;377:21 13-2122.
Steiner TJ , Paemeleire K, Jensen R, Valade D, Savi L , Lainez MJA, et al. European principles of 
management of common headache disorders in primary  care. J Headache Pain 
2007;Oct;8 Suppl 1:S3-47.
Steiner TJ, Stover LJ, Birbeck GL. Migraine: The Seventh Disabler . Headache 2013 Feb;227 -229.
Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight Project. J 
Headache Pain. 2010:1 1;289 -299.
Takeshima T , Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, et al. Population -based 
door- to-door survey  of migraine in Japan: the Daisen study . Headache 2004;44:8 - 19.
Yu S. Guidelines for Prevention and T reatment of Migraine in China. Chinese journal of pain 
medicine 2016;22(10):721-727.
Vos T, Flaxman AD, Naghavi M, L ozano R, Michaud C, Ezzati M, et al. Years lived with 
disability  (YLDs) for 1 160 sequelae of 289 diseases and injuries 1990 -2010: a sy stemic anal ysis 
for the Global Burden of Disease Stud y 2010. Lancet. 2012;380:2163 -2196.
Allergan Confidential Protocol 3101-303-002 Amendment 3
9112. Attachments
12.1 International Classification of Headache Disorders, 3rdEdition 
Allergan Confidential Protocol 3101-303-002 Amendment 3
921.Migraine
1.1 Migraine without aura
1.2 Migraine with aura
1.2.1 Migraine with typical aura
1.2.1.1 Typical aura with headache
1.2.1.2 Typical aura without headache
1.2.2 Migraine with brainstem aura
1.2.3 Hemiplegic migraine
1.2.3.1 Familial hemiplegic migraine
(FHM)
1.2.3.1.1 Familial hemiplegic migraine 
type 1 (FHM1)
1.2.3.1.2 Familial hemiplegic migraine 
type 2 (FHM2)
1.2.3.1.3 Familial hemiplegic migraine 
type 3 (FHM3)
1.2.3.1.4 Familial hemiplegic migraine, 
other loci
1.2.3.2 Sporadic hemiplegic migraine
(SHM)
1.2.4 Retinal migraine
1.3 Chronic migraine
1.4 Complications of migraine
1.4.1 Status migrainosus
1.4.2 Persistent aura without infarction
1.4.3 Migrainous infarction
1.4.4 Migraine aura-triggered seizure
1.5 Probable migraine
1.5.1 Probable migraine without aura
1.5.2 Probable migraine with aura
1.6 Episodic syndromes that may be associated
with migraine
1.6.1 Recurrent gastrointestinal disturbance
1.6.1.1 Cyclical vomiting syndrome
1.6.1.2 Abdominal migraine
1.6.2 Benign paroxysmal vertigo
1.6.3 Benign paroxysmal torticollis
Coded elsewhere:
Migraine -like headache secondary to another 
disorder (symptomatic migraine ) is coded as a 
secondary head -ache attributed to that disorder.
General comment
Primary or secondary headache or both? Three 
rules apply to migraine -like headache, 
according to circumstances.
1.When a new headache with the 
characteristics of migraine occurs for the 
ﬁrst time in close temporal relation to 
another disorder known to cause head -
ache, or fulﬁls other criteria for causation 
by that disorder, the new headache is 
coded as a secondary headache attributed
tothecausative disorder.
2.When pre-existing migraine becomes
chronic inclose temporal relation to such a 
causative disorder, both the initial migraine 
diagnosis and the secondary diagnosis should be given. 8.2 Medication -overuse head -ache is a 
particularly important example of this: both the 
migraine diagnosis (episodic or chronic) and the 
diagnosis 8.2Medication -overuse headache should
be given when medication overuse is present.
3.When pre-existing migraine is made signi ﬁcantly 
worse (usually meaning a twofold or greater
increase in frequency and/or severity) in close 
temporal relation to such a causative disorder, both 
the initial migraine diagnosis and the secondary 
headache diagnosis should be given, provided that 
there is good evidence that the disorder can cause
headache.
Introduction
Migraine is a common disabling primary headache dis-
order . Many epidemiological studies have documented its 
high prevalence and socio -economic and personal impacts. 
In the Global Burden of Disease Study 2010 (GBD2010), 
it was ranked as the third most prevalent disorder in the 
world. In GBD2015, it was ranked the third-highest cause 
of disability worldwide in both males and females under 
the age of 50 years.
Migraine has two major types: 1.1 Migraine without 
aura is a clinical syndrome characterized by headache 
with speci ﬁc features and associated symptoms; 1.2
Migraine with aura is primarily characterized by the 
transient focal neurological symptoms that usually 
precede or sometimes accompany the headache. Some 
patients also experience a prodromal phase, occurring 
hours or days before the headache, and/or a postdromal 
phase following headache resolution. Prodromal and 
postdromal symptoms include hyperactivity, hypoactiv ity, 
depression, cravings for particular foods, repetitive 
yawning, fatigue and neck sti ﬀness and/or pain.
When a patient ful ﬁls criteria for more than one type, 
subtype or subform of migraine, all should be diagnosed 
and coded. For example, a patient who has frequent 
attacks with aura but also some attacks without aura 
should be coded as 1.2 Migraine with aura and 1.1
Migraine without aura .However, since thediagnostic 
criteria for 1.3 Chronic migraine subsume attacks of all 
types, subtypes or subforms, additional coding is 
unnecessary for episodic subtypes of migraine.
1.1 Migraine without aura
Previously used terms: Common migraine; hemicrania 
simplex
Description: Recurrent headache disorder manifesting 
in attacks lasting 4–72 hours Typical characteristics of 
the headache are unilateral location, pulsating quality, 
moderate or severe intensity, aggravation by routine 
physical activity and association with nausea and/or 
photophobia and phonophobia.
Allergan Confidential Protocol 3101-303-002 Amendment 3
93Diagnostic criteria:
A. At least ﬁve attacks1fulﬁlling criteria B–D
B. Headache attacks lasting 4–72 hours 
(when untreated or unsuccessfully
treated)2,3
C. Headache has at least two of the following 
four characteristics:
1. unilateral location
2. pulsating quality
3. moderate or severe pain intensity
4. aggravation by or causing avoidance of 
routine physical activity (eg,walking or
climbing stairs)
D. During headache atleast oneofthefollowing:
1. nausea and/or vomiting
2. photophobia and phonophobia
E. Not better accounted for by another ICHD -3 
diagnosis.
Notes:
1.One or a few migraine attacks may be difficult to 
distinguish from symptomatic migraine -like 
attacks. Furthermore, the nature of a single or a 
few attacks may be difficult to understand. 
Therefore, at least ﬁve attacks are required. 
Individuals who otherwi se meet criteria for 1.1 
Migraine without aura but have had fewer than 
ﬁve attacks should be coded 1.5.1 Probable 
migraine without aura .
2.When the patient falls asleep during a migraine 
attack and wakes up without it, duration of the 
attack isreckoned untilthetime ofawakening.
3.In children and adolescents (aged under 18 years), 
attacks may last 2–72 hours (the evidence for 
untreated durations of less than two hours in 
children has not been substantiated).
Comments: Migraine headache in children and
adolescents (aged under 18years) ismore often bilateral
than isthecase inadults; unilateral pain usually emerges
in lateadolescence orearly adult life. Migraine headache 
is usually frontotemporal. Occipital headache in 
children is rare and calls for diagnostic caution. A subset 
of otherwise typical patients have facial location of pain,
which iscalled ‘facial migraine’ intheliterature; there is
noevidence thatthese patients form a separate subgroup 
of migraine patients. Prodromal symptoms may begin 
hours or a day or two before theother symptoms ofa
migraine attack with-out aura. They include various 
combinations of fatigue, diﬃculty in concentrating, neck 
stiﬀness, sensitivity to light and/or sound, nausea, blurred 
vision, yawning and pallor. Postdromal symptoms, most
commonlyfeeling tired or weary, difficulty with concentration and
neck stiffness, may follow resolution of the headache,
persisting for up to 48 hours; these are less well studied.
Migraine attacks can be associated with cranial 
autonomic symptoms and symptoms of cutaneous 
allodynia.
In young children, photophobia and phonophobia 
may be inferred from their behaviour.
A minority (<10%) of women have attacks of 
migraine in association with the majority of their 
menstrual cycles; most such attacks are without aura. 
Attacks during menstruation tend to be longer and 
accompanied by more severe nausea than attacks out-
side the menstrual cycle. ICHD -3 offers criteria for 
A1.1.1 Pure menstrual migraine without aura , A1.1.2 
Menstrually related migraine without aura and A1.1.3 
Non-menstrual migraine without aura , but in the 
Appendix because of uncertainty over whether they 
should be regarded as separate entities. Criteria arealso 
offered for A1.2.0.1 Pure menstrual migraine with aura , 
A1.2.0.2 Menstrually related migraine with aura and 
A1.2.0.3 Non-menstrual migraine with aura to 
encourage better characterization of these uncommon 
subforms if they are separate entities.
Very frequent migraine attacks are distinguished as 1.3 
Chronic migraine . When there is associated medication
overuse, both ofthediagnoses 1.3Chronic migraine and
8.2Medication -overuse headache should beapplied. 1.1 
Migraine without aura isthedisease most prone to
accelerate with frequent useofsymptomatic medication.
Regional cerebral blood ﬂowimaging shows no
changes suggestive of cortical spreading depression
(CSD) during attacks of 1.1 Migraine without aura ,
although blood ﬂow changes inthebrainstem may 
occur, as may cortical changes secondary to pain
activation. This contrasts with thepathognomonic
spreading oligaemia of1.2Migraine with aura .While the
bulk oftheliterature suggests that CSD does not occur in
1.1Migraine without aura , some recent studies disagree.
Furthermore, ithasbeen suggested that glial waves or
other cortical phenomena may be involved in1.1
Migraine without aura . The messenger molecules nitric
oxide (NO), serotonin (5 -hydroxytryptamine; 5-HT) and
calcitonin gene -related peptide (CGRP) areinvolved.
While the disease was previously regarded asprimarily 
vascular, the importance of sensitization of pain path-
ways, andthepossibility thatattacks may originate inthe
central nervous system, have gained increasing attention
over the last decades. At the same time, the circuitry of 
migraine pain, thetrigeminovascular system, andseveral
aspects of its neurotransmission peripherally and inthe
trigeminal nucleus caudalis, central mesencephalic grey
and thalamus, have been recognized. Highly receptor -
speci ﬁc acute medications including 5-HT 1B/Dreceptor
agonists (triptans), 5 -HT 1Freceptor agonists andCGRP
receptor antagonists have demonstrated efficacy inthe
Allergan Confidential Protocol 3101-303-002 Amendment 3
94acute treatment of migraine attacks. Because of their 
high receptor -speci ﬁcity, their mechanisms ofaction
pro-vide new insight into migraine mechanisms. It is 
now clear that 1.1 Migraine without aura isa
neurobiological disorder, while clinical aswell asbasic
neuroscience stu-dies continue to advance our 
knowledge of migraine mechanisms.
1.2 Migraine with aura
Previously used terms: Classic or classical migraine; 
ophthalmic, hemiparaesthetic, hemiplegic or aphasic 
migraine; migraine accompagne´ e;complicated migraine.
Description: Recurrent attacks, lasting minutes, of 
unilateral fully reversible visual, sensory or other 
central nervous system symptoms that usually develop 
gradually and are usually followed by headache and 
associated migraine symptoms.
Diagnostic criteria:
A. Atleast two attacks fulﬁlling criteria B and C
B. One or more of the following fully reversible 
aura symptoms:
1. visual
2. sensory
3. speech and/or language
4. motor
5. brainstem
6. retinal
C. Atleast three ofthefollowing six
characteristics:
1. at least one aura symptom spreads gradually 
over 5 minutes
2. two or more aura symptoms occur in
succession
3. each individual aura symptom lasts 5 –60 
minutes1
4. at least one aura symptom is unilateral2
5. atleast oneaura symptom ispositive3
6. the aura is accompanied, or followed within 
60 minutes, by headache
D. Not better accounted for by another ICHD -3 
diagnosis.
Notes:
1.When, for example, three symptoms occur during 
an aura, the acceptable maximal duration is 3 x 60 
minutes. Motor symptoms maylast upto72
hours.
2.Aphasia is always regarded as a unilateral 
symptom; dysarthria may or may no tbe.
3.Scintillations and pins and needles are positive 
symptoms of aura.Comments: Many patients who have migraine attacks with 
aura also have attacks without aura; they should be coded 
as both 1.2 Migraine with aura and 1.1 Migraine without
aura .
Field testing has compared the diagnostic criteria for 1.2 
Migraine with aura in the main body of ICHD -3 beta with 
those for A1.2 Migraine with aura in the Appendix. The 
latter performed better in distinguishing migraine with aura 
from transient ischaemic attacks. These are now adopted in 
ICHD -3, which no longer has Appendix criteria for this
disorder.
The aura is the complex of neurological symptoms that 
occurs usually before the headache of 1.2 Migraine with 
aura , but it may begin after the headache phase has 
commenced orcontinue into theheadache phase.
Visual aura is the most common type of aura, occur -
ring in over 90% of patients with 1.2 Migraine with aura , 
at least in some attacks. It often presents as a fortiﬁcation 
spectrum: a zigzag ﬁgure near thepoint of ﬁxation that 
may gradually spread right or left and assume a laterally 
convex shape with an angulated scintillating edge, leaving 
absolute or variable degrees of relative scotoma in its wake. 
In other cases, scotoma without positive phenomena may 
occur; this is often perceived as being of acute onset but, on 
scrutiny, usually enlarges gradually. In children and 
adolescents, less typical bilateral visual symptoms occur 
that may represent an aura. A visual aura rating scale with 
high speci ﬁcity and sensitivity has been developed and
validated.
Next in frequency are sensory disturbances, in the form 
of pins and needles moving slowly from the point oforigin
andaﬀecting agreater orsmaller partofoneside of thebody,
face and/or tongue. Numbness may occur in its wake, but 
numbness may also be the only symptom.
Less frequent are speech disturbances, usually aphasic 
but often hard to categorize.
Systematic studies have demonstrated that many 
patients with visual aura occasionally have symptoms in 
the extremities and/or speech symptoms. Conversely, 
patients with symptoms in the extremities and/or speech or 
language symptoms almost always also exper ience visual 
aura symptoms at least during some attacks. A distinction 
between migraine with visual aura, migraine with 
hemiparaesthetic aura and migraine with speech and/or 
language aura is probably artiﬁcial, and therefore not
recognized inthisclassi ﬁcation: they areall coded as 1.2.1 
Migraine with typical aura .
When aura symptoms are multiple, they usually follow 
one another in succession, beginning with visual, then 
sensory, then aphasic; but the reverse and other orders have 
been noted. The accepted duration for most aura symptoms 
is one hour, but motor symptoms are often longer lasting.
Patients with aura symptoms arising from the brain -stem
arecoded as1.2.2 Migraine with brainstem aura ,but
Allergan Confidential Protocol 3101-303-002 Amendment 3
95they almost always have additional typical aura symptoms. 
When the aura includes motor weakness, the dis-order 
should be coded as 1.2.3 Hemiplegic migraine or one of its 
subforms. 1.2.3 Hemiplegic migraine is classiﬁed as a 
separate subtype because of genetic and patho physiological
differences from 1.2.1 Migraine with typical aura . Patients 
with 1.2.3 Hemiplegic migraine often have brainstem 
symptoms inaddition.
Patients often ﬁndithard todescribe their aura
symptoms, in which case they should be instructed to time 
and record them prospectively. The clinical picture then 
becomes clearer. Common mistakes are incorrect reports of 
lateralization, of sudden rather than gradual onset and of 
monocular rather than homonymous visual disturbances, as 
well as of duration of aura and mistaking sensory loss for 
weakness. After an initial consult ation, useofanaura diary
may clarify thediagnosis.
Migraine aura is sometimes associated with a head -
ache that does notfulﬁllcriteria for1.1Migraine without 
aura , but this is still regarded as a migraine headache 
because of its relation to the aura. In other cases, migraine 
aura may occur without headache.
Before or simultaneously with the onset of aura 
symptoms, regional cerebral blood ﬂow is decreased in the 
cortex corresponding to the clinically affected area and 
often over a wider area. Blood ﬂow reduction usually starts 
posteriorly and spreads anteriorly, and is usually above the 
ischaemic threshold. After one to several hours, gradual 
transition into hyperaemia occurs in the same region. 
Cortical spreading depression ofLea˜ oisthe likely
underlying mechanism.
The previously deﬁned syndromes, migraine with 
prolonged aura and migraine with acute -onset aura , have 
been abandoned. It is not rare for aura to last more than one 
hour but, in most such cases, patients have at least two of 
the other characteristics of criterion
C. Even when most of a patient’s attacks do not fulﬁl 
criterion C, it is usual that other attacks fulﬁl criteria for 
one of the recognized subtypes or subforms of 1.2 
Migraine with aura , and this should be the diagnosis. The 
few other cases should be coded to 1.5.2 Probable migraine 
with aura, specifying the atypical feature (pro-longed aura or 
acute -onset aura) in parenthesis. The diagnosis is usually 
evident after a careful history alone, although there are rare 
secondary mimics including carotid dissection, arteriovenous 
malformation andseizure.
Prodromal symptoms may begin hours oradayortwo 
before the other symptoms of a migraine attack with aura. 
They include various combinations of fatigue, difﬁculty in
concentrating, neck stiﬀness, sensitivity tolight and/or 
sound, nausea, blurred vision, yawning and pallor. The 
term ‘prodrome’, wh ich has replaced ‘pre -monitory phase’ 
or ‘premonitory symptoms’, does not include aura. 
Postdromal symptoms, most commonly feeling tired or 
weary, difficulty with concentration andneck stiffness, may follow resolution of the headache, 
persisting for up to 48 hours; these are less well studied.
1.2.1 Migraine with typical aura
Description: Migraine with aura, in which aura 
consists of visual and/or sensory and/or 
speech/language symptoms, but no motor weakness, 
and is characterized by gradual development, duration 
of each symptom no longer than one hour, a mix of 
positive and negative features and complete 
reversibility
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2 Migraine with 
aura and criterion B below
B. Aura with both of the following:
1. fully reversible visual, sensory and/or 
speech/ language symptoms
2. no motor, brainstem or retinal symptoms.
1.2.1.1 Typical aura with headache
Description: Migraine with typical aura in which aura 
is accompanied or followed within 60 minutes by 
head -ache with or without migraine characteristics.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.1 Migraine with 
typical aura and criterion B below
B. Headache, with orwithout migraine
characteristics, accompanies orfollows theaura
within 60minutes.
1.2.1.2 Typical aura without headache
Description: Migraine with typical aura in which aura is 
neither accompanied nor followed by headache of any sort.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.1 Migraine with 
typical aura and criterion B below
B. No headache accompanies or follows the aura 
within 60 minutes.
Comments: In some patients, a typical aura is always 
followed by migraine headache, but many patients 
have, in addition, attacks with aura followed by a less 
distinct headache or even wit hout headache. A number 
of patients have, exclusively, 1.2.1.2 Typical aura 
with-outheadache .
Allergan Confidential Protocol 3101-303-002 Amendment 3
96In the absence of headache fulﬁlling criteria for 1.1 
Migraine without aura ,theprecise diagnosis ofaura and 
its distinction from mimics that may signal serious dis-
ease (eg,transient ischaemic attack) becomes more 
difﬁcult and often requires investigation. When aura 
occurs for the ﬁrst time after age 40, when symptoms 
are exclusively negative (eg,hemianopia) or when aura 
is prolonged or very short, other causes, particularly 
transient ischaemic attacks, should beruled out.
1.2.2 Migraine with brainstem aura
Previously used terms: Basilar artery migraine; basilar 
migraine; basilar -type migraine.
Description: Migraine with aura symptoms clearly 
originating from the brainstem, but no motor weakness.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2 Migraine with 
aura and criterion B below
B. Aura with both of the following:
1. at least two of the following fully reversible 
brainstem symptoms:
a. dysarthria1
b. vertigo2
c. tinnitus
d. hypacusis3
e. diplopia4
f.ataxia not attributable to sensory
deﬁcit
g. decreased level of consciousness (GCS 
≤13)5
2. no motor6or retinal symptoms.
Notes:
1.Dysarthria should be distinguished from aphasia.
2.Vertigo does not embrace and should be 
distinguished from dizziness.
3.This criterion is not ful ﬁlled by sensations of ear 
fullness.
4.Diplopia does not embrace (or exclude) blurred 
vision.
5.The Glasgow Coma Scale (GCS) score may have 
been assessed during admission; alternatively, 
deficits clearly described by the patient allow GCS 
estimation.
6.When motor symptoms are present, code as 1.2.3
Hemiplegic migraine .
Comments: Originally the terms basilar artery 
migraine or basilar migraine were used but, since 
involvement of the basilar artery is unlikely, the term 
migraine with brainstem aura ispreferred.There are typical aura symptoms in addition to the 
brainstem symptoms during most attacks. Many 
patients who have attacks with brainstem aura also 
report other attacks with typical aura and should be 
coded for both 1.2.1 Migraine with typical aura
and 1.2.2 Migraine with brainstem aura .
Many of the symptoms listed under criterion B1 
may occur with anxiety and hyperventilation, and are 
therefore subject to misinterpretation.
1.2.3 Hemiplegic1migraine
Description: Migraine with aura including
motor weakness.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2 Migraine with 
aura and criterion B below
B. Aura consisting ofboth ofthefollowing:
1. fully reversible motor weakness2
2. fully reversible visual, sensory and/or 
speech/ language symptoms.
Notes:
1.The term plegic means paralysis in most languages, 
but most attacks are characterized by motor 
weakness.
2.Motor symptoms generally last less than 72 hours 
but, in some patients, motor weakness may persist 
forweeks.
Comment: It may be difficult to distinguish weakness 
from sensory loss.
1.2.3.1 Familial hemiplegic migraine (FHM)
Description: Migraine with aura including motor 
weak -ness, and at least one ﬁrst-or second -degree 
relative has migraine aura including motor weakness.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3 Hemiplegic 
migraine
B. At least one ﬁrst-or second -degree relative has 
had attacks fulﬁlling criteria for 1.2.3 
Hemiplegic migraine .
Comments: New genetic data have allowed amore
precise deﬁnition of 1.2.3.1 Familial hemiplegic 
migraine than was previously possible. Speci ﬁc 
genetic subforms have been identi ﬁed: in FHM1 there 
are mutations in the
Allergan Confidential Protocol 3101-303-002 Amendment 3
97CACNA1A gene (coding foracalcium channel) on 
chromosome 19; in FHM2 there are mutations in the 
ATP1A2 gene (coding for a K/Na -ATPase) on chromo -
some 1; and in FHM3 there are mutations in the SCN1A 
gene (coding for a sodium channel) on chromosome 2. 
There may beother loci notyetidentiﬁed. When genetic 
testing isdone, thegenetic subform (ifdiscovered) should be
speci ﬁedattheﬁfth digit.
It has been shown that 1.2.3.1 Familial hemiplegic 
migraine very often presents with brainstem symptoms in 
addition to the typical aura symptoms, and that headache 
almost always occurs. Rarely, during FHM attacks, 
disturbances of consciousness (sometimes including coma), 
confusion, fever and cerebrospinal ﬂuid (CSF) pleocytosis 
can occur.
1.2.3.1 Familial hemiplegic migraine may bemistaken for 
epilepsy and treated (unsuccessfully) as such. FHM attacks 
can be triggered by (mild) head trauma. In approximately 
50% of FHM families, chronic progressive cerebellar 
ataxia occurs independently of the migraine attacks.
1.2.3.1.1 Familial hemiplegic migraine type 1 (FHM1)
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3.1 Familial 
hemiplegic migraine
B. A mutation on the CACNA1A gene has been 
demonstrated.
1.2.3.1.2 Familial hemiplegic migraine type 2 (FHM2)
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3.1 Familial 
hemiplegic migraine
B. A mutation on the ATP1A2 gene has been 
demonstrated.
1.2.3.1.3 Familial hemiplegic migraine type 3 (FHM3)
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3.1 Familial 
hemiplegic migraine
B. A mutation on the SCN1A gene has been 
demonstrated.
1.2.3.1.4 Familial hemiplegic migraine, other loci
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3.1 Familial 
hemiplegic migraineB. Genetic testing has demonstrated no mutation
on the CACNA1A , ATP1A2 or SCN1A genes.
1.2.3.2 Sporadic hemiplegic migraine (SHM)
Description: Migraine with aura including motor 
weak -ness, and no ﬁrst-or second -degree relative has 
migraine aura including motor weakness.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3 Hemiplegic 
migraine
B. No ﬁrst-or second -degree relative ful ﬁls criteria 
for 1.2.3 Hemiplegic migraine.
Comments: Epidemiological studies have shown that 
sporadic cases occur with approximately the same 
prevalence as familial cases.
The attacks in 1.2.3.2 Sporadic hemiplegic 
migraine have the same clinical characteristics as 
those in 1.2.3.1 Familial hemiplegic migraine .Some
apparently sporadic cases have known FHM mutations 
and, in some, a ﬁrst-or second -degree relative later 
develops hemiplegic migraine, thus completing
fulﬁlment ofthecriteria for
1.2.3.1 Familial hemiplegic migraine and requiring a 
change of diagnosis.
Sporadic cases usually require neuroimaging and 
other tests to rule out other causes. A lumbar puncture 
may be necessary to rule out 7.3.5 Syndrome of 
transient headache and neurological deﬁcits with
cerebrospinal ﬂuid lymphocytosis (HaNDL) .
1.2.4 Retinal migraine
Description: Repeated attacks of monocular visual 
disturbance, including scintillations, scotomata or 
blindness, associated with migraine headache.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2 Migraine with 
aura and criterion B below
B. Aura characterized byboth ofthefollowing:
1. fully reversible, monocular, positive and/or 
negative visual phenomena ( eg,scintillations, 
scotomata or blindness) conﬁrmed during 
an attack by either orboth ofthe
following:
a. clinical visual ﬁeld examination
b. the patient’s drawing of a monocular 
ﬁeld defect (made after clear
instruction)
2. at least two of the following:
a. spreading gradually over ≥ 5 minutes
b. symptoms last 5 –60minutes
Allergan Confidential Protocol 3101-303-002 Amendment 3
98c. accompanied, or followed within 60 
minutes, by headache
C. Not better accounted for by another ICHD -3 
diagnosis, and other causes of amaurosis fugax 
have been excluded.
Comments: Some patients who complain of 
monocular visual disturbance in fact have hemianopia. 
Some cases without headache have been reported, but 
migr aine as the underlying aetiology cannot be 
ascertained.
1.2.4 Retinal migraine is an extremely rare cause 
of transient monocular visual loss. Cases of permanent 
monocular visual loss associated with migraine have 
been described. Appropriate investigations are 
required to exclude other causes of transient 
monocular blindness.
1.3 Chronic migraine
Description: Headache occurring on 15 or more 
days/ month for more than three months, which, on 
at least eight days/month, hasthefeatures ofmigraine
headache.
Diagnostic criteria:
A. Headache (migraine -like or tension -type-like1) 
on 15 days/month for >3 months, and fulﬁlling
criteria B and C
B. Occurring in a patient who has had at least ﬁve 
attacks fulﬁlling criteria B–D for1.1Migraine
with-out aura and/or criteria B and C for 1.2 
Migraine with aura
C. On 8 days/month for >3 months, ful ﬁlling any of 
thefollowing2:
1. criteria C and D for 1.1 Migraine without
aura
2. criteria BandCfor1.2Migraine with aura
3. believed by the patient to be migraine at 
onset and relieved by a triptan or ergot
derivative
D. Not better accounted for by another ICHD -3 
diagnosis.3–5
Notes:
1.The reason forsingling out1.3Chronic migraine
from types of episodic migraine is that it is 
impossible to distinguish the individual episodes 
of headache in patients with such frequent or 
continuous headaches. In fact, the characteristics 
of the headache may change not only from day to 
day but even within the same day. Such patients 
are extremely diﬃcult to keep medication -free in 
order to observe the natural history of the 
headache. In this situation, attacks with and those 
without aura are both counted, as are both 
migraine -like and tension -type-like headaches (but 
not secondary headaches).2.Characterization of frequently recurring 
headach e generally requires aheadache diary to
record information on pain and associated 
symptoms day by day for at least one month.
3.Because tension -type-like headache is within the 
diagnostic criteria for 1.3 Chronic migraine , this 
diagnosis excludes the diagnosis of 2. Tension -
type headache or its types.
4.4.10 New daily persistent headache may have
features suggestive of1.3Chronic migraine .The
latter disorder evolves over time from 1.1Migraine
without aura and/ or 1.2 Migraine with aura ; 
therefore, when these criteria A–C are fulﬁlled by 
headache that, unambiguously, is daily and 
unremitting from <24 hours after itsﬁrstonset,
code as4.10 New daily persistent head -ache .
When themanner ofonset isnotremembered or is
otherwise uncertain, code as1.3Chronic migraine .
5.The most common cause of symptoms suggestive
ofchronic migraine ismedication overuse, as
deﬁned under 8.2Medication -overuse headache .
Around 50% of patients apparently with 1.3 
Chronic migraine revert to an episodic migraine 
type after drug withdrawal; such patients are in a 
sense wrongly diagnosed as 1.3 Chronic migraine . 
Equally, many patients apparently overusing 
medication do not improve after drug withdrawal; 
the diagnosis of 8.2 Medication -overuse headache 
may be inappropriate for these (assuming that 
chronicity induced by drug overuse is always 
reversible). For these reasons, and because of the 
general rule to apply all relevant diagnoses, 
patients meeting criteria for 1.3 Chronic migraine 
and for 8.2 Medication -overuse headache should 
be coded for both. After drug withdrawal, 
migraine will either revert to an episodic type or 
remain chronic and should be re-diagnosed 
accordingly; in the latter case, the diagnosis of 8.2 
Medication -overuse headache may berescinded.
1.4 Complications of migraine
Comment: Code separately for both the migraine type, 
subtype or subform and for the complication.
1.4.1 Status migrainosus
Description: A debilitating migraine attack lasting for 
more than 72 hours.
Diagnostic criteria:
A. A headache attack ful ﬁlling criteria B and C
B. Occurring in a patient with 1.1 Migraine without 
aura and/or 1.2 Migraine with aura , and typical 
of previous attacks except foritsduration and
severity
Allergan Confidential Protocol 3101-303-002 Amendment 3
99C. Both of the following characteristics:
1. unremitting for >72 hours1
2. pain and/or associated symptoms are debilitating2
D. Not better accounted for by another ICHD -3 
diagnosis.
Notes:
1.Remissions of up to 12 hours due to medication or 
sleep are accepted.
2.Milder cases, notmeeting criterion C2, are
coded
1.5.1 Probable migraine without aura .
Comment: Headache with the features of 1.4.1 Status 
migrainosus may often be caused by medication overuse. 
When headache in these circumstances meets the criteria for 
8.2 Medication -overuse headache , code for this dis- order 
and the relevant type or subtype of migraine but not for 
1.4.1 Status migrainosus . When overuse of medication is of 
shorter duration than three months, code for the appropriate 
migraine type or subtype(s) only.
1.4.2 Persistent aura without infarction
Description: Aura symptoms persisting for one week 
or more without evidence of infarction on 
neuroimaging.
Diagnostic criteria:
A. Aura ful ﬁlling criterion B
B. Occurring in a patient with 1.2 Migraine with
aura and typical of previous auras except that 
one or more aura symptoms persists for 1 week
C. Neuroimaging shows no evidence of infarction
D. Not better accounted for by another ICHD -3 
diagnosis.
Comments: Persistent aura symptoms are rare but well 
documented. They are often bilateral and may last for 
months or years. The one-week minimum in criterion 
B is based on the opinion of experts and should be 
formally studied.
Diagnostic work -up must distinguish 1.4.2
Persistent aura without infarction from 1.4.3 
Migrainous infarction and exclude symptomatic aura 
due to cerebral infarction of other causes. Attacks with
prolonged aura lasting less than one week and not 
fulﬁlling criteria for 1.2.1 Migraine with typical aura 
are coded 1.5.2 Probable migraine with aura.
1.4.3 Migrainous infarction
Description: One or more migraine aura symptoms 
occurring in association with an ischaemic brainlesion in the appropriate territory demonstrated by 
neuroimaging, with onset during the course of a 
typical migraine with aura attack.
Diagnostic criteria:
A. A migraine attack ful ﬁlling criteria B and C
B. Occurring in a patient with 1.2 Migraine with 
aura and typical of previous attacks except that 
one or more aura symptoms persists for >60
minutes1
C. Neuroimaging demonstrates ischaemic 
infarction in a relevant area
D. Not better accounted for by another ICHD -3 
diagnosis.
Note:
1. There may be additional symptoms attributable to
theinfarction.
Comments: Ischaemic stroke in a migraine sufferer 
may be categorized as cerebral infarction of other 
cause coexisting with 1. Migraine , cerebral infarction 
ofother cause presenting with symptoms resembling 
1.2 Migraine with aura , or cerebral infarction 
occurring during the course of a typical attack of 1.2 
Migraine with aura. Only the last fulﬁls criteria for 
1.4.3 Migrainous infarction .
1.4.3 Migrainous infarction mostly occurs in the
posterior circulation and in younger women.
A twofold increased risk of ischaemic stroke in 
patients with 1.2 Migraine with aura has been 
demonstrated in several population -based studies. 
However, it should be noted that these infarctions are 
not migrainous infarctions. The mechanisms of the 
increased risk of ischaemic stroke in migrai ne 
sufferers remain unclear; likewise, the relationship 
between increased risk and frequency of aura and the 
nature of aura symptoms denoting the increase in risk 
are unknown. Most studies have shown a lack of 
association between 1.1 Migraine without aura and 
ischaemic stroke.
1.4.4 Migraine aura -triggered seizure
Description: A seizure triggered by an attack of 
migraine with aura.
Diagnostic criteria:
A. A seizure fulﬁlling diagnostic criteria for one 
type of epileptic attack, and criterion B below
B. Occurring inapatient with 1.2Migraine with
aura , and during or within one hour after an 
attack of migraine with aura
Allergan Confidential Protocol 3101-303-002 Amendment 3
100C. Not better accounted for by another ICHD -3 
diagnosis.
Comment: Migraine and epilepsy are prototypical 
examples of paroxysmal brain disorders. While
migraine -like headaches are quite frequently seen in 
the epileptic post-ictal period, sometimes aseizure
occurs during or following a migraine attack. This 
phenomenon, sometimes referred to as migralepsy , is 
a rare event, originally described in patients with 1.2 
Migraine with aura . Evidence of an association with 
1.1 Migraine without aura islacking.
1.5 Probable migraine
Previously used term: Migrainous disorder.
Coded elsewhere: Migraine -like headache secondary 
to another disorder (symptomatic migraine ) is coded 
according to that disorder.
Description: Migraine -like attacks missing one of the 
features required to fulﬁl all criteria for a type or sub-
type of migraine coded above, and not fulﬁlling 
criteria for another headache diso rder.
Diagnostic criteria:
A. Attacks fulﬁlling allbut one ofcriteria A–D
for
1.1Migraine without aura ,orallbutoneof
criteria A –C for 1.2 Migraine with aura
B. Not fulﬁlling ICHD -3 criteria for any other 
head -ache disorder
C. Not better accounted for by another ICHD -3 
diagnosis.
Comment: In making a headache diagnosis, attacks 
that fulﬁl criteria for both 2. Tension -type headache 
and 1.5 Probable migraine are coded as the former in 
accordance with the general rule that a deﬁnite 
diagnosis always trumps a probable diagnosis. 
However, in patients who already have a migraine 
diagnosis, and where the issue is to count the number 
of attacks they are having ( eg, as an outcome measure 
in a drug trial), attacks fulﬁlling criteria for 1.5 
Probable migraine should be counted as migraine. 
The reason for this is that mild migraine attacks, or 
attacks treated early, often do not achieve all 
characteristics necessary for a migraine attack 
diagnosis but nevertheless respond to speci ﬁc 
migraine treatments.1.5.1 Probable migraine without aura Diagnostic criteria:
A. Attacks fulﬁlling allbut one ofcriteria A–D for
1.1 Migraine without aura
B. Not fulﬁlling ICHD -3 criteria for any other 
head -ache disorder
C. Not better accounted for by another ICHD -3 
diagnosis.
1.5.2 Probable migraine with aura
Diagnostic criteria:
A. Attacks fulﬁlling allbut one ofcriteria A–C for1.2
Migraine with aura or any of its subtypes
B. Not fulﬁlling ICHD -3 criteria for any other 
head -ache disorder
C. Not better accounted for by another ICHD -3 
diagnosis.
1.6 Episodic syndromes that may be 
associated with migraine
Previously used terms: Childhood periodic 
syndromes; periodic syndromes of childhood.
Comments: This group of disorders occurs in patients 
who also have 1.1 Migraine without aura or 1.2 
Migraine with aura , or who have an increased 
likelihood to develop either of these disorders. 
Although historically noted to occur in childhood,
they may also occur in adults.
Additional conditions that may also occur in these 
patients include episodes of motion sickness and 
periodic sleep disorders including sleep walking, sleep 
talking, night terrors and bruxism.
1.6.1 Recurrent gastrointestinal disturbance
Previously used terms: Chronic abdominal pain; 
functional abdominal pain; functional dyspepsia; 
irritable bowel syndrome; functional abdominal pain 
syndrome.
Description: Recurrent episodic attacks of abdominal 
pain and/or discomfort, nausea and/or vomiting, 
occurring infrequently, chronically or at predictable 
intervals, that may be associated with migraine.
Allergan Confidential Protocol 3101-303-002 Amendment 3
101Diagnostic criteria:
A. At least ﬁve attacks with distinct episodes of 
abdominal pain and/or discomfort and/or nausea 
and/or vomiting
B. Normal gastrointestinal examination and evaluation
C. Not attributed to another disorder.
1.6.1.1 Cyclic vomi ting syndrome
Description: Recurrent episodic attacks of intense 
nausea and vomiting, usually stereotypical in the 
individual and with predictable timing of episodes. 
Attacks may be associated with pallor and lethargy. 
There is complete resolution of symptoms between
attacks.
Diagnostic criteria:
A. At least ﬁve attacks of intense nausea and 
vomiting, ful ﬁlling criteria B and C
B. Stereotypical in the individual patient and recur -
ring with predictable periodicity
C. All of the following:
1. nausea and vomiting occur at least four 
times per hour
2. attacks lastfor ≥ 1 hour, up to 10 days
3. attacks occur ≥ 1 week apart
D. Complete freedom from symptoms between 
attacks
E. Not attributed to another disorder.1
Note:
1. In particular, history and physical examination do 
not show signs of gastrointestinal disease.
Comments: 1.6.1.1 Cyclic vomiting syndrome is 
typically a self-limiting episodic condition occurring 
inchild -hood, with periods of complete normality 
between episodes. The cyclic nature is the hallmark, 
and attacks are predictable.
This disorder was ﬁrst included as a childhood 
periodic syndrome in ICHD -II. The clinical features 
of this syndrome resemble those found in association 
with migraine headaches, and multiple threads of 
research over the last years have suggested that 1.6.1.1 
Cyclic vomiting syndrome is a condition related to 
migraine.
1.6.1.2 Abdominal migraine
Description: An idiopathic disorder seen mainly in 
children as recurrent attacks of moderate to severe 
midlineabdominal pain, associated with vaso motor symptoms, 
nausea and vomiting, lasting 2–72 hours and with 
normality between episodes. Headache does not occur 
during these episodes.
Diagnostic criteria:
A. At least ﬁve attacks of abdominal pain, fulﬁlling 
criteria B–D
B. Pain has at least two of the following three 
characteristics:
1. midline location, periumbilical or poorly 
localized
2. dull or ‘just sore’ quality
3. moderate or severe intensity
C. At least two of the following four associated 
symptoms or signs:
1. anorexia
2. nausea
3. vomiting
4. pallor
D. Attacks last2–72hours when untreated or
unsuccessfully treated
E. Complete freedom from symptoms between 
attacks
F. Not attributed to another disorder.1
Note:
1.In particular, history and physical examination do 
not show signs of gastrointestinal or renal disease, 
or such disease has been ruled out by appropriate 
investigations.
Comments: Pain of 1.6.1.2 Abdominal migraine is 
severe enough to interfere with normal daily activities.
In young children, the presence of headache is 
often overlooked. A careful history of presence or 
absence of headache must be taken and, when 
headache or head pain during attacks is identiﬁed, a 
diagnosis of 1.1 Migraine without aura should be 
considered.
Children may ﬁnd it difficult to distinguish 
anorexia from nausea. Pallor is often accompanied by 
dark shadows under the eyes. In a few patients, 
ﬂushing is the predominant vasomotor phenomenon.
Most children with abdominal migraine will 
develop migraine h eadache later in life.
1.6.2 Benign paroxysmal vertigo
Description: A disorder characterized byrecurrent 
brief attacks of vertigo, occurring without warning and 
resolving spontaneously, in otherwise healthy children.
Allergan Confidential Protocol 3101-303-002 Amendment 3
102Diagnostic criteria:
A. Atleast ﬁve attacks fulﬁlling criteria B and C
B. Vertigo1occurring without warning, maximal at 
onset and resolving spontaneously after minutes
to hours without loss of consciousness
C. At least one of the following ﬁve associated 
symptoms or signs:
1. nystagmus
2. ataxia
3. vomiting
4. pallor
5. fearfulness
D. Normal neurological examination and 
audiometric and vestibular functions between
attacks
E. Not attributed to another disorder.2
Notes:
1.Young children with vertigo may not be able to 
describe vertiginous symptoms. Parental 
observation of episodic periods of unsteadiness 
may be interpreted as vertigo in young children.
2.In particular, posterior fossa tumours, seizures and 
vestibular disorders have been excluded.
Comment: The relationship between 1.6.2 Benign
paroxysmal vertigo and A1.6.6 Vestibular migraine 
(see Appendix) needs to be further examined.
1.6.3 Benign paroxysmal torticollis
Description: Recurrent episodes of head tilt to one 
side, perhaps with slight rotation, which remit 
spontaneously. The condit ion occurs in infants and 
small children, with onset in the ﬁrst year.
Diagnostic criteria:
A. Recurrent attacks1in a young child, fulﬁlling 
criteria B and C
B. Tilt of the head to either side, with or without 
slight rotation, remitting spontaneously after 
minutes to days
C. At least one of the following ﬁve associated 
symptoms or signs:
1. pallor
2. irritability
3. malaise
4. vomiting
5. ataxia2
D. Normal neurological examination between
attacks
E. Not attributed to another disorder.3Notes:
1.Attacks tend to recur monthly.
2.Ataxia is more likely in older children within the 
affected age group.
3.The differential diagnosis includes gastro -
oesophageal reﬂux, idiopathic torsional dystonia 
and com-plex partial seizure, but particular 
attention must be paid to the posterior fossa and 
craniocervical junction where congenital or 
acquired lesions may pro -duce torticollis.
Comments: The child’s head can be returned to the 
neutral position during attacks: some resistance may 
be encountered but can be overcome.
These observations need further validation by patient 
diaries, structured interviews and longitudinal data
collection.
1.6.3 Benign paroxysmal torticollis may evolve into
1.6.2 Benign paroxysmal vertigo or 1.2 Migraine with 
aura (particularly 1.2.2 Migraine with brainstem 
aura ) or cease without further symptoms.
Bibliography
1 Migraine in general
Arruda MA, Guidetti V, Galli F, et al. Primary head -
aches in childhood –a population -based study. 
Cephalalgia 2010; 30: 1056 –1064.
Diener HCand Silberstein SD. Medication over-use 
headache. In: Olesen J, Goadsby PJ, Ramadan NM, 
et al. (eds) The headaches, 3rd edition . 
Philadelphia: Lippincott Williams & Wilkins, 
2006, pp.971 –979.
GBD 2015 Disease and Injury Incidence and 
Prevalence Collaborators. Global, regiona l, and 
national incidence, prevalence, and years lived
with disability for 310 diseases and injuries, 1990 –
2015: a systematic analysis for the Global Burden 
of Disease Study 2015. Lancet 2016; 388: 1545 –
1602.
Gelfand AA, Fullerton HJ and Goadsby PJ. Child
neurology: migraine with aura in children. 
Neurology 2010; 75(5): e16 –e19.
Goadsby PJ. Migraine pathophysiology. Headache
2005; 45(Suppl 1): S14 –S24.
Goadsby PJ. Recent advances in the diagnosis and
man-agement of migraine. BMJ 2006; 332: 25–29.
Katsarava Z, Manack A, Yoon MS, et al. Chronic 
migraine: classiﬁcation and comparisons. 
Cephalalgia 2011; 31: 520 –529.
Lipton RB, Bigal ME, Steiner TJ,etal.Classi ﬁcation 
of primary headaches. Neurology 2004; 63: 427 –
435.
Allergan Confidential Protocol 3101-303-002 Amendment 3
103Martelletti P,Haimanot RT, Lainez MJ, etal.The 
Global Campaign (GC) to Reduce theBurden of 
Headache Worldwide. The International Team for 
Specialist Education (ITSE). J Headache Pain 2005; 
6: 261– 263.
Silberstein SD. Migraine. Lancet 2004; 363: 381 –391.
Vetvik KG, Macgregor EA, Lundqvist C, et al. Prevalence 
of menstrual migraine : a population -based study. 
Cephalalgia 2014; 34: 280 –288.
Vetvik KG, Benth JSˇ , MacGregor EA, et al . Menstrual 
versus non -menstrual attacks of migraine without aura in 
women wi th and without menstrual migraine. Cephalalgia 
2015; 35: 1261 –1268.
Vos T, Flaxman AD, Naghavi M, et al. Years lived with 
disability (YLD) for 1160 sequelae of 289 dis-eases 
and injuries 1990 –2010: a systematic analysis for the 
global burden of disease study 2010. Lancet 2012; 380:
2163 –2196.
1.2 Migraine with aura
Cao Y,Welch KM, Aurora S, et al. Functional MRI -
BOLD of visually triggered headache in patients with 
migraine. Arch Neurol 1999; 56: 548 –554.
Charles A and Brennan K. Cortical spreading depression –
new insights and persistent questions. Cephalalgia 
2009; 29: 1115 –1124.
Cologno D, Torelli P and Manzoni GC. Migraine with 
aura: a review of 81 patients at 10 –20 years’ follow -up. 
Cephalalgia 1998; 18: 690 –696.
Cutrer FM, Sorensen AG, Weissko ﬀRM, et al. Perfusion -
weighted imaging defects during spontaneous 
migrainous aura. Ann Neurol 1998; 43: 25 –31.
Eriksen MK, Thomsen LL, Andersen I, et al. Clinical
characteristics of 362 patients with familial migraine
with aura. Cephalalgia 2004; 24: 564 –575.
Eriksen MK, Thoms en LL and Olesen J. The Visual Aura 
Rating Scale (VARS) for migraine aura diagnosis. 
Cephalalgia 2005; 25: 801 –810.
GiﬃnNJ, Lipton RB, Silberstein SD, etal. The 
migraine postdrome: an electronic diary study. 
Neurology 2016; 87: 309–313.
Hadjikhani N, Sanchez del Rio M, Wu O, et al. Mechanisms 
of migraine aura revealed by functional MRI in human 
visual cortex. PNAS 2001; 98: 4687 –4692.
Hansen JM, Lipton R, Dodick D, et al. Migraine head -
ache is present in the aura phase –a prospective study. 
Neurol ogy 2012; 79: 2044 –2049.
Jensen K, Tfelt -Hansen P, Lauritzen M, et al. Classic 
migraine. A prospective recording of symptoms. Acta 
Neurol Scand 1986; 73: 359 –362.
Kallela M, Wessman M, Farkkila M, et al. Clinical 
characteristics of migraine in a population -based twin 
sample: similarities and di ﬀerences betweenmigraine with and without aura. Cephalalgia
1999; 19: 151– 158.
Kelman L. The premonitory symptoms (prodrome): a 
tertiary care study of 893 migraineurs. Headache 
2004; 44: 865 –872.
Lauritzen M. Pathophysiology of the migraine aura. 
The spreading depression theory. Brain 1994; 
117(Pt 1): 199–210.
Leao AAP. Spreading depression of activity in the 
cere-bral cortex. J Neurophysiol 1944; 7: 359 –390.
Lebedeva ER, Gurary NM, Gilev DV, et al.
Prospective testing of ICHD -3 beta diagnostic 
criteria for migraine with aura and migraine with 
typical aura in patients with transient ischemic 
attacks. Cephalalgia . Epub ahead of print 1 
January 2017. DOI: 10.1177/0333102417702121.
Li D, Christensen AF and Olesen J. Field -testing of 
the ICHD -3 beta/proposed ICD-11 diagnostic 
criteria for migraine with aura. Cephalalgia 2015; 
35: 748 –756.
Olesen J, Friberg L, Olsen TS, et al. Timing and 
topography of cerebral blood ﬂow, aura, and 
headache during migraine attacks. Ann Neurol 
1990; 28: 791 –
798.
Queiroz LP, Friedman DI, Rapoport AM, et al. 
Characteristics of migraine visual aura in Southern 
Brazil and Northern USA. Cephalalgia 2011; 31: 
1652 –1658.
Rasmussen BK and Olesen J. Migraine with aura and 
migraine without aura: an epidemiological study. 
Cephalalgia 1992; 12: 221 –228 (discussion 186).
Salhofer -Polanyi S, Frantal S, Brannath W, et al. 
Prospective analysis of factors related to migraine 
aura –The PAMINA Study. Headache 2012; 52: 
1236 –1245.
Schoonman GG, Evers DJ, Terwindt GM, et al. The 
prevalence of premonitory symptoms in migraine: 
a questionnaire study in 461 patients. Cephalalgia 
2006 ; 26: 1209 –1213.
Ulrich V, Gervil M, Kyvik KO, et al. Evidence of a 
genetic factor in migraine with aura: A population -
based Danish twin study. Ann Neurol 1999; 45: 
242–246.
1.2.1 Migraine with typical aura
Eriksen MK, Thomsen LL and Olesen J. Implications
of clinical subtypes of migraine with aura.
Headache 2006; 46: 286–297.
Hansen JM, Goadsby PJ and Charles AC. Variability
of clinical features in attacks of migraine with aura. 
Cephalalgia 2016; 36: 216–224.
Matharu MJ and Goadsby PJ. Post-traumatic chronic 
paroxysmal hemicrania (CPH) with aura. 
Neurology 2001; 56: 273 –275.
Allergan Confidential Protocol 3101-303-002 Amendment 3
104Morrison DP. Abnormal perceptual experiences in 
migraine. Cephalalgia 1990; 10: 273 –277.
Silberstein SD, Niknam R, Rozen TD, et al. Cluster 
headache with aura. Neurology 2000; 54: 219 –221.
Viana M, Linde M, Sances G, et al. Migraine aura 
symptoms: duration, succession and temporal 
relationship to headache. Cephalalgia 2016; 36: 
413–421.
Wijman CA, Wolf PA, Kase CS, et al. Migrainous 
visual accompaniments are not rare in late life: the 
Framingham Study. Stroke 1998; 29: 1539 –1543.
1.2.2 Migraine with brainstem aura
Ambrosini A, D’Onofrio M, Grieco GS, et al. Familial 
basilar migraine associated with a new mutation in 
the ATP1A2 gene. Neurology 2005; 65: 1826 –1828.
Bickerstaff ER. Basilar artery migraine. Lancet 1961; 
i:15–17.
Caplan LR. Migraine and vertebrobasilar ischemia.
Neurology 1991; 41: 55 –61.
Eriksen MK, Thomsen LL and Olesen J. Implicat ions 
of clinical subtypes of migraine with aura. Headache 
2006; 46: 286–297.
Kirchmann M, Thomsen LL and Olesen J. Basilar -type 
migraine: clinical, epidemiologic, and genetic 
features. Neurology 2006; 66: 880 –886.
Lempert T, Neuhauser H and Daroff RB. Vert igo as a 
symptom ofmigraine. AnnNYAcad Sci2009; 1164: 
242– 251.
Li D, Christensen AF and Olesen J. Field -testing of the 
ICHD -3 beta/proposed ICD-11 diagnostic criteria 
for migraine with aura. Cephalalgia 2015; 35: 748–
756.
Sturzenegger MH and Meienberg O. Basilar artery  
migraine: a follow -up study of 82 cases. Headache 
1985; 25: 408 –415.
Swanson JW and Vick NA. Basilar artery migraine 12 
patients, with an attack recorded 
electroencephalographically. Neurology 1978; 28: 
782–786.
Thomsen LL, Eriksen MK, Roemer SF, etal.A 
population -based study of familial hemiplegic 
migraine suggests revised diagnostic criteria. Brain 
2002; 125: 1379 –1391.
Thomsen LL, Ostergaard E, Olesen J, et al. Evidence 
for a separate type of migraine with aura: sporadic 
hemiplegic migraine. Neurology 2003; 60: 595 –601.
1.2.3 Hemiplegic migraine
Ambrosini A, D’Onofrio M, Grieco GS, et al. Familial 
basilar migraine associated with a new mutation in 
the ATP1A2 gene. Neurology 2005; 65: 1826 –1828.
De Fusco M, Marconi R, Silvestri L, et al. 
Haploinsu ﬃciency of ATP1A2 encoding the Naþ/Kþpump a2 subunit associated with familial 
hemiplegic migraine type 2. Nat Genet 2003; 33:
192–196.
DeVries B,Frants RR, Ferrari M,etal.Molecular 
genetics of migraine. Hum Genet 2009; 126: 115–
132.
Dichgans M, Freilinger T, Eckstein G, et al. Mutation 
in the neuronal voltage- gated sodium channel 
SCN1A in familial hemiplegic migraine. Lancet 
2005; 366: 371–377.
Dreier JP, Jurkat- Rott K, Petzold GC, et al. Opening
of the blood –brain barrier preceding cortical 
edema in a severe attack of FHM type II. 
Neurology 2005; 64: 2145 –2147.
Eriksen MK, Thomsen LL and Olesen J. Implications 
of clinical subtypes of migraine with aura.
Headache 2006; 46: 286–297.
Hansen JM, Schytz HW, Larsen VA, et al. Hemiplegic 
migraine aura begins with cerebral hypoperfusion: 
imaging in the acute phase. Headache 2011; 51: 
1289 –1296.
Hansen JM, Thomsen LL, Olesen J, et al. Coexisting 
typical migraine in familial hemipleg ic migraine. 
Neurology 2010; 74: 594 –600.
Iizuka T, Takahashi Y, Sato M, et al. Neurovascular 
changes in prolonged migraine aura in FHM with 
a novel ATP1A2 gene mutation. J Neurol 
Neurosurg Psychiatry 2012; 83: 205 –212.
Jurkat -Rott K, Freilinger T, Dreier JP, et al. 
Variability of familial hemiplegic migraine with 
novel A1A2 Naþ/Kþ-ATPase variants. Neurology 
2004; 62:
1857 –1861.
Kirchmann M, Thomsen LL and Olesen J. Basilar -
type migraine: clinical, epidemiologic, and genetic 
features. Neurology 2006; 66: 880–886.
Leo L, Gherardini L, Barone V, et al. Increased 
susceptibility to cortical spreading depression in 
the mouse model of familial hemiplegic migraine 
type 2. PloS Genet 2011; 7: e1002129.
Thomsen LL, Eriksen MK,Roeme SF, et al. A 
population -based study of familial hemiplegic 
migraine suggests revised diagnostic criteria. 
Brain 2002; 125: 1379 –1391.
Thomsen LL, Kirchmann M, Bjornsson A, et al. The 
genetic spectrum of a population -based sample of 
familial hemiplegic migraine. Brain 2007; 130:
346–
356.
Thomsen LL, Ostergaard E,Olesen J,etal.Evidence 
for a separate type ofmigraine with aura: sporadic 
hemiplegic migraine. Neurology 2003; 60: 595 –
601.
Vanmolkot KRJ, Kors EE, Turk U, et al. Two de novo 
mutations in the Na,K -ATPase gene ATP1A2 
associated with pure familial hemiplegic migraine. 
Eur J Hum Genet 2006; 14: 555 –560.
Allergan Confidential Protocol 3101-303-002 Amendment 3
1051.2.4 Retinal migraine
Carroll D. Retinal migraine. Headache 1970; 10: 9–13.
Chronicle EP and Mulleners WM. Visual system 
dysfunction in migraine: a review of clinical and 
psychophysical ﬁndings. Cephalalgia 1996; 16: 525–
535.
Grosberg BM, Solomon S, Friedman DI, et al. Retinal 
migraine reappraised. Cephalalgia 2006; 26: 1275 –
1286.
Hedges TR. Isolated ophthalmic migraine in the di ﬀerential 
diagnosis of cerebroocular ischemia. Stroke 1976; 7: 
379–381.
Hill DL, Daroff RB, Ducros A,etal.Most cases labeled
as ‘‘retinal migraine’’ are not migraine. J 
Neuroophthalmol 2007; 27: 3–8.
Martin TJ and Corbett JJ. Disorders of the eye. In: 
Silberstein SD, Lipton RB and Dalessio DJ (eds) 
Wolff’s headache and other head pain. New York: 
Oxford University Press, 2001, pp.459– 474.
Troost T and Zagami AS. Ophthalmoplegic migraine and 
retinal migraine. In: Olesen J, Tfelt -Hansen P and 
Welch KMA (eds) The headaches, 2nd edition . 
Philadelphia: Lippincott Williams & Wilkins, 2000, 
pp.511 –516.
1.3 Chr onic migraine
Aurora SK. Is chronic migraine one end of a spectrum of 
migraine or a separate entity? Cephalalgia 2009; 29: 
597–605.
Bigal ME and Lipton RB. Concepts and mechanisms of 
migraine chroni ﬁcation. Headache 2008; 48: 7 –15.
Bigal M, Rapoport A, Sheftell F, et al. The International 
Classi ﬁcation of Headache Disorders revised criteria 
for chronic migraine –ﬁeld testing in a headache
specialty clinic. Cephalalgia 2007; 27: 230 –234.
Bigal ME, Serrano D, Reed M, et al. Chronic migraine in 
the population: burden, diagnosis, and satisfaction with 
treatment. Neurology 2008; 71: 559 –566.
Bigal ME, Sheftell FD, Rapoprt AM, et al. Chronic 
daily headache inatertiary care population:
correlation between the International Headache 
Society diagnostic criteria andproposed revisions of
criteria for chronic daily headache. Cephalalgia 
2002; 22: 432 –438.
Bloudek LM, Stokes M, Buse DC, et al. Cost of health -
care for patients with migraine in ﬁve European 
countries: results from the International Burden of 
Migraine Study (IBMS). J Headache Pain 2012; 13: 
361–378.
Buse DC, Manack AN, Fanning KM, et al. Chron ic 
migraine prevalence, disability, and sociodemographic 
factors. Results from the American Migraine 
Prevalence and Prevention Study. Headache 2012; 52:
1456 –1470.Buse D, Manack A, Serrano D, et al. Headache impact 
of chronic and episodic migraine: resul ts from the 
American Migraine Prevalence and Prevention 
study. Headache 2012; 52: 3 –17.
Diamond S. A view of chronic daily headache.
Headache Q 2000; 11: 177.
Diener HC, Dodick DW, Goadsby PJ, et al. Chronic 
migraine –classiﬁcation, characteristics and 
treatment. Nat Rev Neurol 2012; 8: 162 –171.
Goadsby PJ and Hargreaves R. Refractory migraine 
and chronic migraine: pathophysiological 
mechanisms. Headache 2008; 48: 799–804.
Katsarava Z, Manack A, Yoon MS, et al. Chronic 
migraine: classiﬁcation and comparisons. 
Cephalalgia 2011; 31: 520 –529.
Manzoni GC, Bonavita V, Bussone G, et al.;
ANIRCEF (Associazione Neurologica Italiana 
Ricerca Cefalee). Chronic migraine classiﬁcation: 
current knowledge and future perspectives. J 
Headache Pain 2001; 12: 585–592.
Mathew NT, Stubits Eand Nigam MP. Transformed 
or evolutive migraine. Headache 1987; 27: 102–
106. 
Natoli JL, Manack A, Dean B, et al. Global 
prevalence of chronic migraine: a systematic 
review. Cephalalgia 2010; 30: 599 –609.
Scher AI, Stewart WF, Liberman J, et al. Prevalence 
of frequent headache in a population sample.
Headache 1998; 38: 497–506.
Scher AI, Stewart WF, Ricci JA, et al. Factors 
associated with the onset and remission of chronic 
daily headache in a population -based study. Pain 
2003; 106: 81 –89.
Silberstein SD, Lipton RB and Sliwinski M. 
Classi ﬁcation of daily and near-daily headaches: 
ﬁeld trial of revised IHS criteria. Neurology 1996; 
47: 871 –875.
Silberstein SD, Lipton RB, Solomon S, et al. 
Classi ﬁcation of daily and near-daily headaches: 
proposed revisions to the IHS criteria. Headache 
1994; 34: 1 –7.
Stewart WF, Scher AI and Lipton RB. Stressful life 
events and risk of chronic daily headache: results 
from the frequent headache epidemiology study. 
Cephalalgia 2001; 21: 279. Abstract no: OR32.
Yalın OO¨,Uluduz D,O¨  zgeA,etal.Phenotypic
features ofchronic migraine. JHeadache Pain
2016; 17: 26.
Zeeberg P, Olesen J and Jensen R. Probable 
medication -overuse headache: the eﬀect of a 2-
month drug -free period. Neurology 2006; 66: 
1894 –1898.
Zeeberg P, Olesen J and Jensen R. Medication overuse 
headache and chronic migraine in a specialized 
headache centre: ﬁeld-testing proposed new 
appen -dix criteria. Cephalalgia 2009; 29: 214–
220.
Allergan Confidential Protocol 3101-303-002 Amendment 3
1061.4.1 S tatus migrainosus
Akhtar ND, Murray MA and Rothner AD. Status 
migrainosus in children and adolescents. Semin 
Pediatr Neurol 2001; 8: 27 –33.
Beltramone M and Donnet A. Status migrainosus and 
migraine aura status in a French tertiary -care 
center: An 11-year retrospective analysis. 
Cephalalgia 2014; 34: 633–637.
Couch JR and Diamond S. Status migrainosus. 
Causative and therapeutic aspects. Headache 
1983; 23: 94 –101.
Cure J and Rothrock J. Prolonged status migrainosus 
complicated by cerebellar infarction. Headache 
2007; 47: 1091 –1092.
Gentile S, Rainero I, Daniele D, et al. Reversible MRI 
abnormalities in a patient with recurrent status 
migrainosus. Cephalalgia 2009; 29: 687 –690.
Lanfranconi S, Corti S, Bersano A, et al. Aphasic and 
visual aura with increased vasogenic leakage: an 
atypical migrainosus status. J Neurol Sci2009; 
285: 227–229.
Perucca P, Terzaghi M and Manni R.Status
epilepticus migrainosus: clinical, 
electrophysiologic, and imaging characteristics. 
Neurolo gy 2010; 75:
373–374.
Raskin NH. Treatment of status migrainosus: the 
American experience. Headache 1990; 30(Suppl 
2): 550– 553.
1.4.2 Persistent aura without infarction
Ambrosini A, de Noordhout AM and Schoenen J. 
Neuromuscular transmission in migraine patients 
with prolonged aura. Acta Neurol Belg 2001; 101: 
166–170.
Bento MS and Esperanca P. Migraine with prolonged 
aura. Headache 2000; 40: 52 –53.
Chen WT, Fuh JL, Lu SR,et al. Persistent migrainous 
visual phenomena might be responsive to 
lamotrigine. Headache 2001; 41: 823 –825.
Chen WT, Lin YY, Fuh JL,etal.Sustained visual 
cortex hyperexcitability in migraine with 
persistent visual aura. Brain 2011; 134(Pt 8): 
2387 –2395.
Evans RW and Lay CL. A persistent migraine aura.
Headache 2000; 40: 696 –698.
Haan J, Sluis P, Sluis IH, et al. Acetazolamide 
treatment for migraine aura status. Neurology 
2000; 55: 1588 –1589.
Haas DC. Prolonged migraine aura status. Ann Neurol
1982; 11: 197 –199.
Lebedeva ER, Gurary NM, Gilev DV, et al.
Prospective testing of ICHD -3 beta diagnostic 
criteria for migraine with aura and migraine withtypical aura in patients with transient ischemic 
attacks. Cephalalgia . Epub ahead of print 1
January 2017. DOI: 10.1177/0333102417702121.
Liu GT, Schatz NJ, Galetta SK, et al. Persistent 
positive visual phenomena in migraine. Neurology 
1995; 45: 664 –668.
Luda E, Bo E, Sicuro L, et al. Sustained visual aura: a 
totally new variation of migraine. Headache 1991; 
31: 582 –583.
Relja G, Granato A, Ukmar M, et al. Persistent aura 
without infarction: description of the ﬁrst case 
studied with both brain SPECT and perfusion MRI. 
Cephalalgia 2005; 25: 56 –59.
Rothrock JF. Successful treatment of persistent 
migraine aura with divalproex sodium. Neurology 
1997; 48: 261–262.
San- Juan OD and Zermen˜ o PF. Migraine with persist -
ent aura inaMexican patient: case report and
review of the literature. Cephalalgia 2007; 27: 
456–460.
Smith M, Cros D and Sheen V. Hyperperfusion with 
vasogenic leakage by fMRI in migraine with pro-
longed aura. Neurology 2002; 58: 1308 –1310.
Wang YF, Fuh JL, Chen WT, et al. The visual aura 
rating scale as an outcome predictor for persistent 
visual aura without infarction. Cephalalgia 2008;
28: 1298 –1304.
1.4.3 Migrainous infarction
Bono G, Minonzio G, Mauri M,et al. Complications
of migraine: migrainous infarction. Clin Exp 
Hypertens 2006; 28: 233–242.
Bousser MG, Conard J, Kittner S, et al. 
Recommendations on the risk of ischemic stroke 
associated with use of combined oral 
contraceptives and hormone replacement therapy 
in women with migraine. The International 
Headache Society Task Force on Combined Oral 
Contraceptives & Hormone Replacement Therapy. 
Cephalalgia 2000; 20: 155–156.
Chang CL, Donaghy M and Poulter N. Migraine and 
stroke in young women: case–control study. The 
World Health Organization Collaborative Study of 
Cardiovascular Disease and Steroid Hormone 
Contraception. BMJ 1999; 318: 13–18.
Connor CCR. Complicated migraine. A study of 
permanent neurological and visual defects. Lancet 
1962; ii: 1072 –1075.
Laurell K, Artto V, Bendtsen L, et al. Migrainous 
infarction: a Nordic multicenter study. Eur J
Neurol 2011; 18: 1220 –1226.
MacGregor EA and Guillebaud J. Combined oral 
contraceptives, migraine and ischemic stroke. 
Clinical and Scienti ﬁc Committee of the Faculty of
Allergan Confidential Protocol 3101-303-002 Amendment 3
107Family Planning and Reproductive Health Care 
and the Family Planning Association. Br J Fam 
Plann 1998; 24: 55 –60.
Olesen J, Friberg L, Olsen TS, et al. Ischaemia -
induced (symptomatic) migraine attacks may be 
more frequent than migraine induced ischemic
insults. Brain 1993; 116: 187 –202.
Rothrock JF, Walicke P, Swenson MR, et al.
Migrainous stroke. Arch Neur ol 1988; 45: 63–67.
Schulz UG, Blamire AM, Davies P, et al. Normal 
cortical energy metabolism in migrainous stroke: 
A 31P-MR spectroscopy study. Stroke 2009; 40: 
3740 –3744.
Tietjen GE. The relationship of migraine and stroke.
Neuroepidemiology 2000; 19: 13–19.
Tzourio C, Kittner SJ, Bousser MG, et al. Migraine
and stroke in young women. Cephalalgia 2000; 
20: 190 –199.
Vollbracht S, Robbins MS and Kister I. Classi ﬁcation 
challenge in migrainous infarction. Headache 
2014; 54: 170 –171.
Wolf ME, Szabo K, Grieb e M, et al. Clinical and MRI 
characteristics of acute migrainous infarction. 
Neurology 2011; 76: 1911 –1917.
1.4.4 Migraine aura- triggered seizure
Belcastro V Striano P,Kasteleijn -Nolst Trenite´ DG,et al.
Migralepsy, hemicrania epileptica, postictal 
headache and ‘‘ictal epileptic headache’’: a
proposal for terminology and classiﬁcation 
revision. J Headache Pain 2011; 12: 289–294.
Davies PT and Panayiotopoulos CP. Migraine 
triggered seizures and epilepsy triggered headache
and migraine attacks: a need for re-assessment. J 
Headache Pain 2011; 12: 287–288.
Friedenberg S and Dodick DW. Migraine -associated 
seizure: a case of reversible MRI abnormalities
and persistent nondominant hemisphere syndrome. 
Headache 2000; 40: 487–490.
Maggioni F, Mampreso E, Ruﬀatti S, et al. 
Migralepsy: is the current deﬁnition too narrow? 
Headache 2008; 48: 1129 –1132.
Marks DA and Ehrenberg BL. Migraine -related 
seizures in adults with epilepsy, with EEG 
correlation. Neurology 1993; 43: 2476 –2483.
Merlino G, Valente MR, D’Anna S, et al.Seizures
with prolonged EEG abnormalities during an
attack of migraine without aura. Headache 2007;
47: 919 –922.
Parisi P and Kasteleijn -Nolst Trenite` DGA. 
‘‘Migralepsy’’: acall for revision of the
deﬁnition.
Epilepsia 2010; 51: 932 –933.
Rogawski MA. Common pathophysiologic 
mechanisms in migraine and epilepsy. Arch 
Neurol 2008; 65: 709 –714.Sances G, Guaschino E, Perucca P, et al. Migralepsy: 
a call forrevision ofthedeﬁnition. Epilepsia 2009;
50: 2487 –2496.
Ter Berg HW. Migraine -associated seizure: a case of 
reversible MRI abnormalities and persistent non-
dominant hemisphere syndrome. Headache 2001; 
41: 326 –328.
Velioglu SK and Ozmenoglu M. Migraine -related 
seizures in an epileptic population. Cephalalgia 
1999; 19: 797 –801.
Verrotti A, Coppola G, Di Fonzo A, et al. Should 
‘‘migralepsy’’ be considered an obsolete concept?
A multicenter retrospective clinical/EEG study and 
review of the literature. Epilepsy Behav 2011; 21: 
52–59.
1.5 Probable migraine
Granell a F, Alessandro RD, Manzoni GC, et al. 
International Headache Society classiﬁcation: 
inter -observer reliability in the diagnosis of 
primary head -aches. Cephalalgia 1994; 14: 16 –20.
Rains JC, Penzien DB, Lipchik GL, et al. Diagnosis of 
migraine: empirical analysis of a large clinical 
sample of atypical migraine (IHS 1.7) patients and 
proposed revision of the IHS criteria. Cephalalgia 
2001, 21: 584 –595.
Rasmussen BK, Jensen Rand Olesen J.A
population- based analysis of the diagnostic 
criteria of the International Headache Society.
Cephalalgia 1991; 11: 129– 134.
Russell MB and Olesen J. Migrainous disorder and its 
relation to migraine without aura and migraine 
with aura. A genetic epidemiological study. 
Cephalalgia 1996; 16: 431 –435.
1.6.1 Recurrent gastrointestinal 
disturbance
Abu-Arafeh I and Russel G. Prevalence and clinical 
features of abdominal migraine compared with
those of migraine headache. Arch Dis Child 1995; 
72: 413 –417.
Al-Twaijri WA and Shevell MI. Pediatric migraine 
equivalents: occurre nce and clinical features in 
prac-tice. Pediatr Neurol 2002; 26: 365 –368.
Dignan F, Abu -Arafeh I and Russell G. The prognosis 
of childhood abdominal migraine. Arch Dis Child 
2001; 84: 415 –418.
Drossman DA and Dumitrascu DL. Rome III: new 
standard for functional gastrointestinal disorders. J 
Gastrointestin Liver Dis 2006; 15: 237 –241.
Farquar HA. Abdominal migraine in children. BMJ
1956; i: 1082 –1085.
Fleisher DR. Cyclic vomiting syndrome and migraine.
J Pediatr 1999; 134: 533 –535.
Haan J, Kors EE and Ferrari MD. Familial cyclic 
vomiting syndrome. Cephalalgia 2002; 22: 552 –
554.Li BU. Cyclic vomiting syndrome: age-oldsyn-drome 
and new insights. Semin Pediatr Neurol 2001; 8:
13–21.
Li BUK, Lefevre F, Chelimsky GG, et al. North 
American Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition consensus statement on 
the diagnosis and management of cyclic vomiting 
Allergan Confidential Protocol 3101-303-002 Amendment 3
108syndrome. J Pediatr Gastroenterol Nutr 2008; 47: 
379–393.
Rashed H, Abell TL, Familoni BO, et al. Autonomic 
function in cyclic vomiting syndrome and classic 
migraine. Dig Dis Sci 1999; 44(Suppl 8): 74S–78S.
Russell G, Abu-Arafeh I and Symon DN. Abdominal 
migraine: evidence for existence and treatment 
options. Paediatr Drugs 2002; 4: 1 –8.
Thiessen PN. Recurrent abdominal pain. Pediatr Rev
2002; 23: 39 –46.
Welch KM. Scienti ﬁc basis of migraine: speculation 
on therelationship tocyclic vomiting. DigDisSci
1999; 44(Suppl 8): 26S–30S.1.6.2 Benign par oxysmal vertigo
Drigo P, Carli G and Laverda AM. Benign 
paroxysmal vertigo of childhood. Brain Dev 
2001; 23: 38 –41.
Dunn DW and Snyder CH. Benign paroxysmal
vertigo of childhood. Am J Dis Child 1976; 
130: 1099 –1100.
Fenichel GM. Migraine asacause ofbenign
paroxysmal vertigo of childhood. J Pediatr 
1967; 71: 114–115.
1.6.3 Benign par oxysmal torticollis
Drigo P, Carli G and Laverda AM. Benign 
paroxysmal torticollis of infancy. Brain Dev 
2000; 22: 169 –172. 
Giffin NJ, Benton S and Goadsby PJ. Benign 
paroxysmal torticollis of infancy: four new 
cases and linkage to CACNA1A mutation. 
Dev Med Child Neurol 2002; 44: 490 –493.
Rosman NP, Douglass LM, Sharif UM, et al. The 
neurology of benign paroxysmal torticollis of 
infancy: report of 10 new cases and review of 
the literature. J Child Neurol 2009; 24: 
155–160.
Allergan Confidential Protocol 3101-303-002 Amendment 3
10912.2 Examples of Pr ohibited Medications
The following medications are prohibited 30 day s prior to screening and throughout the study  
period:
Strong OATP1B1 inhibitors, eg, gemfibrozil (Lop id™) *, cyclosporine
Strong/m oderate CYP3A4 inducers Strong/m oderate CYP3A4 inhibitors
Anti-Depressants/ 
Anti-AnxietyBarbiturates 
Amobarbital (Amytal™)
Aprobarbital (Alurate™) *
Butalbital (Fiorinal™, Fioricet™) *
Butabarbital (Busodium™, 
Butisol™) *
Mephobarbital (Mebaral™) *
Pentobarbital (Nembutal™)
Phenobarbital (Luminal™, 
Solfoton™)
Secobarbital (Seconal™)Nefazodone (Serzone™) *
Anti-Seizure Carbamazepine (Atretol™, Carbatrol™, 
Epitol™, Equetro™, Tegretol™)
Oxcarbazepine (Trileptal™) *
Phenytoin ( Dilantin™, Phenytek™)
Primidone (Myidone™, Mysoline™)
Diabetes Pioglitazone (Actos™)
Troglitazone (Rezulin™, Resulin™) *
Antiemetic Aprepitant (Emend™)
Anti-Hypertension Diltiazem (Cardizem™)
Verapamil (Calan™, Calan SR™)
Glucocorticoid 
(Systemic)Betam ethasone (Celestone™)
Dexamethasone (Baycadron™, DexPak™)
Hydrocortisone (Cortef™)
Methylprednisolone (Medrol™)
Prednisolone (Prelone™)
Prednisone (Deltasone™)
Triamcinolone (Kenalog™)
Antibiotics Rifabutin (Mycobutin™) 
Rifampicin/Rifampin (Rifadin™, Rifater™, 
Rimactane™) Erythromycin (Benzamycin™, EryTab™)
Clarithromycin (Biaxin™)
Telithromycin (Ketek™)
Anti-Fungal Fluconazole (Diflucan™, Trican™)
Itraconazole (Sporanox™)
Ketoconazole (Nizoral™)
Anti-HIV Efavirenz (Stocrin™, Sustiva™) 
Nevirapine (Viramune™) Indinavir (Crixivan™)
Nelfinavir (Viracept™) 
Ritonavir (Norvir™)
Saquinavir (Fortovase™, Invirase™)
Immune 
SuppressantCyclosporine - Oral/IV only (Neoral™, 
Sandimmune™)
Others St. John’s wort 
Enzalutamide (Xtandi™)
Modafinil (Provigil™)
Armodafinil (Nuvigil™) *Buprenorphine (Cizol™, Subutex™, 
Suboxone™)
Quinine
Allergan Confidential Protocol 3101-303-002 Amendment 3
110Drugs with narrow  therapeutic margins 
with potential for CYP drug interactionsWarfarin (Coumadin™)
Digoxin (Digitek™, Lanoxin™, Digox™)
Cisapride (Prepulsid™, Propulsid™) *
Pimozide (Orap™)
Non-pharm acologic headache 
interventions:Acupuncture
Non-invasive neuromodulation devices (eg, transcutaneous 
supraorbital neurostimulator single pulse transcranial magnetic 
stimulator vagus nerve stimulator)
Cranial traction
Nociceptive trigeminal inhibition
Occipital nerve block treatments
Dental splints for headache
*not approved in Japan
The following tr eatments ar e prohibited 6 months prior  to screening and thr oughout the 
study period:
Therapeutic or cosmetic botulinum toxin injections (eg, Dy sport®, Botox®, Xeomin®, 
Myobloc®, JeuveauTM) into areas of the head, face, or neck
Injectable monoclonal antibodies blocking the CGRP pathway  (eg, AimovigTM, 
Emgalit yTM, Ajovy®)
Allergan Confidential Protocol 3101-303-002 Amendment 3
11112.3 List of Migraine Preventive Medications With Pr oven Efficacy & 
Criteria for Determining that a Prior Migraine Preventive Medication 
Has Been Failed
12.3.1 List of Migraine Preventive Medications With Pr oven Efficacy
Below is a list of migraine preventive medications considered ef fective or probabl y effective 
sorted by  mechanism of action. Of note, topiramate and valproic acid derivatives are considered 
separate categories. A history  of inadequate response (based on inadequate ef ficacy  or inadequate 
tolerability )to more than 4 of these medications (2 of which have dif ferent mechanisms of 
action) will exclude the participant from the stud y.
Pharm acologic Category Drug Nam e(all regions unless otherwise noted)
Antiepileptic Valproic acid, sodium valproate, divalproex so dium
Topiramate
Tricyclic antidepressant Amitriptyline
Nortriptyline
Beta-blockers Metoprolol
Bisoprolol
Atenolol
Nadolol
Propranolol
Timolol
Calcium channel blocker Flunarizine
Lomerizine (Japan)
Verapamil (Japan)
Angiotensin receptor blocker (ARB) Candesartan
Angiotensin -converting enzyme (ACE) inhibitor Lisinopril
Serotonin -norepinephrine reuptake inhibitor (SNRI) Desvenlafaxine
Venlafaxine
Miscellaneous Oxetorone (Europe ), pizotifen (Japan, Taiw an,Korea, 
Australia ,andEurope )
Source: Evers 2009, Hoffmann 2014, Schürks 2008, Silberstein 2012, Steiner 2007 .
Allergan Confidential Protocol 3101-303-002 Amendment 3
11212.3.2 Criteria for Determining That a Prior Migraine Preventive 
Medication has Been Failed 
The criteria below should be used to determ ine how to stratify  each participant based on the 
number of prior migraine preventive medications failed wit h unique mechanisms of action. 
Failure of a migraine preventive medication can be assessed on the basis of tolerabili ty or 
efficac y and is based on i nvestigator judgment.
For efficacy , investigators must consider:
oFailure is defined as no meaningful reduction in frequency  of migraine day s after 
an adequate trial of at least 2 months at generall y accepted therapeutic doses, per 
investigator judgement and partici pant interview.
oMedications must have been started within the past 7 y ears.
oNote the following for participants who are currently  taking a stable dose of one 
of the migraine prevention medications listed and meet the efficacy  criteria:
If the participant meets all st udy entry  criteria, this participant is eligible to 
be rand omized provided that the participant agrees to continue to take this 
migraine preventive medication for the duration of the study .
This medication should be considered as one of the fa iled drugs for the 
prevention of migraine.
Enrollment of participants with current use of a migraine prevention 
medication will be capped at ~15% .
For tolerability , investigators should consider:
oFailure is defined as discontinuation of a drug treatment du e to adverse effects. 
oIn assessing failure of a migraine preventive drug on the basis of inadequate 
tolerability , the entire medical history  can be co nsidered. For example, a 
participant who tried and discontinued topiramate 10 y ears ago for cognitive 
clo
uding should be considered to have failed this treatment.
Allergan Confidential Protocol 3101-303-002 Amendment 3
11312.4 Study Visits Conducted Remotely
Remote study  visits, conducted virtuall y or b y phone, are permitted if the Investigator determines 
there to be a public health risk due to viral infection (eg ,COVID -19) to the participant or site 
staff. During remote study  visits, the Remote Visit Schedule of Assessments ( Table 5) should be 
followed. Remote visits m ay be conducted between Visit 3 –Visit 8 but participants must attend 
in office assessments at V isit 3or Visit 4 to ensure laboratory  samples are obtained within the 
first 4
-weeks of treatment s and remote visits should not be performed for greater than 8 weeks.
Missed in- person safety assessments (ie, clinical laboratory  samples, vital signs and ECGs) 
should be collected at the next in -person visit. Patient reported outcomes collected onthe eT ablet 
during in -office visits, will be collected using a web -based portal during remote visits, if 
available .
Allergan Confidential Protocol 3101-303-002 Amendment 3
114Table 5 Remote V isits Schedule of Assessments (ie, Schedule of V isits and Procedur es)
Study PeriodScreening/
Baseline
(4 weeks)Double -blind Treatment Period (12 weeks)Follow -up 
Period 
(4weeks)
Visit # Visit 1a Visit 2a
(Randomization)Visit 3aVisit 4aVisit 5 Visit 6 Visit 7/ETVisit 8
(End of Study)
Day/Week Week -4 Day 1Week 2 
(Day 14)Week 4 
(Day 28)Week 6 
(Day 42)Week 8 
(Day 56)Week 12 
(Day 84)Week 16
(Day 112)
Visit WindowsDay –35 to 
Day -28NA ± 3 days ± 3 days ± 3 days ± 3 days + 3 days ± 3 days
Dispense study intervention
(ie, atogepant)b X X X X X
Revie w of atogepant compliance X X X X X
Participant eDiary Data CollectioncX
Revie w eDiary  data and compliance X X X X X X
Perform urine pregnancy testb,dX X X X X X X X
C-SSRS (eTablet or w eb portal) X X X X X X X X
HIT-6 (web portal)eX X X X X
PGIC (web portal)eX
PGI- S (web portal)eX X X X
WPAI:MIGRAINE (web portal)eX X X X
PSSM (web portal)eX X X
EQ-5D-5LfX X X X X X X X
MIDAS (web portal)eX X
MSQ v2.1 (web portal)eX X X X X
PROMIS -PI (web portal)eX X X X
PHQ -9 (web portal)eX X
Adverse events X
Concomitant medications/concurrent 
proceduresX
Allergan Confidential Protocol 3101-303-002 Amendment 3
115AIM -D = Activity Impairment in Migraine –Diary ; C-SSRS = Columbia Suicide Severity Rating Scale; ECG =electrocardiogram; eDiary = electronic diary; 
EQ-5D-5L = European Quality of Life – 5 Dimensional; ET = early termination; eTablet = electronic tablet; HIT -6 = Headache Impact Test; INR = international 
norm alized ratio; IWRS = interactive web response system; MIDAS = Migraine Disability Assessment; MSQ v2.1 = Migraine Specific Quality of Life 
Questionnaire, V ersion 2.1; PGIC = Patient Global Impression of Change; PGI -S = Patient Global Impression –Severity; PHQ -9 = Patient Health Questionnaire; 
PK = pharmacokinetic; PRO =patient -reported outcome; PROMIS -PI = Patient -Reported Outcomes Measurement Information System Pain Interference –Short 
Form  6a; VCT = verified clinical trial; WP AI:MIGRAINE = Work Productivity and Activity Impairment Questionnaire: Migraine V2.0.
aVisit 1, Visit 2 , and either Visit 3 or Visit 4 must be conducted in office, to ensure laboratory assessment sare performed within the first 4 w eeks of study 
intervention.
bStudy medication to cover 1 remote study visit andurine pregnancy tests may be dispensed at an office visit (if the next visit is anticipated to be remote), for 
curbside pick -up or shipped to participants via an overnight courier .
cDaily eDiary data collection includes: Headache Frequency, Duration, Characteristics, and Symptoms; Acute Medication Use and Triptan Use; AIM -D; 
Activity Level and Activity Limitation.
dFemale participants are to take an at -home pregnancy test (provided by sites) and report the results during virtual visits.
eIf available, p articipants will complete on a web -based portal.
fParticipants will complete in eDiary on V isit 1 to 7 and on the w eb-based portal (i favailable) at V isit 8 (W eek 16).
Allergan Confidential Protocol 3101-303-002 Amendment 3
11612.5 Glossary of Abbr eviations
Term/Abbr eviation Definition
AE adverse event
AIM-D Activity  Impairment in Migraine –Diary
ALT alanine aminotransferase
ANCOV A analysis of covariance
AR adverse reaction
ASC -12 allody nia s ymptom checklist
AST aspartate aminotransferase
BID twice dail y
BP blood pressure
CBD cannabidiol
CGRP calcitonin gene -related peptide
CM chronic migraine
CRF case report form
C-SSRS Columbia -Suicide Severity  Rating Scale
CYP3A4 cytochrome P450 3A4
DSMB Data Safety  Monitoring Board
DSM -IV Diagnostic and Statistical Manual of Mental Disorders, 4thedition
ECG electrocardiogram
eCRF electronic case report form
eDiary electronic diary
EM episodic migraine
EMA European Medicines Agency
EQ-5D- 5L European Quality  of L ife – 5 Dimensional
ET early termination
eTablet electronic tablet
EU European Union
FDA Food and Drug 
Administration
GCP Good Clinical Practice
GLP Good Laboratory  Practice
HIPAA Health Insurance Portability  and Accountability  Act
HIT-6 Headache Impact Test
HSG hysterosalpingogram
HIV Human immunodeficiency virus
Allergan Confidential Protocol 3101-303-002 Amendment 3
117Term/Abbr eviation Definition
ICF informed consent form
ICH International Conference on Harmonisation
ICHD -3 International Classification of Headache Disorders, 3rdedition
IEC Independent Ethics Committee
IgM immunoglobulin M
INR international normalized ratio
IRB Institutional Review Board
ITT intent -to-treat
IUD intrauterine device
IUS intrauterine hormone releasing s ystem
IV intravenous
IWRS interactive web response sy stem
MAR missing -at-random
MI multiple imputation
MIDAS Migraine Disability  Assessment
mITT modified intent- to-treat
MMRM mixed -effects model for repeated measures
MNAR missing -not- at-random
MSQ v2.1 Migraine Specific Quality of Life Questionnaire, V ersion 2.1
NSAID nonsteroidal anti-inflammatory  drug
OATP1B1 organic anion transporting pol ypeptide 1B1
OL open -label
PD pharmacod ynamic
PGIC Patient Global I mpression of Change
PGI-S Patient Global I mpression –Severity
PHQ -9 Patient Health Questionnaire
PK pharmacokinetic
PMM pattern- mixture model
PRO patient -reported outcomes
PROMI S-PI Patient- Reported Outcomes Measurement Information Sy stem 
Pain I nterference –Short Form 6a
PSSM Patient Satisfaction with Study Medication
QTcF QT interval corrected for heart rate using Fr idericia formula 
(QTcF = QT/(RR)⅓)
ROW rest of world
Allergan Confidential Protocol 3101-303-002 Amendment 3
118Term/Abbr eviation Definition
SAE serious adverse event
SAP Statistical Analy sis Plan
SAR serious adverse reaction
SNRI serotonin norepinephrine reuptake inhibitor
SOC system organ class
SSRI selective serotonin reuptake inhibitor
SUSAR suspected unexpected serious adverse reaction
TEAE treatment emergent adverse event
UDS urine drug screen
ULN upper limit of normal
VAS Visual Analogue Scale
VCT verified clinical trials
WPAI:MIGRAINE Work Productivity  and Activity  Impairment Questionnaire: 
Migraine V ersion V2.0
Allergan Confidential Protocol 3101-303-002 Amendment 3
11912.6 Protocol Amendment 1 Summary
Title: A PHASE 3, MUL TICENTER, RANDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, P ARALLEL -GROUP  STUDY  TO EV ALUA TE THE EFFICACY , 
SAFETY , AND TOLERABILITY  OF ATOGEP ANT  FOR THE PREVENTI ON OF CHRONIC 
MIGRAINE (PROGRESS)
Protocol 3101-303-002
Date of Amendment: 08April 2019
Amendment Summary
This amendment includes changes made to Protocol 3101-303- 002 dated 13 December 2018. 
The protocol was amended to: 
Add instructions for st udy conduct in China and Canada
Clarify  primary  and secondary  endpoints for China, and Canada
Clarify  prohibited medications
Update laboratory  parameters
Update the subgroup analy ses
Correct the stud y diagram for the estimand framework
Update the definition of failed migrain
e prevent ive medication
The table below provides details related to content changes that were made in the protocol, and a 
brief rationale for these changes. Minor editorial and document formatting revisions have not 
been summarized.
Allergan Confidential Protocol 3101-303-002 Amendment 3
120Section Revision Rationale
Protocol Title Page Added “Protocol Amendment 1 Date” to the title page To reflect the approval 
date of Amendment 1
Protocol Summary Changed the Condition/Disease from “CM with aura or 
migraine without aura” to “Chronic migraine”For clarity
Protocol Summary Changed text with regard to the primary efficacy 
endpoint to clarify that the primary efficacy endpoint is 
the same for all regulatory authoritiesFor clarity
Protocol Summary Added text to clarify the secondary efficacy endpoint s 
for ChinaStudy will also be 
conducted in China
Protocol Summary Added text to clarify the secondary efficacy endpoints 
for CanadaStudy will also be 
conducted in Canada
Protocol Summary, 
Table 1 Schedule of Visits 
and ProceduresClarified that VCT is applicable for U nited States and 
Canada onlyFor clarity
Protocol Summary, 
Table 1 Schedule of Visits 
and ProceduresAdded HIT -6 to Visit 8 HIT-6 collection at Visit 8 
is needed for estimand 
frame work
Section 1.1 Background Added background information f or China Study will also be 
conducted in China
Section 3.1 Structure Updated number of sites to approximately 140 For accuracy
Section 4.1 Number of 
ParticipantsUpdated number of sites to approximately 140 For accuracy
Section 4.3 Exclusion 
Criteria, criterion 5Added recently approved botulinum toxin injections, 
Myobloc®and JeuveauTMFor clarity and 
completeness
Section 4.3 Exclusion 
Criteria, criterion 24Corrected a typographical error in the developmental 
name of atogepant (MK8031)To correct an error
Section 4.4.2 Prohibited 
Medications/TreatmentsAdded language to exclude use of medications with 
demonstrated efficacy for the prevention of migraine for 
indications other than migraine preventionFor clarity
Section 4.4.2 Prohibited 
Medications/TreatmentsAdded recently approved botulinum toxin injections, 
Myobloc®and JeuveauTMFor clarity and 
completeness
Section 4.4.2 Prohibited 
Medications/Treatment sAdded:
For China, South Korea, and Taiw an, herbal 
and traditional medicine is pr ohibited from the 
time the ICF is signed and for the duration of 
study participation.To clarify that herbal and 
traditional medicines are 
prohibited in countries 
where they are commonly 
used
Section 6.1 Efficacy 
MeasuresCorrected the Study Days and visi t windows for the 
EQ-5D-5LTo correct an error
Section 6.5.3 Clinical 
Laboratory 
Determinations, Table 6-1 
Clinical Laboratory 
Parameters Deleted gamma glutamyl transferase Parameter is not measured
Section 7.2.2 Secondary 
Efficacy EndpointsAdded text to clarify the secondary efficacy endpoints 
for ChinaStudy will also be 
conducted in China
Section 7.2.2 Secondary 
Efficacy EndpointsAdded text to clarify the secondary efficacy endpoints 
for CanadaStudy will also be 
conducted in Canada
Allergan Confidential Protocol 3101-303-002 Amendment 3
121Section Revision Rationale
Section 7.2.3 Additional 
Efficacy EndpointsDeleted text concerning countries for additional efficacy 
endpointsFor clarity, because 
additional efficacy 
endpoints are the same for 
all countries
Section 7.2.3 Additional 
Efficacy EndpointsAdded ≥ 30% as an additional range for responders To add granularity to the 
analysis of additional 
efficacy endpoints
Section 7.2.3 Additional 
Efficacy EndpointsAdded Canada to the countries where “Change from 
baseline in the HIT -6 total score at Weeks 4 and 8” w ill 
be analyzedCana da is using the 
European Union 
endpoints
Section 7.2.3 Additional 
Efficacy EndpointsAdded China to the countries where “Change from 
baseline in the HIT -6 total score at Weeks 4, 8, and 12” 
will be analyzedChina is using the United 
States endpoints
Section 7.2.3 Additional 
Efficacy EndpointsAdded Canada to the countries where “Change from 
baseline in mean monthly performance of daily activities 
domain score of the AIM- D across the 12 -week 
treatment period” and “Change from baseline in mean 
monthly p hysical impairment domain s core of the 
AIM -D across the 12 -week treatment period” are 
analyzedCanada is using the 
European Union 
endpoints
Section 7.5 Subgroup 
AnalysesUpdated text for subgroup analysis For clarity
Section 8.1.3 Procedure 
for Duplicate Participant 
Identification –Verified 
Clinical TrialsChanged ROW to Canada VCT only used in the 
United States and Canada
Section 8.4.1 Visit 1 
(Screening/Baseline) 
Day -35 to Day -28Changed “if applicable” to U nited S tates and Canada 
onlyVCT only used in the 
United States and Canada
Section 8.4.3.1 Visit 
8/End of Study (Week 16)Added HIT -6 HIT-6 is being collect ed 
for all participants at 
Week 16
Section 8.8.1 Participants 
Who Discontinue Study 
Intervention Early, 
Figure 2 Study Diagram 
for Estimand Framew orkReplaced the study diagram To correct an error
Section 10 Administrative 
ItemsAdded text to clarify that relevant local regulations 
should be follow edFor clarity
Section 11 References Added references for China background Migraine background in 
China was added to 
Section 1.1
Section 12.2 Examples of 
Prohibited MedicationsAligned text for treatments prohibited 6 months prior to 
screening and throughout the study period w ith the text 
in the protocol bodyFor clarity and internal 
consistency
Allergan Confidential Protocol 3101-303-002 Amendment 3
122Section Revision Rationale
Section 12.3.1 List of 
Migrai ne Prevent ive 
Medications With Proven 
EfficacyAdded “(non -United S tates only)” to Miscellaneous 
categoryFor clarity
Section 12.3.2 Criteria for 
Determining That a Prior 
Migraine Prevent ive 
Medication has Been 
FailedUpdated the failure definition The definition of failure 
has changed
Allergan Confidential Protocol 3101-303-002 Amendment 3
12312.7 Protocol Amendment 2 Summary
Title: A PHASE 3, MUL TICENTER, RANDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, P ARALLEL -GROUP  STUDY  TO EV ALUA TE THE EFFICACY , 
SAFETY , AND TOLERABILITY  OF ATOGEP ANT  FOR THE PREVENTION OF CHRONIC 
MIGRAINE (PROGRESS)
Protocol 3101-303-002
Date of Amendment 2: 23September 2019
Amendment Summary
This amendment includes changes made to Protocol 3101-303-002 Amendment 1, dated 
08April 2019. The protocol was amended to : 
Add instructions for study conduct in Japan 
Add instruction regarding Visit 8 (follow -up) for participants in Japan and China who may  
rollover to a regional, long- term, extension, safet y study
Clarify secondary  efficacy  endpoints for Europe and Canada, and for all other regions except 
Europe and Canada
Update description of the AI M-D health outcomes measure and endpoints
Describe the Hochberg procedure to be used to control the overall Ty pe I error rate at a 0.05 
level (2-sided) for multiple comparisons o f 2 atogepant doses with placebo for the primary  
efficacy  endpoint , only for the analysis in Japan
Describe weekl y data analysis procedures for other efficacy  analy ses
Describe planned subgroup anal yses to evaluate consistency  of treatment across regions and 
subpopulations
Update description of safety  anal ysis
Clarify  criteria for sexual abstinence to be considered as a highl y effective contraceptive 
method 
Add a benefit/risk assessment
Allergan Confidential Protocol 3101-303-002 Amendment 3
124Add definition of the end of the study  
Clarify  exclusion criterion based on h ypersensitivity  to study  intervention s
Clarify  the instructions regarding prohibited medication/treatments
Clarify  instructions for the participant
s
Clarify  instructions regarding assessment of causality  of adverse events
Add definition of adverse reaction, serious adverse reaction, and suspected unexpected serious 
adverse reaction
Clarify  instruction regarding changes to the protocol.
The table below provides details on the content changes that were made in the protocol, and a 
brief rationale for these changes. Minor editorial and document formatting revisions have not 
been summarized.
Allergan Confidential Protocol 3101-303-002 Amendment 3
125Section Revision Rationale
Protocol Summary Bolded text added to Number of Participants : 
Approximately 750 participants will be randomized into 
this global study ( North Am erica, Europe, Japan, 
China, Other) .Clarification
Protocol Summary, 
Table 1 Schedule of Visits 
and Procedures, 
Section 3.1 StructureClarified end of study visit schedule for participants in 
Japan and China who may rollover to a regional, long-
term, extension, safety studyClarification
Table 1 Schedule of Visits 
and ProceduresConsolidated rows pertaining to eDiary, AIM -D and 
activity level and activity limitation:
“Revie w eDiary  data (headache duration, frequency, 
characteristics and sym ptoms, acute medication use, 
AIM -D, activity level and activity limitation) and 
compliancei”Clarification, as AIM -D, 
activity level and activity 
limitation data are also 
recorded on eDiary
Table 1 Schedule of Visits 
and Procedures,
Section 8.4.2.3 Visit 7/ Early 
Term ination Week 12),
Section 8.4.3.1 Visit 8/ End 
of Study (Week 16)Clarified when the eDiary is to be collected for 
participants who complete the double -blind treatment 
period and for those patients who discontinue study 
intervention earlyClarification
Section 1.1 Background Added background information for Japan Study will also be 
conducted in Japan
Section 1.5 Benefit/ Risk 
AssessmentAdded Section 1.5 Benefit/Risk Assessment Added in accordance 
with EU protocol review
Section 3.4 End of Study 
DefinitionAdded Section 3.4 End of Study Definition
“The end of the study is defined as the date of the last 
visit of the last participant in the study.”Added in accordance 
with EU protocol review  
Section 4.3 Exclusion 
CriteriaBolded text added to exclusion criterion #25:
25.History of hypersensitivity or clinically significant 
adverse reaction to a CGRP receptor antagonist or 
hypersensitivity to any com ponent of the study 
interventions (atogepant or placebo) .Clarification 
Section 4.4.2 Prohibited 
Medications/TreatmentsBolded text added and strikethrough text removed:
Therapy considered necessary for the participant's 
welfare m ay be given at the discretion of the 
investigator . The decision to administer a prohibited 
medication/treatment is done with the safety of the study 
participant as the primary consideration. When possible, 
Allergan should be notified before the prohibited 
medication/treatment is administered . The sponsor
should be notified about administration of prohibited 
medicat ion/treatm ent as soon as possible.
Asterisks added to indicate the specified medications that 
are not approved in Japan. 
Clarified that herbal and traditional medicine is also 
prohibited in Japan.Clarification 
Allergan Confidential Protocol 3101-303-002 Amendment 3
126Section Revision Rationale
Section 4.4.3 Definition of 
Wom en of (Non -) 
Childbearing Potential 
and/or Acceptable 
Contraceptive MethodsBolded text added to definition of sexual abstinence
Sexual abstinence, defined as refraining from 
heterosexual intercourse for the entire duration of the 
study, from Visit 1 through the end of study (Visit 
8/Safety Follow -up Visit). 
oNote: Periodic abstinence (calendar, 
symptotherm al, post -ovulation m ethods) is not 
an acceptable m ethod of contraception. The 
reliability of sexual abstinence should be 
evaluated in relation to the duration of th e 
clinical trial and the preferred and usual 
lifestyle of the participant.Clarification in 
accordance w ith UK’s 
MHRA request
Section 4.4.4 Special Diet or 
ActivitiesAdded mL equivalents to the definition of an alcohol 
drink.Clarification
Protocol Summ ary,
Section 6.1 Efficacy 
Measures, 
Section 6.2.1 Activity 
Impairm ent in Migraine –
Diary (AIM -D),
Section 6.2.2 Activity Level 
and Activity LimitationUpdated description of AIM -D
Patient Difficulty in Concentrating and Difficulty in 
Thinking Clearly it ems are no longer considered stand -
alone items but part of the AIM -DBased on psychometric 
(quantitative) analyses, 
AIM -D is now an 
11-item PRO measure
that includes the items 
'patient difficulty in 
concentrating' and 
'difficulty in thinking 
clearly'.
Protocol Summary,
Section 7.2.2 Secondary 
Efficacy EndpointsClarify secondary efficacy endpoints for Europe and 
Canada, and for all other regions except Europe and 
Canada
Updated secondary efficacy endpoints related to AIM -D To specify key 
secondary endp oints by 
region.
To align with updated 
AIM -D description
Section 7.2.3 Additional 
Efficacy EndpointsUpdated additional efficacy endpoints for HIT -6.
Added change from baseline in weekly migraine days at 
Weeks 1 -4.
Updated additional efficacy endpoints r elated to AIM -DTo align with the 
estimand framework
To understand the onset 
effect
To align with updated 
AIM -D description
Section 7.3.2 Secondary 
Efficacy AnalysesUpdated description of AIM -D endpoints
Added description of the Hochberg procedure to be used 
to control the overall Type I error rate at a 0.05 level 
(2-sided) for multiple comparisons of 2 atogepant doses 
with placebo for the primary efficacy endpoint only for 
the analysis in Japan.To align with updated 
AIM -D description
To align with PMDA’s 
feedback
Section 7.3.3 Additional 
Efficacy AnalysesDescribe w eekly data analysis procedures for other 
efficacy analyses.To understand the onset 
effect
Section 7.3.4 Safety 
AnalysisUpdated description of safety analyses. Clarification
Allergan Confidential Protocol 3101-303-002 Amendment 3
127Section Revision Rationale
Section 7.5.1 Subgroup 
Analyses for Evaluating the 
Consistency of Treatment 
Effects Across Regions and 
SubpopulationsAdded description of subgroup analyses to evaluate 
consistency of treatment effects across regions and 
subpopulation.
Description of other subgrou p analyses was moved to 
Section 7.5.2.Study will be conducted 
in multiple regions. 
Section 8.1.3 Procedure for 
Duplicate Participant 
Identification –Verified 
Clinical Trials ,
Section 8.4.1 Visit 1 
(Screening/Baseline) Day --5 
to Day -28Added the phrase “at participating sites” to text 
describing VCT.For clarification, as VCT 
is optional for sites in 
Canada
Section 8.4.2.2 Visits 3 to 6 
(Week 2 to 8),
Section 8.4.2.3 Visit 7/Early 
Term ination (Week 12)Removed duplicate bullet:
Revie w medication complianceClarification, as review 
of medication 
compliance is included 
inbullet that states: 
“Collect previous visit 
study intervention, 
review participant 
compliance, and perform 
accountability”
Section 8.5 Instructions for 
the ParticipantsBolded tex t added to instruction for taking study 
intervention:
Study intervention m ay be taken with or without 
food. Water is allowed as desired.Clarification 
Section 9.1.4 Assessment of 
CausalityBolded text added to bullet point below:
•For each AE or SAE, the investigator must document 
in the medical notes that he/she has revie wed the AE 
or SAE and has provided an assessment of causality. 
In evaluating causality, the investigator will need 
to m ake a Yes/No assessment (ie, related or not 
related) regarding a reasonable possibility that the 
study intervention caused the event.Clarification 
Allergan Confidential Protocol 3101-303-002 Amendment 3
128Section Revision Rationale
Section 9.1.6 Adverse 
Reactions, Serious Adverse 
Reactions, and Suspected 
Unexpected Serious Adverse 
ReactionsAdded Section 9.1.6 Adverse Reactions, Serious Adverse 
Reactions, and Suspected Unexpected Serious Adverse 
Reactions with the following text:
“For the purposes of expedited reporting within the EU, 
the Sponsor will follow the applicable definitions for 
ARs, SARs, and SUSARs (for example, as out lined in 
Article 2 [n,o,p] of Directive 2001/20/EC, see below ). 
Also, seriousness criteria for AEs/ARs (as would apply to 
SARs and SUSARs) are currently included in the 
protocol, listed in Section 9.1.2.
•Adverse Reaction: all untoward and unintended 
responses to an investigational medicinal product 
related to any dose administered
•Serious Adverse Reaction: an adverse reaction that 
results in death, is life -threatening, requires 
hospitalisation or prolongation of existing 
hospitalisation, results in pers istent or significant 
disability or incapacity, or is a congenital anomaly or 
birth defect (see Section 9.1.2 for further details 
pertaining to seriousness criteria)
•Suspected Unexpected Serious Adverse Reaction: a 
serious adverse reaction, the nature or severity of 
which is not consistent with the applicable product 
information (eg, the Investigator’s Brochure).”Added in accordance 
with EU protocol review  
Section 9.4 Exposure to 
Study Intervention During 
PregnancyStrikethrough font removed from statement below :
Abnorm al pregnancy outcomes (eg, spontaneous or 
elective abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs. 
Elective abortions can be SAEs or AEs depending on the 
reason for the elective aborti on (eg, fetal death, still birth, 
congenital anomalies, ectopic pregnancy, which would 
make the elective abortion an SAE).Clarification
Section 10.3 Changes to the 
ProtocolBolded text added:
The investigator must not implement any deviation from 
or chan ges of the protocol w ithout approval by the 
sponsor and prior review  and documented 
approval/favorable opinion from the IRB/IEC (and the 
appropriate regulatory agency, if required by 
national law) of a protocol amendment, except where 
necessary to eliminat e immediate hazards to study 
participants, or when the changes involve only logistical 
or administrative aspects of the study (eg, change in 
monitors, change of telephone numbers).Clarification 
Section 11 References Updated reference list. In accordance with 
amendm ent revisions
Section 12.2 Examples of 
Prohibited MedicationsAsterisks added to indicate the specified medications that 
are not approved in Japan.Clarification 
Allergan Confidential Protocol 3101-303-002 Amendment 3
12912.8 Protocol Amendment 3 Summary
Title: A PHASE 3, MUL TICENTER, RANDOMIZED, DOUBLE- BLIND, 
PLACEBO -CONTROLLED, P ARALLEL -GROUP  STUDY  TO EV ALUA TE THE EFFICACY , 
SAFETY , AND TOLERABILITY  OF ATOGEP ANT  FOR THE PREVENTION OF CHRONIC 
MIGRAINE (PROGRESS)
Protocol 3101-303-002
Date of Amendment 3: 29 May 2020
Amendment Summary
This amendment includes changes made to Protocol 3101-303-002 Amendment 2, dated 
23September 2019. 
The following is a summary  of changes that were made to each section of the protocol, and a 
brief rationale for these changes.
Minor editorial and document formatting revisions have not been summarized.
Section Revision Rationale
Protocol Summary,
Study Design: 
Randomization/
StratificationAdded footnote 2:
Approximately 70% of randomized participants will have taken at least 
1prior migraine prevention medication with proven efficacy (see 
Attachment 12.3).2
2: All French participants must have taken at least 1 prior m igraine 
prevention medication with proven efficacy to be eligible for Study 
3101 -303- 002.Requirement by 
French authorities.
Added text: 
Approximately 70% of randomized participants will have taken at least 
1prior migraine prevention medication with proven efficacy (see 
Attachment 12.3).2Randomization will be stratified based on migraine 
prevention medication exposure (Current Use, Pas t Use, or Never 
Used ) with proven efficacy. Participants with current or past use will 
be further stratified based on the number of medications failed w ith 
unique mechanisms of action: “failed 0 medications or failed 1 or more 
medication(s) w ith the same m echanism of action” or “failed 2 to 4 
medications with different mechanisms of action” (see 
Attachment 12.3).Enrollm ent of participants with current use of a 
migraine prevention medication will be capped at ~15%.Based on data 
review of recent 
migraine 
prevention studies
Added bullet:
Randomization will be stratified by r egion (ie, North America, 
Europe, Japan, China, Other)Clarification of the 
randomization and 
stratification 
process to include 
region
Allergan Confidential Protocol 3101-303-002 Amendment 3
130Section Revision Rationale
Protocol Summary,
Study Design: Visit 
ScheduleRevised text:
Participation w ill begin with a 4 -week screening/baseline period. 
Participants who complete the 4 -week screening/baseline period and meet 
all entry criteria will be randomized to the double -blind treatment period 
of the thisstudy at Visit 2 (Randomization Visit). The double blind 
treatment period w ill last 12 weeks, with a subsequent follow -up period of 
4 additional w eeks. 
There will be 8 scheduled clinic visits: Visit 1 (screening/baseline), 
Visit 2 (randomization), Visit 3 (Week 2), Visit 4 (Week 4), Visit 5 
(Week 6), Visit 6 (Week 8), Visit 7 (Week 12), and Visit 8 (follow -up). 
The Visit 8 (follow -up) must be completed for all participants who take at 
least 1 dose of study medication, except for participants rolling over into 
Study 3101 -312-002 (long -term  safety extension study in regions, 
excluding Japan and China) , Study 3101 -306-002 (long -term safety 
extension study in Japan), or Study 3101 -311-002 ( open -label safety 
extension study in China). For these rollover 
participants Visit 8 of S tudy 
3101-303- 002 is not required, because the Follow -up Visit (Visit 8) will 
be performed after the OL treatm ent in the respective long-term safety 
study. For participants who screen fail for the long -term safety  study, the
Follow -up Visit (Visit 8) of Study 3101 -303-002 must be completed. For 
more details, see Table 1, Schedule of Visits and Procedures.Clarified 
participation in 
Visit 8/EOS for 
rollover 
participants, by 
region and 
respective long -
term safety 
extension study , 
and added 
information t o 
allow  for 
participants to roll 
over to 
the 
respective OL 
long-term 
extension study .
Protocol Summary,
Study Population 
Characteristics, 
Number of 
ParticipantsRevised text:
(North America, Asia/Pacific, and Europe) w as changed to: (ie, North 
America, Europe, Japan, China, Other)Adapted 
description of 
regions for 
consistency with 
stratification
Protocol Summary,
General Statistical 
Methods and Types 
of AnalysesRevised text:
All efficacy analyses will be performed using the modified intent -to-treat 
(mITT) population, which consists of all randomized participants who 
received at least 1 dose of study intervention, had an evaluable baseline 
period of eDiary data and at least 1 evaluable postbaseline 4-week period 
(Weeks 1 to 4, 5 to 8, and 9 to 12) of eDiary data during the double- blind 
treatm ent period . All safety analyses will be performed using the safety 
population, which consists of all participants who took at least 1 dose of 
study intervention. The analysis population for Off -treatment 
Hypothetical Estim and includes all randomized participants who 
received at least 1 dose of study intervention , had an evaluable 
baseline period of eDiary data and had at least 1 evaluable
postbaseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to 12) of eDiary 
data duri ng the study, regardless of whether on study treatm ent or 
off study treatm ent. This population is used for the primary estim and 
to support filing in Europe.Clarification and 
description of the 
ITT and mITT 
population, and 
the analysis 
population for 
off-treatment 
hypothetical 
estimand for the 
primary efficacy 
analysis to support 
filing in Europe.
Protocol Summary,
General Statistical 
Methods and Types 
of Analyses, 
Primary Efficacy 
EndpointAdded subsection on primary endpoint definition (matching protocol 
Section 7.2.1 ):
Primary Efficacy Endpoint
The prim ary efficacy endpoint is the change from  baseline in mean 
monthly migraine days across the 12 -week treatm ent period. Baseline 
is defined as the number of migraine days during the last 28 days 
prior to the random ization date.
And edited sentence to add ‘region’ tostatistical model: 
The statistical model will include treatment group, visit, region, acute 
medications during the baseline period (medication overuse Y/N), current 
and past use of migraine prevention medications and the number of 
medications failed with unique mechanisms of action (Current Use and 
“failed 0 medications or failed 1 or more medication(s) with the same Clarification of 
primary endpoint
and added the 
statistical model 
term ‘region’ to
theMMRM model
for primary 
analysis .
Allergan Confidential Protocol 3101-303-002 Amendment 3
131Section Revision Rationale
mechanism of act ion”, Current Use and “failed 2 to 4 medications with 
different mechanisms of action”, Past Use only and “ failed 0 medications 
or failed 1 or more medication(s) w ith the same mechanism of action”, 
Past Use only and “failed 2 to 4 medications with different mechanisms of 
action”, and Never Used), and treatment group by visit interaction as 
categorical fixed effects.
Protocol Summary,
General Statistical 
Methods and Types 
of Analyses, 
Secondary Efficacy 
Endpoints for all 
regions, except 
Europe and 
Canada :Revised text:
Change from baseline in mean AIM D monthly functioning and 
activity impairment score across the 12 w eek treatment per iod
Changed the above/previous AIM -D endpoint to the following 
2endpoints :
Change from  baseline in mean m onthly Perform ance of Daily 
Activities dom ain score of the AIM -Dacross the 12 -week treatm ent 
period.
Change from  baseline in mean m onthly Physical Impairment 
dom ain score of the AIM -D across the 12-week treatm ent period. Clarification of the 
AIM -D related 
secondary 
endpoint , based on 
psychometric 
evidence of the 
AIM -D consisting 
of 2 domains, 
performance of 
daily activities and 
physical 
impairm ent
Protocol Summary,
General Statistical 
Methods and Types 
of Analyses,
Secondary Efficacy 
Endpoints for all 
regionsChanged w ording of secondary endpoints for all regions to:
At least a 50% reduction in 3-month average of m onthly migraine 
daysTo clarify 
secondary 
endpoints
Protocol Summary,
General Statistical 
Methods and Types 
of Analyses,
Secondary Efficacy 
EndpointsRevised text:
The secondary endpoints for headache days, acute medication use da ys, 
MSQ v2.1 Role Function -Restrictive domain score, AIM D functioning 
and activity impairment score Perform ance of Daily Activities dom ain 
score of the AIM -D, Physical Impairment dom ain score of the 
AIM -D, and HIT -6 total score w ill be analyzed in the same manner as 
that used to analyze the primary endpoint.
The secondary endpoint of 50% responders, defined as participants 
with at least a 50% reduction from  baseline in the 3 -month average of 
monthly migraine days, will be assessed for each individual. The 
secondary endpoint of at least a 50% reduction from baseline in monthly 
migraine days will be summarized for each 4 week period during the 12
week treatment period.
A logistic regression generalized linear mixed model will be used to 
analyze 50% responders as repeated measures across the 12 -week 
treatment period. This model assumes a binary distribution for the 
response and uses a logit link. The analysis model will include treatment 
group, region visit, acute medications during the baseline period 
(medication overuse Y/N), current and past use of migraine prevention 
medications and the number of medications failed with unique 
mechanisms of action ,and treatment group byvisit interaction as 
categorical fixed effects; baseline value and baseline byvisit intera ction 
will be included as a covariate s. Participants will be included as random 
effects with unstructured covariance matrix in the model to account for 
the correlation among repeated measurements. The analysis will be 
performed based on all postbaseline values using only the observed cases 
without imputation of missing values. The treatment difference in terms 
of odds ratio betw een each atogepant dose group and placebo w ill be 
estimated and tested from this model. Clarification that 
50% responder 
will be assessed 
for each 
individual. The 
corresponding 
model is changed 
consequently.
Clarification of 
statistical analysis 
model for 
secondary analysis
Allergan Confidential Protocol 3101-303-002 Amendment 3
132Section Revision Rationale
Table 1 Schedule of 
Visits and 
Procedures Added table footnote a:
a:Visit 1, Visit 2, and either Visit 3 or Visit 4 must be conducted in 
office. All other visits, should be conducted in office unless it is 
necessary to conduct rem ote visits for the safety of participants (eg, 
COVID -19 or other pandemic): for details pleas e refer to the Rem ote 
Visit Schedule of Assessments in Attachm ent 12.4)
Added table footnote c:
c:All participants who take at least 1 dose of study intervention must 
complete the follow -up period, except for participants rolling over 
into Study 3101 -312- 002 (long -term  safety extension study in regions 
excluding Japan and China), participants rolling over into 
Study 3101- 306-002 (long -term  safety extension study in Japan), or 
Study 3101 -311-002 (open -label safety extension study in China). For 
these rollover participants the Follow -up Visit will be perform ed after 
the com pletion of the OL treatm ent in the respective long -term  safety 
extension study.
Added to table footnote j:
j:Clinicians will complete on eTablet. The screening/baseline 
assessment of the C -SSRS will be completed. At all other visits, the 
‘Since Last Visit’ C SSRS will be completed.
Added table footnote k:
k:Participant will com plete on eTablet.
Added table footnote n:
n:eDiary will be collected on Visit 2 for screen failures.
Added table footnote q:
q:The first dose of study intervention should be taken at the study 
site.To add flexibility 
and safety for 
participants and 
staff to the 
conduct of this 
study, when 
remote visits are 
necessary due to 
COVID -19 or 
other pandemic
Clarified 
participation in 
Visit 8/EOS for 
rollover 
participants, by 
region and 
respective long -
term safety 
extension study, 
added information 
to allow  for 
participants to roll 
over to the 
respective OL 
long-term 
extension study.
Clarifications
Section 3 Study 
Design ,Section 3.1 
Structure Added footnote 2: 
Approximately 70% of randomized participants will have taken at least 
1prior migraine prevention medication with proven efficacy (see 
Attachment 12.3).2
2: All French participants must have taken at least 1 prior m igraine 
prevention medication with proven efficacy to be eligible for Study 
3101 -303- 002. Requirement by 
French authorities.
Added text: 
Approximately 70% of randomized participants will have taken at least 
1prior migraine prevention medication with proven efficacy (see 
Attachment 12.3).2Randomization will be stratified based on migraine 
prevention medication exposure (Current Use, Past Use, or Never 
Used ) with proven efficacy. Participants w ith current or past use will 
be further stratified based on the number of medications failed w ith 
unique mechanisms of action: “failed 0 medications or failed 1 or more 
medication(s) with the same mechanism of action” or “failed 2 to 
4medications with dif ferent mechanisms of action” (se e 
Attachment 12.3).Enrollm ent of participants with current use of a 
migraine prevention medication will be capped at ~15%.Based on data 
review of recently 
published 
migraine 
prevention studies
Added bullet:
Randomization will be stratified by region (ie, North America, 
Europe, Japan, China, Other)To clarify the 
randomization 
stratification 
process.
Allergan Confidential Protocol 3101-303-002 Amendment 3
133Section Revision Rationale
Change dtext:
Participation w ill begin with a 4 -week screening/baseline period. 
Participants who complete the 4 -week scree ning/baseline period and meet 
all entry criteria will be randomized to the double -blind treatment period 
of the thisstudy at Visit 2 (Randomization Visit). The double blind 
treatment period w ill last 12 weeks, with a subsequent follow -up period of 
4 addit ional w eeks. 
There will be 8 scheduled clinic visits: Visit 1 (screening/baseline), Visit 
2 (randomization), Visit 3 (Week 2), Visit 4 (Week 4), Visit 5 (Week 6), 
Visit 6 (Week 8), Visit 7 (Week 12), and Visit 8 (follow -up). The Visit 8 
(follow -up) m ust b e completed for all participants who take at least 1 
dose of study m edication, except for participants rolling over into 
Study 3101 -312-002 (long -term  safety extension study in regions, 
excluding Japan and China), Study 3101 -306-002 (long -term  safety 
exten sion study in Japan), or Study 3101 -311-002 ( open -label safety 
extension study in China). For these rollover participants Visit 8 of 
Study 3101 -303-002 is not required, because the Follow -up Visit (Visit 
8) will be perform ed after the OL treatm ent in the respective long -
term  safety study. For participants who screen fail for the long -term  
safety study, the Follow -up Visit (Visit 8) of Study 3101 -303-002 m ust 
be completed. For m ore details on details study schedule, please see 
Table 1, Schedule of Visits and Procedures.
Only Japanese or Chinese participants completing the double blind 
treatment period in this study may be eligible to continue in either Study
3101 306002 (long term safety extension study in Japan) or Study 3101
311002 (long term safety extension study in China). For these rollover 
participants, a Visit 8 is not required in the present study, as the Follow
up Visit will be performed in the lo ngterm safety study. For participants 
who screen fail for the long term safety study, the Follow up Visit must 
be completed.Clarified 
participation in 
Visit 8/EOS for 
rollover 
participants, by 
region and 
respective long -
term safety 
extension study. 
And a dded 
information to 
allow  for 
participants to roll 
over into the 
respective OL 
long-term 
extension study.
Section 3.4 End of 
Study DefinitionAdded sentence:
The end of the study is defined as the date of the last visit of the last 
participant in the stud y. For Russia, end of study is defined as the last 
Close Out Visit.To comply with 
Russian 
requirement to call 
it Close Out Visit
Section 4.1 Number 
of ParticipantsRevised text:
(North America, Asia/Pacific, and Europe) w as changed to: (ie, North 
America, Europe, Japan, China, Other)Adapted 
description of 
regions for 
consistency with 
stratification
Section 4.3, 
Exclusion Criterion 
number 14. Changed text:
14.Any clinically sig nificant hematologic, endocrine, cardiovascular, 
cerebrovascular, pulmonary, renal, hepatic, gastrointestinal, or 
neurologic diseaseClarification 
Allergan Confidential Protocol 3101-303-002 Amendment 3
134Section Revision Rationale
Section 4.4.2 
Proh ibited 
Medications/
TreatmentsRevised text and added bullet :
Medications with demonstrated efficacy for the prevention of 
migraine (eg, amitriptyline, propranolol, topiramate) are prohibited 
when used for any indication other than migraine prevention. See 
Attachment 12.3.
oParticipants taking onemedication with demonstrated efficacy 
for the prevention of migraine may be randomized provided that 
in the opinion of the investigator:
 Dose has been stable and the medication has been well -
tolerated for at least 12 weeks prior to Visit 1 AND
 Participant is willing and able to maintain at a stable dose 
and dosage regimen during the study , which should be 
assessed to ensure compliance at each study visit
 Enrollment of participants with current use of a 
migraine prevention medication will be capped at 
~15%
…
Cannabidiol (CBD) oil, cannabis.Clarification
Section 4.5 Screen 
FailuresRevised text:
Screen failures are defined as participants who consent to participate in 
the study but are not subsequently randomized to treatment. Rescreening 
of screen failures is permitted in certain situations (ie, failure to 
adequately screen due to COVID -19), with permission from the 
sponsor. How ever, participants with clinically significant laboratory 
values at Visit 1 ( ie, screening; including ALT or AST >1 × the ULN, 
total bilirubin >1 ×ULN or serum albumin < 2.8 g/dL), or those with a 
positive UDS result at Visit 1 for recreational (including marijuana 
regardless of legality) or illicit drugs or non -disclosed5concom itant 
medications are not allowed to be rescreened. 
Footnote5:For participants in the People’s Republic of China , a 
positive UDS will result in screen failure regardless of disclosed 
concom itant medications.
And for Table 3 in Section 6.5.3 , the same footnote was added as table
footnoteClarification 
Section 5.2 Control 
Intervention(s)Revised text:
5.2 Control Intervention sand Formulations
Tablets containing matching placebo 30 m g(Formulation 011326X) for
atogepant 30 mg and matching placebo 60 m g(Formulation 011317X) 
foratogepant 60 mg .Clarification 
Section 5.3 
Methods for 
Masking/BlindingRevised text:
All participants will be instructed to take their study intervention twice 
daily (2 tablets in the morning and 2 tablets in the evening) at 
approximately the same time seach day. Participants, therefore, will 
receive either placebo BID, atogepant 30 m g BID, ora morning dose of 
atogepant 60 mg with an evening dose of placebo.Clarification of 
blinded study 
intervention taken 
by eligible 
participants
Section 5.4 
Treatment 
Allocation Ratio 
and StratificationAdded bullet:
Randomization will be stratified by r egion (ie, North America, 
Europe, Japan, China, Other)Clarification of the 
randomization and 
stratification 
process to include 
region
Allergan Confidential Protocol 3101-303-002 Amendment 3
135Section Revision Rationale
Section 5.6 Study 
Intervention 
Regimen and 
DosingRevised text and Table 2 :
Treatments to be used in this trial are list ed in Table 2 . Participants who 
meet all the study entry criteria at Visit 2 will be randomized and 
provided w ith study intervention to be taken on an outpatient basis. Sites 
will subsequently dispense study intervention to participants at Visits 3, 4, 
5, and 6. Participants will take their first dose of study intervention at the 
clinic at Visit 2 . All participants will be instructed to take their study 
intervention twice daily (2 tablets in the morning and 2 tablets in the 
evening) at approximately the same time s each day. Details of PK 
samples with respect to timing of study intervention are provided in 
Section 6.3. Study intervention will be administered orally for 12 weeks, 
and participants will be followed for 4 w eeks following study completion 
or discontinuation of study intervention.
Table 2Study Interventions
Drug/
DoseStudy Intervention Product 
andMatching PlaceboStudy 
Intervention 
FrequencyRoute of 
Admini -
stration
Placebo Placebo 30 mg and Placebo 60 mg BID Oral
Atogepant 
30 mg Atogepant 30 mg andPlacebo 60 
mgBID Oral
Atogepant 
60 mg AM: Atogepant 60 mg and
Placebo 30 mgBID OralPM: Placebo 30 mg andPlacebo 
60 mg
AM = m orning dose; BID = twice daily; PM = evening dose .Clarification of 
blinded study 
intervention taken 
by eligible 
participants
Section 6.2.1 
Activity 
Impairm ent in 
Migraine – Diary 
(AIM -D)Revised text:
The AIM -D is an 11 -item daily diary PRO measure that assesses the 
impact of m igraine functioning and is comprised of two dom ains that 
evaluate perform ance of daily activities (7 item s) and physical activity
impairm ent (4 items) .in m igraine patients . Participants are asked to rate 
the level of difficulty experienced in the past 24 hours with perform ance 
of daily activities functioning and activity impairment (ie, difficulty with 
household chores, errands, leisure activities at home, leisure or social 
activities outside the home, strenuous physical activities, concentrating, 
and thinking clear ly) and physical impairment (ie, difficulty walking, 
moving body, bending forward, moving head ), concentrating, and 
thinking clearly) using the6-point rating scale :ranging from “Not 
difficult at all,” “A little difficult,” “Somewhat difficult,” “Very difficult,” 
“Extremely difficult,” and “I could not do it at all.” Three items include a 
response of “I did not…,” for example, “I did not have errands planned.” 
The AIM -D was devel oped as an electronica daily d eDiary with the same 
set of questions administered in headache and non -headache versions. The 
Headache version is administered on days when a participant reports a 
headache and the Non -Headache version is administered on days when a 
participant does not report having a headache. The AIM -D instructs 
participants to answer each question based on the level of difficulty 
experienced in the past 24 hours for both versions, with “during your 
headache” indicated for the AIM -D Headache version. In addition to the 
two dom ainAIM Dscores , a total score using all 11 item s can also be 
calculated. Each raw daily dom ain score, as well as the raw daily total Clarification of the 
AIM -D diary 
questionnaire, 
based on 
psychometric 
evidence of the 
AIM -D consisting 
of 2 domains, 
performance of 
daily activities and 
physica l 
impairm ent
Allergan Confidential Protocol 3101-303-002 Amendment 3
136Section Revision Rationale
score, are transform ed to a range from 0-100 scale , to 5with higher 
scores indicating greater impact of migraine (ie, higher disease 
burden). in functioning and activity impairment.
Section 6.7 
Summary of 
Methods of Data 
CollectionRevised text:
An IWRS will be used to randomize participants and manage study 
intervention inventory. All office visit data (ie, non -diary data) for this 
study will be collected by either onthe eTablet or, if conducted rem otely 
(Attachm ent 12.4), utilizing a web -portal (eg, questionnaires for PROs) 
or eCRFs via an electronic data capture system.To adapt text to 
remote visits 
necessary due to 
COVID -19
Section 7.1 
Analysis 
PopulationsAdded text to first paragraph:
The ITT population will consist of all randomized participants. All 
efficacy analyses will be performed using the mITT population, consisting 
of all randomized participants who received at least 1 dose of study 
intervention, had an evaluable baseline period of eDiary data, and had at 
least 1 evaluable postbaseline 4-week period (Weeks 1 to 4, 5 to 8, and 
9to 12) of eDiary data during the double -blind treatm ent period . All 
safety analyses will be performed using the safety populatio n, consisting 
of all participants who received at least 1 dose of study intervention. 
Added 2ndparagraph:
The prim ary efficacy analysis population to support filing in Europe 
for off -treatm ent estimand (defined in Section 7.4) includes all 
randomized par ticipants who received at least 1 dose of study 
intervention , had an evaluable baseline period of eDiary data and had 
at least 1 evaluable postbaseline 4-week period (Weeks 1 to 4, 5 to 8, 
9to 12) of eDiary data during the study , regardless of whether on 
study treatm ent or off study treatm ent. Clarification and 
description of the 
ITT and mITT 
population, and 
the analysis 
population for 
off-treatment 
hypothetical 
estimand for the 
primary efficacy 
analysis to support 
filing in Europe.
Section 7.2 
Collection and 
Derivation of 
Primary and 
Secondary Efficacy 
AssessmentsRevised text:
On a daily basis during the 28 -day baseline period and throughout the 
study double blind treatment period , participants are to record, into an 
eDiary, information on the d aily total duration of headache, headache 
specific characteristics and symptoms, the worst pain severity, and use of 
any acute medication. 
Therefore, for data analysis purposes, the number of migraine days during 
the last 28 daysprior to the randomizatio n date of the baseline phase 
(ie, Day 28 to 1), will serve as the baseline, and change from baseline 
will be calculated for consecutive 28 -day periods beginning with the date 
of the first dose of study intervention Day 1.Clarification of 
collection of 
migraine days and 
baseline for 
migraine days 
Section 7.2.1 
Primary Efficacy 
EndpointRevised text:
The primary efficacy endpoint is the change from baseline in mean 
monthly migraine days across the 12 -week treatment period. Baseline is 
defined as the number of migraine days during the last 28 days prior to 
the randomization date. of the baseline phase (ie, Day 28 to 1)Clarification of 
primary endpoint 
Section 7.2.2 
Secondary Efficacy 
Endpoints for all 
regions, except 
Europe and CanadaRevised text:
Change from baseline in mean AIM D monthly functioning and 
activity impairment score across the 12 week treatment period
Changed the above/previous AIM -D endpoint to the following 
2endpoints :
Change from  baseline in mean m onthly Perform ance of Daily 
Activities dom ain score of the AIM -Dacross the 12 -week treatm ent 
period.
Change from  baseline in mean m onthly Physical Impairment 
dom ain score of the AIM -D across the 12-week treatm ent period. Clarification of the 
AIM -D related 
secondary 
endpoint, based on 
psychometric 
evidence of the 
AIM -D consisting 
of 2 domains, 
performance of 
daily activities and 
physical 
impairm ent
Allergan Confidential Protocol 3101-303-002 Amendment 3
137Section Revision Rationale
Section 7.2.2 
Secondary Efficacy 
Endpoints 
Secondary Efficacy 
Endpoints for all 
regions, except 
Europe and Canada , 
and for Europe and 
Canad aChanged w ording of secondary endpoints to:
At least a 50% reduction in 3-month average of m onthly migraine 
daysTo clarify that 
50% responder 
will be assessed 
for each 
individual. The 
corresponding 
model is changed 
consequently.
Section 7.2.3 
Additional Efficacy 
EndpointsAdded text:
Additional efficacy endpoints for the United States and the Europe 
are provided below. Related analysis will be documented in the SAP.Added text for 
clarification 
Section 7.2.3 
Additional Efficacy 
EndpointsChanged, added , and deleted additional efficacy endpoints:
≥ 25%, ≥ 30%, ≥ 75%, 100% improvement (decrease) in 3-month 
average of m onthly migraine days across the 12 week treatment 
period
Change from baseline in monthly headache free days at Weeks 1 to 4, 5 
to 8, 9 to 1 2, and average across the 12 week treatment period
Change from baseline in monthly headache day pain intensity at Weeks 
1 to 4, 5 to 8, 9 to 12, and average across the 12 week treatment period
Participant having a m igraine day on the day of initial dose and on 
each day of the 6 days post the initial dose.
Participant assessed by the PGIC as “much better” or “very much 
better” at Week 12
Participant reporting “satisfied” or “extremely satisfied” with study 
medication for migraine prevention at Weeks 4, 8, and 12
Change from baseline in EQ 5D5L descriptive system index score at 
Weeks 1 to 2, at specified w indow s around Weeks 4, 6, 8, 12, and 
Week 16
Change from baseline in the EQ 5D5L VAS score at Weeks 1 to 2, at 
specified windows around Weeks 4, 6, 8, 12 , and Week 16
Change from  baseline in monthly Perform ance of Daily Activities 
dom ain score of the AIM -D at Weeks 1 to 4, 5 to 8, and 9 to 12
Change from  baseline in monthly Physical Impair ment dom ain 
score of the AIM -D at Weeks 1 to 4, 5 to 8, and 9 to 12
Change from  baseline in mean m onthly Perform ance of Daily 
Activities dom ain score of the AIM -D across the 12 -week treatm ent 
period (for Europe and Canada only)
Change from  baseline in mean m onthly Physical Impairment 
dom ain score of the AIM -D across the 12 -week treatm ent period 
(for Europe and Canada only)
Change from  baseline in monthly AIM -D total score at Weeks 1 to 
4, 5 to 8, 9 to 12, and average across the 12 -week treatm ent period
Change from baseline in AIM D monthly functioning and activity 
impairm entscore at Weeks 1 to 4, 5 to 8, and 9 to 12
Change from baseline in mean AIM D monthly functioning and 
activity impairment score across the 12 week treatment period (for 
Europe and Canada)
Change from baseline in PROMIS PI total score at Weeks 4, 8, and 1 2To remove 
redundancy 
because monthly 
headache free days 
will be 
complem entary to 
monthly headache 
day, and headache 
pain intensity can 
be interpreted 
using monthly 
moderate/severe 
days. 
To add the 
endpoint for 
evaluating the 
onset effect.
Allergan Confidential Protocol 3101-303-002 Amendment 3
138Section Revision Rationale
Section 7.2.3.1 
Other Health 
Outcome VariablesMoved the following additional efficacy endpoints from Section 7.2.3 to
this subsection:
Change from  baseline in EQ -5D-5L descriptive system index score 
at Weeks 1 to 2, at specified windows around Weeks 4, 6, 8, 12, and 
16
Change from  baseline in the EQ -5D-5L VAS score at Weeks 1 to 2, 
at specified windows around Weeks 4, 6, 8, 12, and 16
Change from  baseline in PROMIS -PI total score at Weeks 4, 8, and 
12To classify other 
health outcomes 
together because 
related anal yses 
will be described 
in the health 
economics and 
outcomes research 
SAP.
Section 7.3.1 
Primary Efficacy 
AnalysisAdded 2sentences to the 2nd paragraph in this section (description of the 
primary analysis with the MMRM model): 
This is the prim ary analysis method for the prim ary efficacy endpoint 
in support of the US filing. Only data collected during the double -
blind period will be included in the analysis. Participants are always 
analyzed based on the treatment group assigned by randomization.
Added the following 2new subsections, each describing a different 
sensitivity analysis, as outlined below  (no bold font used, for preserving 
the overview on subsections):
7.3.1.1 Sensitivity Analyses in Missing Data Handling
Multiple sensitivity analyses for missing data handling will be conducted 
and summarized below . Details of the sensitivity analyses will be 
provided in the SAP.
ANCOVA Model Based on 3 -month Average of the Monthly Migraine 
Days
A supportive analysis will b e performed on the primary endpoint using an 
ANCOVA model. The response variable for the ANCOVA model is the 
change from baseline in the calculated average monthly migraine days 
during the 12 -week treatment period for each participant. The ANCOVA 
model inc ludes terms for treatment, region, acute medications during the 
baseline period (medication overuse Y/N), current or past use of migraine 
prevention medications and the number of medications failed w ith unique 
mechanisms of action, and baseline score. The treatment difference for 
atogepant doses versus placebo w ill be estimated and reported along with 
the corresponding 95% CI and nominal p -value for superiority testing.
Within -group Imputation Based on Observed Data
Sensitivity analysis will be performed based on imputation using 
participants from the same treatment group with observed data under the 
MAR assumption. Missing data for participants who prematurely 
discontinued are assumed to copy the profile of participants in the same 
treatment group with observed data.
Copy -Reference Approach
Copy -reference approach will be performed on the primary endpoint to 
assess the robustness of the MMRM analysis to possible violation of the 
missing at random (MAR) assumption. This sensitivity analysis is one 
type of pat tern mixture models (PMM), under w hich data could be 
missing not at random (MNAR), w ith repeated analyses combined via the 
reference based multiple imputation (MI) procedure. Participants who 
discontinued in the Atogepant groups are assumed to have no trea tment 
effect after the discontinuation. Participants are assumed to copy the 
profile of placebo arm and missing values are imputed based on the 
distribution estimated from the placebo group under the MAR using copy 
reference approach.
MMRM Based on Primary Measures Collected during the Double -blind 
and Follow -up PeriodsAdded text to the 
description of the 
primary analysis 
with the MMRM 
model.
To align with the 
atogepant clinical 
program .
Allergan Confidential Protocol 3101-303-002 Amendment 3
139Section Revision Rationale
The details for this analysis are provided in Section 7.4. The primary 
analysis in support of EU filing will serve as one sensitivity analysis in 
support of US filing.
7.3.1.2 Sensitivity Analysis for Possible Violation of Normality 
Assu mption
The normality test is performed on the residuals which are generated by 
the same MMRM as used for the primary efficacy analysis. The residuals 
are scaled by the inverse Cholesky root of its estimated v ariance -
covariance matrix. The Kolmogorov -Smirnov test for normality is applied 
to the de- correlated and scaled residuals and normality test is rejected if 
p-value from the Kolmogorov -Smirnov test is less than 0.01. 
If the normality test is rejected, the sensitivity analysis uses MI in 
conjunction with robust regression to assess the robustness of the primary 
MMRM analysis to the possible violation of normality assumption. This 
method has been described and referred as ADAP [R] in Mehrotra 2012. 
The detail of the sensitivity analyses will be provided in the SAP.
Section 7.3.2 
Secondary Efficacy 
AnalysisChanged 1stand 2ndparagraph:
The secondary endpoints for headache days, acute medication use days, 
MSQ v2.1 Role Function -Restrictive domain score, AIM D functioning 
and activity impairment score Perform ance of Daily Activities dom ain 
score of the AIM -D, Physical Impairment dom ain scor e of the 
AIM -D, and HIT -6 total score w ill be analyzed in the same manner as 
that used to analyze the primary endpoint.
The secondary endpoint of 50% responders, defined as participants 
with at least a 50% reduction from  baseline in the 3 -month average of 
monthly migraine days, will be assessed for each individual . A logistic 
regression generalized linear mixed model will be used to analyze 50% 
responders as repeated measures across the 12 -week treatment period. 
This model assumes a binary distribution for the response and uses a logit 
link. The analysis model will include treatment group, region visit, acute 
medications during the baseline period (medication overuse Y/N), current 
and past use of migraine prevention medications and the number of 
medications failed with unique mechanisms of action ,and treatment 
group byvisit interaction as categorical fixed effects; baseline value and 
baseline byvisit interaction will be inclu ded as a covariate s. Participants 
will be included as random effects with unstructured covariance matrix in 
the model to account for the correlation among repeated measurements.
The analysis will be performed based on all postbaseline values using 
only the observed cases without imputation of missing values. The 
treatment difference in terms of odds ratio between each atogepant dose 
group and placebo w ill be estimated and tested from this model.Clarification of the 
AIM -D related 
secondary 
endpoint, based o n 
psychometric 
evidence of the 
AIM -D consisting 
of 2 domains, 
performance of 
daily activities and 
physical 
impairm ent.
To clarify that 
50% responder 
will be assessed 
for each 
individual. The 
corresponding 
model is changed 
consequently.
Section 7.3.3 
Addi tional Efficacy 
AnalysisChanged paragraph:
Descriptive statistics will be provided by visit for each efficacy variable 
by treatment group. Analysis of some variables will be limited to 
descriptive summary statistics. For ASC 12, the number and percentage of 
randomized participants will be summarized by presence of allodynia as 
measured by the sum of score (absence: 0 to 2, presence > 2). Details will 
be specified in the SAP.Clarification
Allergan Confidential Protocol 3101-303-002 Amendment 3
140Section Revision Rationale
Section 7.4 Off-
treatm ent 
Hypothetical 
Estimand 
Fram ework for 
EMAClarified section title and added text with subsection s(no bold font used 
to preserve overview over subsections) as follows:
7.4Off-Treatm ent Hypothetical Estimand Framework for EMA
This section defines an estimand, termed as off -treatment hypothetical 
estimand, which will be the primary estimand in support of EU filing and 
serve as one sensitivity analysis in support of US filing.
7.4.1 Treatment Condition of Interest
Participants take assigned treatment by randomization during the double -
blind treatment period. In addition, permissible and prohibited mediations 
are described below:
Participants are allow ed to take acute migraine medications 
(Section 4.4.1) to keep the participants in the study
Medications with demonstrated efficacy for the prevention of migraine 
(eg, amitriptyline, propranolol, topiramate) are prohibited when used 
for any indication other than migraine prevention. See Attachment 12.3
oParticipants taking one medication with demonstrated efficacy 
for the prevention of migraine may be rando mized provided that 
in the opinion of the investigator:
Dose has been stable and the medication has been well -
tolerated for at least 12 w eeks prior to Visit 1 AND
Participant is willing and able to maintain at a stable 
dose and dosage regimen during the st udy, which should 
be assessed to ensure compliance at each study visit
Enrollment of participants with current use of a migraine 
prevention medication will be capped at ~15%To align with ICH 
E9R1 (issued on 
Nov 20, 2019) 
Section A.3.3.
Section 7.4.4 
Accounting o f
Intercurrent EventsChanged text:
Intercurrent events and their handling rules are as follows:
Participants who started a new migraine prevention treatm ent 
after the first dose of DB treatm ent will have their data after the 
end of DB treatm ent period following the start of the new 
migraine prophylaxis treatment excluded from  the 
analysis. Participants who discontinue study intervention and switch 
to other prophylaxis treatment w ill have their data collected after 
switching treatment, but such d ata collected after discontinuation of 
study intervention will be excluded from the analysis.
Participants who discontinue study intervention due to all reasons 
other than starting a new m igraine prophylaxis 
treatm entswitching treatment will have their dat a collected after 
discontinuation of study intervention, and those off -treatm ent data 
will be included in the analysis.
Participants with missing data up to 12 week treatment period w ill have 
their data imputed using participants in the same treatment grou p who 
provide data while off study intervention. Detailed methods and 
procedures w ill be documented in the SAP prior to the study completion.To align with 
atogepant clinical 
program
Section 7.4.5 
Population -Level 
SummaryAdded the following text as 2ndparagraph:
Participants are always analyzed based on their treatm ent assignment 
by random ization. To obtain the estim ate of treatm ent effect defined 
in the off -treatm ent hypothetical estim and, a MMRM similar to the 
primary analysis specified in Section 7. 3.1will be performed on 
observed data including both on -treatm ent and off -treatment 
monthly migraine days.To propose the 
analysis method to 
obtain the 
population -level 
summary for the 
primary endpoint.
Allergan Confidential Protocol 3101-303-002 Amendment 3
141Section Revision Rationale
Section 7.4.6 Off-
treatm ent 
Hypothetical 
Estimand Approach 
for the Secondary 
EndpointsClarified text in 2ndparagraph:
Secondary endpoint of 50% responders w ill be derived using both 
on-treatm ent and off -treatment observed data as defined in the primary 
endpoint above. The population -level summary for th is endpoint is the 
odds ratio for each atogepant group relative to placebo.Clarification
Section 7.5.2 Other 
Subgroup AnalysesChanged first sentence to:
A subgroup analysis by exposure to migraine prevention medication , 
preventive m edication failures, and by acute m edication overuse is 
planned for the following efficacy endpoints:
Changed w ording of secondary endpoints to:
At least a 50% reduction in 3-month average of m onthly migraine 
days
At least a 75% reduction in 3-month average of m onthly migrain e 
days
A 100% reduction in 3-month average of m onthly migraine days
Deleted the following text:
Subgroup analyses by number of preventive medications failed w ith 
unique mechanisms of action, by ≥ 1, ≥ 2, and ≥ 3 preventive medication 
failures (irrespective of class) and by medication overuse are also planned 
for the following efficacy endpoints:
Change from baseline in mean monthly migraine days across the 
12week treatment period
Change from baseline in mean monthly headache days across the 
12week treatment period
Change from baseline in mean monthly acute medication use 
days across the 12 week treatment period
At least a 50% reduction in 3 month average of monthly 
migraine daysModified the 
description of 
responders to be 
consistent with 
Sections 7.2.2 and 
7.2.3
Subgroup analyses 
for presence of 
allodynia will be 
included in SAPs 
in support of 
business 
objectives such as 
a separate SAP 
relevant to health 
technology 
assessment and 
publications.
Section 11. 
ReferencesAdded reference:
Mehro tra DV, Li X, Liu J, Lu K. Analysis of longitudinal clinical 
trials with m issing data using m ultiple imputation in conjunction with 
robust regression. Biometrics. 2012;68(4):1250 -1259. As per text 
additions in 
Section 7.3.1 
Allergan Confidential Protocol 3101-303-002 Amendment 3
142Section Revision Rationale
Attachment 12.3 Added bullet: 
The criteria below  should be used to determine how to stratify each 
participant based on the number of prior migraine preventive medications 
failed with unique mechanisms of action. Failure of a migraine preventive 
medication can be assessed on the basis of tolerability or efficacy and is 
based on investigator judgment.
For efficacy, investigators must consider:
oFailure is defined as no meaningful reduction in frequency of 
migraine days after an adequate trial of at least 2 months at 
generall y accepted therapeutic doses, per investigator judgement 
and participant interview.
oMedications must have been started w ithin the past 7 years.
oNote the following for participants who are currently taking a 
stable dose of one of the migraine prevention med ications listed 
and meet the efficacy criteria:
If the participant meets all study entry criteria, this 
participant is eligible to be randomized provided that the 
participant agrees to continue to take this migraine 
preventive medication for the duration o f the study.
This medication should be considered as one of the 
failed drugs for the prevention of migraine.
Enrollment of participants with current use of a 
migraine prevention medication will be capped at 
~15%Clarification
Additional 
Attachment 12.4Added Attachment 12.4 with text (see below ) and Table 5 Remote Visits 
Schedule of Assessments, to explain in more detail the conduct of remote 
study visit for the safety of participants and site staff (ie, COVID -19 or 
other pandemic).
Rem ote study visits, conducted virtually or by phone, are permitted if 
the Investigator determ ines there to be a public health risk due to 
viral infection (eg, COVID -19) to the participant or site staff. During 
remote study visits, the Remote Visit Schedule of Assessments 
(Tab le12 1) should be followed. Rem ote visits may be conducted 
between Visit 3 –Visit 8 but participants must attend in office 
assessments at Visit 3 or Visit 4 to ensure laboratory samples are 
obtained within the first 4 -weeks of treatm ents and remote visit s 
should not be performed for greater than 8 weeks. Missed in -person 
safety assessments (ie, clinical laboratory sam ples, vital signs and 
ECGs) should be collected at the next in- person visit. Patient reported 
outcom es collected on the eTablet during in -office visits, will be 
collected using a web -based portal during rem ote visits, if available. To outline conduct 
of study when 
remote visits are 
necessary due to 
COVID -19